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In this thesis will be described research towards the development of bioorthogonal bond-cleavage 
reactions, and their applications in targeted drug delivery (Figure 1). The first project relates to the 
development of a palladium mediated bond-cleavage or “decaging” reaction which can cause a 
propargyl carbamate to decompose and release an amine. This was further developed by the 
incorporation of a protein modification handle which allowed an amine-bearing drug to be covalently 
ligated to a protein by a palladium-cleavable linker. This chemistry was demonstrated by the 
conjugation of the anticancer drug doxorubicin to a tumour targeted anti-HER2 nanobody. The drug 
could then be delivered to cancer cells upon addition of a palladium complex.1 
The second project relates to the development of a platinum mediated bond-cleavage reaction. This 
was developed with the aim of using platinum-containing anticancer drugs – such as cisplatin – as a 
catalyst to cause drug release reactions in tumours. In this reaction an alkyne-containing amide can 
decompose to release an amine upon addition of platinum complexes, and was applied to the release 
of prodrugs of the cytotoxins monomethylauristatin E and 5-fluorouracil in cancer cells. A cisplatin-
cleavable antibody-drug conjugate was designed and synthesised, and progress towards its biological 
evaluation will be discussed. 
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1.1 Cancer and Conventional Chemotherapy 
Mortality due to cancer is only expected to rise as the world’s population grows and ages, and it already 
killed as many as 8.2 million in 2012.2 The current method of treatment is generally the surgical excision 
of the majority of a tumour mass, followed by a combination of chemotherapy and radiotherapy 
depending on the particular course followed. 
The combination chosen is selected based on myriad factors, but common to all types of cancer 
treatment is a selection of chemotherapeutics with diverse modes of action. The doses of individual 
drugs can therefore be lower while maintaining a high enough overall dose of chemotherapeutics to 
hopefully eradicate the tumours. Common combinations include: 
In the treatment of colon cancer, the following drugs are used in various combinations: 
fluorodeoxyuridine for the inhibition of RNA synthesis, folinic acid for thymidylate synthase inhibition 
and as a fluorodeoxyuridine adjuvant and oxaliplatin as a DNA cross-linking agent.3 
In the treatment of lung cancer, a common course is cisplatin for DNA cross-linking perhaps in 
combination with vinorelbine as a microtubule-formation inhibitor.4 
In the treatment of breast cancer, one of many courses is epirubicin as a DNA intercalator, 
cyclophosphamide as a DNA alkylator, fluorodeoxyuridine and docetaxel as a microtubule-formation 
inhibitor.5 
These cytotoxins are all slightly selective for tumours and have been shown to be effective treatments 
in practice. The slight selectivity arises as all these agents inhibit the replication of nucleic acids, 
something that tumours do at a much higher rate than healthy cells. The high toxicity of these 
treatments from non-specific cell killing – a dose-limiting factor – therefore determines how effective 
the treatment can be. Higher selectivity would allow lower effective doses and better survival rates for 
cancer patients. 
Cytotoxic chemotherapeutic agents are usually given at their Maximum Tolerated Dose (MTD) to be 
effective, and the more selective these drugs are, the lower their Minimum Effective Dose (MED). The 
issue with very highly cytotoxic drugs (IC50 < 1 nM) is that they often reach their MTD before an MED 
can be achieved. The cytotoxicity of common chemotherapeutics therefore tends to be much lower 
than possible. The possibility of taking highly cytotoxic drugs and adding a targeting moiety to increase 
their selectivity is therefore very exciting. These drugs could then be cleaved from the targeting moiety 
at the desired site of action. 
3 
1.2 First Generation ADCs 
The concept of the antibody-drug conjugate (ADC) arose from the idea of targeting highly potent toxins 
that otherwise cannot be chemotherapeutics. Antibodies are immunoglobulin proteins that bind 
strongly to specific antigens and are therefore a logical choice for a targeting protein. The first report 
of a cytotoxin conjugated to an antibody was in 1958,6 when antibodies were generated by implanting 
hamsters with mouse tumour cells. The hamsters generated antibodies against the tumour and these 
were isolated as a mixture. Methotrexate was then conjugated to these antibodies by diazotisation 
with its amine groups, and coupling these diazonium salts with nucleophilic groups on the antibodies 
(mainly tyrosine). It was shown that when these ADCs were used to treat mouse tumours, the mice 
survived for longer than when given ADCs with non-specific antibodies. Another classic example was 
in 19707 when diphtheria toxin (a protein) was conjugated to a murine antibody targeted to mumps-
virus antigens with toluene diisocyanate. After infecting monkey kidney cells with the mumps-virus, 
the cells presented mumps-virus antigens on their cell membranes. The conjugates could effectively 
target and kill the infected cells. This was followed by a flurry of activity in ADC research. 
During this period of research some ADCs were shown to be more effective on human tumour 
xenografts in mice than the free drug.8,9 Of the ADCs in early human clinical trials, none showed a 
meaningful therapeutic activity. However, the results were used to further refine aspects of ADCs. 
These clinical trials showed a high level of immunogenicity of the ADCs, eventually leading to the use 
of fully human antibodies. Three important areas for research were also highlighted: 
The antibody. Good specificity of the antibodies to antigens on the surface of tumour cells in humans 
was demonstrated by radiolabelling10 or immunohistochemical staining11 for early ADCs. This identified 
the importance of tumour localisation and tissue penetration. 
The drug payload. As drug conjugation to the antibody almost always reduced toxicity of the drug,8,9 
more toxic payloads were sought. It was thought that as the number of cancer antigens was low 
(typically < 105 per cell), a highly toxic drug (IC50 < 1 nm) would be necessary to kill the cell.  
The linker. As non-specific drug release would lead to systemic toxicity, a selective drug-release 
methodology with acid-sensitive hydrazones was demonstrated by incubation of ADCs at various pH.8 
This highlighted the importance of the linker between antibody and drug, which should be stable in 
circulation but be able to release the drug to the tumour. These three major factors are discussed here. 
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1.3 Antibodies for Cancer Treatment 
Antibodies are generated by the immune system as a response to a perceived pathogen. The regions 
of DNA that encode their binding regions have a mutation rate approximately one million times greater 
than normal DNA,12 and therefore large numbers of binding region sequences can be assayed by the 
immune system to find a strongly binding antibody. These antibodies bind strongly to the perceived 
pathogen and can then elicit a number of responses from the immune system including phagocytosis 
and endocytosis. Modern antibodies targeted to a specific purified antigen are most commonly 
generated by phage display, or by taking transgenic mice – with antibody-coding DNA replaced with 
human DNA – innoculating with the antigen of interest and then using hybridoma technology. There 
are many antibody subtypes, but the dominant type in human plasma is the IgG format monoclonal 
antibody (mAb) which is therefore the most widely studied. The format of an IgG antibody derived 
from X-ray crystal structures is shown in Figure 2. 
The first human cancer treatment with monoclonal antibodies was in 1980 when a leukaemia patient 
was treated with murine antibodies targeting AB 89.13 In the following years, the treatment of cancer 
with mAbs was further investigated, but a recurring issue in their development was immune responses 
in the patients. Attempting to circumvent these issues, regions of the murine antibody protein 
sequence were replaced with those of human antibodies, making the mAbs increasingly human-like 
and reducing immune response. 
At first, the entire constant region of the murine mAb was replaced with that of human mAb to create 
“chimeric” antibodies. As these still contained much of the murine antibody sequence, antibodies were 













Mouse Mouse Mouse Mouse 
Chimeric Mouse Mouse Human 
Humanised Mouse Human Human 
Fully Human Human Human Human 
Figure 2: Crystal structure representation of an IgG1 mAb adapted from PDB 5VH514 (Crystallisable fragment, Fc) and 
4G3Y15 (Antigen binding fragment, Fab).15. Light chains are highlighted in light blue, heavy chains in dark blue and purple, 
and glycosylation in grey. Comparison of mouse to fully human IgG antibodies. CDR: complementarity determining region.16 
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The benefits of these fully “humanised” antibodies are increased circulation time (lower metabolism 
rate), and lower immunogenicity. The availability of these technologies has led to commercial 
development of mAbs to treat cancer, a summary of which can be seen in Table 1. 
Table 1: Commercially available mAbs for the treatment of cancer, adapted from the literature.17,18 
mAb Trade name Target Type Indication(s) 
Alemtuzumab Campath CD52 
Humanised 
IgG1 
Chronic lymphocytic leukaemia 
Avelumab Bavencio PD-L1 Human IgG1 Urothelial carcinoma 
Bevacizumab Avastin VEGFR 
Humanised 
IgG1 
Colorectal, renal, lung, and brain 
cancer 




Malignant ascites in patients with 
epCAM+ cancer 
Cetuximab Erbitux EGFR Chimeric IgG1 Head/neck and colorectal cancer 




RANKL Human IgG2 
Breast cancer, prostate cancer, and 
giant cell tumours of the bone 
Durvalumab Imfinzi PD-1 Human IgG1 Urothelial carcinoma 
Ibritumomab Zevalin CD20 Murine IgG1 Non-Hodgkin lymphoma 
Ipilimumab Yervoy CTLA-4 Human IgG1 Melanoma 
Nimotuzumab Nimotuzumab EGFR Human IgGh-R3 Head/neck cancer 
Nivolumab Opdivo PD-1 Human IgG4 Melanoma 
Obinutuzumab Gazyva CD20 Human IgG1 Chronic lymphocytic leukaemia 




Human IgG1 Soft tissue sarcoma 
Panitumomab Vectibix EGFR Human IgG2 Colorectal carcinoma 
Pembrolizumab Keytruda PD-1 
Humanised 
IgG4 
Gastric or gastroesophageal junction 
adenocarcinoma 
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Table 1: Continued… 
mAb Trade name Target Type Indication(s) 




Ramucirumab Cyramza VEGFR 
Humanised 
IgG1 





CD20 Chimeric IgG1 
Chronic lymphocytic leukaemia and 
non-Hodgkin lymphoma 
Siltuximab Sylvant IL-6 Chimeric IgG1 
Castleman disease, multicentric (in 
patients who are HIV negative and 
HHV-8 negative) 
Tositumomab Bexxar CD20 Murine IgG2a Non-Hodgkin lymphoma 




gastric or gastroesophageal junction 
cancer 
1.4 Modified Antibodies and their Derivatives 
Thanks to the advances in monoclonal antibodies, the list of potential ADC targets has grown ever 
longer. There are now many chimeric and humanised antibodies in development as ADCs on their own 
or in combination with other chemotherapeutic agents, as shown in Table 2. 
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Table 2: ADCs currently on the market or in clinical development.19 
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SG3249 (PBD) DLL3 
Val-Ala-PAB carbamate 
cleavage28 















Locally advanced or 
Metastatic breast cancer 
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Table 2: Continued… 




SG1882 (PBD) CD33 Val-Ala cleavage35,36 Acute myeloid leukaemia 
Phase II 
AGS-16C3F MMAF ENPP3 
Retro-Michael and 
protease cleavage37 









CDX-014 MMAE TIM-1 
Val-Cit-PAB carbamate 
cleavage39 















































Small-cell lung cancer and 
neuroendocrine tumours 
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Table 2: Continued… 
Candidate Drug Target Release Mechanism Indication(s) 
Phase II 












SGN15 Doxorubicin Lewis Y 
Hydrazone 
hydrolysis9,51 









SG1882 (PBD) CD33 Val-Ala cleavage35,52 




However, not only the whole IgG monoclonal antibody format has been used in ADCs. It is possible to 
generate modified fragments of IgG antibodies which can retain binding (Figure 3). These can even 
offer improved properties over IgG monoclonal antibodies such as deeper tumour penetration, and 
faster maximum localisation at the tumour site (0.5 h for scFv vs 48-96 h for IgG).53 However some of 
these smaller format antibodies suffer from an increased clearance rate as they can be excreted via 
the kidney due to their smaller size.54 For example an anti-CD30 diabody-auristatin conjugate was 
shown to be cleared 25-34 times faster than its corresponding IgG-auristatin conjugate.55 The Fc region 
plays a critical role in determining the long half-life of IgG antibodies, and therefore antibody 
derivatives with a modified or removed Fc region can have shortened half-lives.56 
11 
 
Figure 3: An overview of the most common antibody fragment and derivative types, adapted from the literature.57 Light 
chains are highlighted in light blue, heavy chains in dark blue and purple. 
Antibody fragments and their derivatives have been approved for the treatment of human disease by 
the FDA (Table 3). The choice of antibody for a particular ADC therapy is not just reliant on a strong 
binding affinity, and other important factors will be discussed here. 
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Table 3: Commercially available antibody fragment based therapeutics.58,59 
Antibody Trade 
name 
Target Type Indication(s) 
Abatacept Orencia CD80/CD86 CTLA4-Fc fusion Rheumatoid arthritis 
Abciximab ReoPro GPIIb/IIIa Chimeric Fab 






VEGFA VEGF-R-Fc fusion 
Wet age-related macular 
degeneration, colorectal cancer 










Belatacept Nuloji® CD80/CD86 CTLA-4 Fc fusion Organ transplant rejection 
Blinatumomab Blincyto CD19/CD3 
Bispecific 
diabody 






Moderate to severe Crohn’s 
disease 
Dulaglutide Trulicity GLP1R GLP-1-Fc fusion Type 2 diabetes 




Factor IX Fc 
fusion 
Haemophilia B 




Idarucizumab Praxbind Dabigatran Humanized Fab Anticoagulant 
Ranibizumab Lucentis VEGF-A Humanised Fab 
















1.5 Internalisation and Metabolism 
An important factor in ADCs is the efficiency of internalisation. Depending on the antibody and antigen, 
ADCs can be internalised to varying degrees. This is most often thought to happen by receptor 
mediated clathrin-dependent endocytosis into acidic lysosomes where degradation can occur as ADCs 
have been shown to collect in lysosomes of tumours.20,22 However this has been challenged as some 
internalisation can occur into caveolae.60 In another case, internalisation was mediated by actin-
polymerisation, and the receptor subsequently degraded by ubiquitination.61  
For many of the ADCs in development, it is thought that drug release upon internalisation is a pre-
requisite for selective drug delivery and low off-target toxicity. Therefore, antibodies with efficient 
internalisation are sought. The factors determining the efficiency of this internalisation are not always 
clear but in the case of a series of anti-HER2 antibodies, more strongly binding antibodies were found 
to be more efficiently internalised.62 In the same study, it was also found that the highest affinity 
antibodies (0.56 nM) did not penetrate deeply into the tumour whereas those of lowest affinity (270 
nm) penetrated the deepest, and that moderate affinity (23 nM) antibodies had the greatest 
accumulation at the tumour site overall. 
Internalisation does not always mean degradation, as internalised antibodies can be removed from 
the cell by a process of FcRn mediated recycling.56 The FcRn protein is membrane bound, and can 
strongly bind the Fc region of an antibody at pH < 6.5, but not at pH 7.4.63,64 It can therefore mediate 
the transport of antibodies from acidic lysosomes to the exterior of the cell. Large quantities of 
proteins in serum are non-specifically internalised by endothelial cells65 and FcRn recycling can ensure 
that ADCs do not extensively release their drugs off-target. FcRn recycling can therefore extend the 
half-life of an ADC. Engineering the Fc region of antibodies to increase binding affinity with FcRn at 
acidic pH has been successfully employed to increase antibody half-life by 4x in vivo.66 
1.6 Tumour Penetration of ADCs 
In order to effectively treat a whole solid tumour, an ADC would have diffuse deep into the tumour. 
For this to be effective, the ADC has to have efficient extravasation from the blood stream. Fluid 
pressure in healthy tissue is lower than that of the blood stream, aiding the transport of fluid from 
blood to tissue which is then directed to the lymph system. In tumours, the abnormal vasculature leads 
to leaky blood vessels and heterogeneous flow,67 ultimately meaning a higher pressure in tumours 
than the blood stream.68 This means that extravasation into tumours is compromised. Not only that, 
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but diffusion of drugs or ADCs is also limited by an abnormally dense extracellular matrix of 
proteoglycans and fibrous proteins such as collagens, fibronectins and laminins.69 Greater particle size 
correlates with poorer diffusion through tumours.70 It is for this reason that smaller antibody 
fragments are favoured for applications where rapid tumour penetration is crucial, such as imaging.71 
Antibody-cytokine conjugates also frequently employ antibody fragments lacking the Fc region as this 
limits exposure of Fc receptor bearing cells (such as immune cells) to cytokines.57 
1.7 Drug Payloads 
Another major area of importance in ADCs is the drug for conjugation. An antigen on a cancer cell is 
considered highly expressed when the copy number of the targeted antigen is > 105 per cell.16 The 
number of drug molecules that can be delivered to a cancer cell is limited by the number of receptors 
on its surface. Therefore the drug has to be highly toxic to ensure cell death. In reality, not all antigens 
will bind ADC and not all binding events will result in drug delivery. However, receptors may be recycled 
to the cell surface after internalisation and allow further drug to be delivered. Upon cell death, the 
drug may also be released and go on to kill the surrounding cells which is known as the bystander 
effect.20 
Of the disclosed drugs used as payloads in modern ADCs, most are of at least nanomolar IC50 potency. 
A selection of payloads most commonly used in ADCs can be seen in Table 4. These more successful 
ADCs frequently share common characteristics in their drugs: at least nanomolar IC50 and functional 
groups and physicochemical properties that make them amenable to protein modification. In the case 
of monomethylauristatin F (MMAF), it is thought that its intracellular toxicity is much higher than its 
IC50 in standard cellular assays. This is because it bears a carboxylic acid group, and the negative charge 
inhibits membrane permeation and therefore access to its intracellular target tubulin. When this acid 
is protected as the methyl ester (MMAF-OMe, 1), the toxicity is increased more than 105 times.24 This 




Table 4: Examples of drug payloads commonly used in clinical ADCs. 










1.10 72 Variousa 




0.205 72 Variousa 




0.825 24 Variousa 




170 24 Variousa 
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Table 4: Continued… 












0.3 74 Variousa 





0.01 75 L1210 










77 77 Variousa 
a) This value is the mean of various cell lines assayed. b) The free acid causes poor cell penetration, but if the acid is 
protected as the methyl ester: MMAF-OMe 1 IC50 < 0.001 nm (Karpas cells).24 c) In cases where the exact drug is 
undisclosed, or the drug has no literature known IC50, a closely related analogue has been given. 
1.8 Linkers 
ADC linkers are thought to play a pivotal role in drug release and have therefore been the focus of 
much attention. Of utmost importance are the sites of conjugation,78 drug-to-antibody ratio (DAR),79 
and the choice of drug release mechanism. For ADCs, the convention is that a “cleavable” linker has a 
designed cleavage mechanism (e.g. enzymatic cleavage, acid hydrolysis or disulfide reduction) whereas 
a “non-cleavable” linker is designed to be more stable to digestion than the antibody. Typically, ADCs 
are thought to be internalised and trafficked into lysosomes to undergo metabolism. 
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1.9 Site-Selective Conjugation 
When conjugating drugs to antibodies, the functional groups used for conjugation are highly 
important. The local protein environment at the site of conjugation is also highly important as it can 
intimately affect the stability of the conjugate. For maleimide-thiol conjugates it has been shown that 
highly solvent accessible sites of conjugation lead to increased maleimide-exchange with endogenous 
thiols – e.g. glutathione (GSH) or albumin – and that these processes are slower for less solvent-
accessible conjugation sites. In the same study, it was shown that an overall positive charge in a less 
solvent accessible conjugation site can lead to further increased stability, as it promotes succinimide 
hydrolysis after maleimide conjugation.78 Therefore if a cysteine is engineered into an antibody to 
facilitate site-specific conjugation, the stability of the resulting conjugates must be extensively studied 
with respect to the choice of conjugation site.80,81 Hydrolysed succinimides are much less capable of 
thiol-exchange, which has been used to generate self-hydrolysing succinimides to further increase 
stability.82–84 
Selectivity of conjugation is important for many reasons, for example: reproducibility of conjugation, 
site of conjugation and number of conjugated drugs. Early ADCs largely utilised lysine labelling 
strategies to introduce their drugs. For example, in the development of anti-A7 ADCs N-hydroxy 
succinimidyl esters were used to label anti-A7 antibodies and introduce a maleimide functionality.85 
However as lysine is such an abundant amino acid this leads to non-specific labelling across the 
antibody. Only with careful control of reaction conditions is the DAR kept reasonably constant – in this 
case DAR = 1-6. Each of these different antibodies in the mixture will have different properties, making 
studying their effects less reproducible and more complex. This chemistry would later be used in the 
development of trastuzumab emtansine – now on the market for the treatment of HER2+ breast 
cancer – with a mean DAR of 3.5. A similarly modified ADC, huN901–DM1, was studied by mass 
spectrometry in combination with protease cleavage to identify modification sites. Despite having a 
mean DAR between 3 and 4, the studies revealed DAR ranging from 1 to 6, with 40 out of 86 lysines 
potentially being modified.86 Remarkably, no modification was detected in the binding regions, and 
modifications were generally in flexible, solvent accessible regions. Succinimidyl esters have also been 
shown to react with cysteine and tyrosine to form unstable thioesters and esters which degrade even 
at neutral pH.87 
Later ADCs were made by reducing interchain disulfides (in this case with dithiothreitol, DTT) and then 
alkylating the liberated cysteines with maleimide-linker-drug constructs.88 The issue with this 
technique is that there are potentially too many reactive cysteines, and not all should be alkylated. 
This is because reducing all these reactive interchain disulfides and alkylating them leads to a DAR of 
1. Antibody-Drug Conjugates for Cancer Therapy 
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8. While this leads to higher in vitro potency of the ADCs (due to more drugs being delivered per ADC), 
the greatly increased hydrophobicity of the ADC can lead to increased aggregation or plasma clearance 
and therefore lower potency in vivo.79 However this effect has been shown to be alleviated when using 
highly hydrophilic linkers, leading to high in vivo potency ADCs with DAR of 8.89 While the interchain 
disulfides are more prone to reduction/alkylation, this chemistry is still not highly specific, and these 
ADCs require a challenging purification by hydrophobic interaction chromatography.90 A further 
possibility is mutating some native cysteines to serines, thereby reducing the number of possible sites 
for conjugation to cysteine.91 Another method using mutagenesis is to insert cysteines into the 
antibody in particularly solvent accessible or reactive sites, thereby allowing selective 
reduction/alkylation of these cysteines.78,92 In order to affect the folding of the antibody as little as 
possible, it is clearly favourable to leave structural intrachain and interchain disulfides intact (Figure 
4). 
 
Figure 4: Different methods of antibody conjugation and their distributions of payload. 
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1.10 Mechanisms of Drug Release 
A striking feature of ADCs is the lack of diversity in their mechanisms of drug release, as all those that 
have progressed beyond Phase I clinical trials rely on degradation by acid, proteases or reduction. 
Common structural motifs and release mechanisms for ADCs which have made it to clinical trials are 
discussed here. 
AMIDES: KS1/4-MTX is the drug methotrexate conjugated to murine antibody KS1/4 via an amide and 
was evaluated in a Phase I trial,11 and again in Phase I at higher doses.93 Although the mechanisms of 
drug release were never studied, a logical step would be amide cleavage catalysed by proteases. There 
was little therapeutic benefit observed from the ADC, and the majority of patients developed anti-ADC 
antibodies. More recently, trastuzumab emtansine has been released to the market and amide 
cleavage has been shown to be responsible for the majority of its drug delivery as Lysine-SMCC-DM1 
(2).22 Vadastuximab talirine bears a Val-Ala motif with an amide bond to an aniline nitrogen.35,36 There 
are many proteases in cells, and the specific nature of an amide bond can greatly affect the specificity 
for a given protease and the rate of cleavage. By optimising the cleavage rate and specificity of peptidic 
linkers on ADCs it has been shown that in vivo efficacy can be improved.94 This was achieved by 
screening many different peptidic linkers including non-proteinogenic amino acids. Denintuzumab 
mafodotin and depatuxizumab mafodotin have achieved Phase II clinical trials with the same linker 
(maleimido caprolyl, mc) and payload (MMAF) but different antibodies. When ADCs with isotopically 
labelled drugs were studied, the only MMAF containing compound that could be detected had resulted 
from protease cleavage of the antibody – producing Cys-mc-MMAF (3).24 The toxicity of this compound 
was not tested, but the charged ammonium of MMAE and MMAF is a key interaction in the binding 
mode their target tubulin (salt bridge with Asp179). As ionic interactions tend to be very strong it is 
likely that the toxicity of Cys-mc-MMAF (3) is much less than that of the parent drug.95,96 AGS-16C3F 
bears the same linker and payload as denintuzumab mafodotin and depatuxizumab mafodotin and is 
likely to follow the same drug release mechanism although it has not been studied.37 
HYDRAZONES: Hydrazones are more stable to hydrolysis than their corresponding Schiff bases, and 
were used to conjugate desacetylvinblastine hydrazide (DAVLB) to KS1/4 murine antibodies to give 
KS1/4-DAVLB. The sugars on the mAb were first oxidised with NaIO4 (which causes cleavage of 1,2 diols 
to aldehydes) then condensed with desacetylvinblastine hydrazide.8 These ADCs were tested in vivo 
against a human tumour xenograft in mice,97 and a Phase I clinical study for immune response.98 The 
hydrolysis of hydrazones is slow at neutral pH, but is thought to be highly efficient in the acidic 
environment of lysosomes. However, no therapeutic benefit could be shown in clinical trials, and the 
majority of patients developed immune responses. Two marketed ADCs, gemtuzumab ozogamicin and 
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inotuzumab ozogamicin, both bear hydrazones as well as disulfides in their linkers. The hydrazone is 
shown to be stable at neutral pH and efficiently hydrolysed in acid.21 However disulfide reduction has 
been shown to be key to toxicity of the calicheamicin payloads99 but the competing rates of hydrazone 
hydrolysis and disulfide reduction in cancer cells were not studied. ADCs hLL1-Dox44,45 and SGN159,51 
also bear the payload doxorubicin (Dox) via a hydrazone linker and have achieved Phase II clinical trials. 
ESTERS: In KS1/4-DAVLB, desacetylvinblastine was conjugated to KS1/4 murine antibody via a short 
succinic ester linker. This was tested in a Phase I clinical trial for drug efficacy against 
adenocarcinoma,10 and a Phase I trial of immune responses.98 While mechanisms of drug release were 
not studied, a logical step would be ester hydrolysis catalysed by esterases analogous to that of KS1/4-
MTX. 
DISULFIDES: Disulfides are one of the best studied linkers and are a common linker in ADCs. Reduction 
of the disulfide is the obvious mechanism of drug release, but this can occur both intra- and 
extracellularly. To investigate the relative rates of drug release, several analogous disulfide-linked 
ADCs were synthesised with varying steric constraints about the disulfide (from RCH2SSCH2R to 
RC(Me)2SSC(Me)2R). Their relative rates of reduction when exposed to DTT were then tested. While 
IC50 in vitro cell killing stayed similar for all conjugates, the RCH2SSCH2R linked ADC showed cleavage 
rates 22000 faster than that of RC(Me)2SSC(Me)2R. In vivo, this corresponded to a half-life of 15 h vs 
218 h respectively. This was greater than the corresponding succinimidyl thioether conjugate, which 
had a half-life of 134 h.100 Perhaps counterintuitively, the conjugates with the greatest therapeutic 
effect in vivo were not the most or least stable, but those of moderate stability. In another study, a 
small immune protein (SIP) format disulfide linked ADC was compared to the analogous IgG ADC. The 
SIP format was found to release drug much faster than the IgG (half-life 3 h and > 48 h respectively), 
and this was attributed to the close proximity of linking cysteines in the SIP format. This could be 
because the two linking cysteines in SIP format are capable of forming an intramolecular disulfide after 
drug cleavage.101 This effect is similar to DTT being a stronger reducing agent than 2-mercaptoethanol, 
as DTT is capable of forming intramolecular disulfides.102 
In another study, tritium labelled maytansinoids were conjugated to antibodies via N-succinimidyl 4-
(pyridin-2-yldisulfanyl)butanoate (SPDB) linkers and these ADCs were used to treat mice in a tumour 
xenograft model. The mouse livers and tumours were then excised, and the metabolites characterised 
by LC-MS with radioactivity detection.22 The most major intracellular metabolite for the disulfide-
linked ADC was S-methyl-DM4 (4) which had an IC50 2 pM against assayed cell lines, followed by a 
minor Lysine-SPDB-DM4 (5) at early time points which was then quickly degraded. This suggests that 
both amide cleavage and disulfide reduction play a fundamental role in drug release (Scheme 1). When 
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a lysosome formation inhibitor was added, the formation of these metabolites was massively reduced. 
The limitation of this study however is that only radioactive metabolites could be detected, and also 
only those detectable using their LC-MS parameters. Lorvotuzumab mertansine (Phase II),47 
coltuximab ravtansine (Phase II) and anetumab ravtansine (Phase II)38 all also bear SPDB linkers. 
Mertansine employs the drug DM4 which has a gem-dimethyl adjacent to its thiol and ravtansine 
employs DM1 which has no methyl groups. Therefore mertansine is expected to reduce more slowly 
than ravtansine due to increased steric shielding of the disulfide. Mirvetuximab soravtansine (Phase 
III)26 bears DM4 with a sulfo-SPDB linker which is modified with a sulfonate group to increase water 
solubility. Gemtuzumab ozogamicin and inotuzumab ozogamicin contain a hydrazone and a disulfide 
in their linkers. The hydrazone is predicted to cleave first21 however disulfide reduction is still necessary 
for the calicheamicin to exert toxicity.99 
 
Scheme 1: Lysosomal degradation pathway of disulfide-linked ADCs and structure of different disulfide linkers. Lysines are 
typically modified via the free ε amine but can be modified at the α amine of an N-terminal lysine. 
SUCCINIMIDYL THIOETHERS: This is by far the most popular means of conjugating drugs to antibodies, 
as the reaction of a thiol with maleimide is incredibly fast, and is used in the production of two ADCs 
currently on the market: trastuzumab emtansine and brentuximab vedotin. These linkers are 
ubiquitous in ADCs despite the fact they have been shown to slowly undergo thiol exchange.78,103 In a 
study of one succinimidyl thioether linked maytansinoid ADC, it was found that lysosomal processing 
was necessary for release of the drug. A tritium labelled maytansinoid was conjugated to an antibody 
via an N-succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) linker – the same 
used in trastuzumab emtansine – and the metabolites from a mouse tumour xenograft monitored by 
LC-MS with radioactivity detection. The only significant metabolite detected was Lysine-SMCC-DM1 
(2), which suggests the drug is mainly released by amide cleavage (Scheme 2). Lysine-SMCC-DM1 (2) 
this was found to have an IC50 of only 0.1 μM against the assayed cell lines, but the ADC still had high 
efficacy against tumour cells. It was hypothesised that Lysine-SMCC-DM1 (2) simply had poor cell 
penetration in the IC50 assay, but once released intracellularly could be highly potent.22 Again, the 
1. Antibody-Drug Conjugates for Cancer Therapy 
22 
limitation of this study is that only radioactive metabolites could be detected, and only those 
detectable using their LC-MS parameters. 
 
Scheme 2: Lysosomal degradation of SMCC-linked ADCs. Lysines are typically modified via the free ε amine but can be 
modified at the α amine of an N-terminal lysine. 
SELF-IMMOLATING PAB: This particular motif has seen success in now marketed brentuximab vedotin, 
which has a valine-citrulline-p-aminobenzyl (Val-Cit-PAB) linker which can undergo 1,6-immolation 
after the Val-Cit linker is cleaved by proteases (e.g. Cathepsin B). When brentuximab vedotin with 14C 
labelled MMAE was used to treat tumour cells in vitro, the only detectable species by LC-MS with 
radioactivity detection was MMAE, showing efficient amide cleavage and 1,6-immolation leading to 
effective drug release (Scheme 3). As well as potent cell killing, these ADCs showed efficient bystander 
killing in co-cultures of cancer and healthy cells as MMAE can freely diffuse out of cells or is still active 
after release from dead cells.20 This study is also limited as non-radioactive metabolites of MMAE 
cannot be detected. The study demonstrates the benefit of having linkers which can release a whole 
drug intact, as opposed to those which release drug-derivatives which may have attenuated toxicity as 
previously discussed for mc-, SMCC- and SPDB-linked ADCs. 
 
Scheme 3: Lysosomal degradation of a Val-Cit-PAB self-immolating linker. 
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SELF IMMOLATION FOR RELEASE OF O-LINKED DRUGS 
Most drug release methodologies from ADCs have focused on the release of amine- and sulfur- linked 
drugs. However many potent drugs do not have these functional groups or they are not amenable to 
conjugation. Strategies have been developed for the release of hydroxyl-containing drugs that have 
been applied in DS-8201a40,41 for Phase II and SYD98532,33 for Phase III clinical trials. In the case of DS-
8201a, protease cleavage is used to release an aminomethyl ether which can then spontaneously 
undergo imine formation and hydroxyl release (Scheme 4). This mechanism is similar to that employed 
for rapid DNA sequencing with the Staudinger reduction.104,105 
 
Scheme 4: Degradation pathway of DS-8201a by protease cleavage. 
In the case of SYD985, the common amide cleavage followed by PAB elimination is used to release a 
reactive amine. The reactive amine is then free to act as a nucleophile and attack into the carbonyl of 
a proximal carbamate. This cyclisation causes the release of hydroxyl bearing drug seco-DUBA (Scheme 
5). 
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Scheme 5: Protease-triggered drug release mechanism of Phase III ADC SYD985. 
NON-INTERNALISING ADC MECHANISMS OF DRUG RELEASE 
The vast majority of ADCs in clinical trials have focused on using linkers that should selectively cleave 
after internalisation into cancer cells. Clear outliers in this trend are sacituzumab govitecan (Phase III) 
and labetuzumab govitecan (Phase II). These are based on the concept that a “moderately stable” 
linker should be able to release its payload after conventional internalisation and degradation but also 
after degradation by the lower concentration of extracellular proteases.29,31 Sacituzumab govitecan 
has shown promising results in a Phase II clinical trial50 and has been advanced to Phase III. The linkers 
of sacituzumab govitecan and labetuzumab govitecan employ a peptide cleavage site and PAB self-
immolation followed by decarboxylation of a carbonate for release of campothecin drug SN-38. 
Moderate stability of the linker is attributed to the carbonate linkage being less hydrolytically stable 
than amides or carbamates. The success of these ADCs highlight the fact that non-internalising ADCs 
may be a path towards the successful treatment of solid tumours. 
Most ADCs in clinical trials contain a peptide drug-release trigger which has been designed to be 
efficiently cleaved by proteases inside cancer cells. For example the most popular would be the Val-
Cit-PAB linker of marketed brentuximab vedotin. The Val-Cit dipeptide was designed to be cleaved by 
Cathepsin B as this protease is often upregulated in cancers. However, when Cathepsin B expression 
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was knocked-down in cancer cells, no decrease in toxicity of a Val-Cit-PAB-MMAE ADC was observed.106 
In fact, it was shown that other proteases could also cleave the linker in various places leading to 
products which could still exert toxicity. 
As cleavage by specific proteases was shown to be unnecessary for efficacious ADCs, it also begs the 
question whether or not internalisation is necessary. The clinical successes of sacituzumab govitecan 
and labetuzumab govitecan have increased efforts to study non-internalising ADCs based on the fact 
that sacituzumab is slowly internalised.107,108 However work was already underway in this field.109 For 
example, extracellular matrix proteins such as fibronectin110 and tenascin-C111 were already being 
targeted with a view to developing cancer treatments. Later, antibody fragments targeting aberrantly 
spliced fibronectin in tumours would be targeted by ADCs of antibody fragments bearing a disulfide 
linker to a thiol-modified cemadotin.112 This was demonstrated to be effective in shrinking solid tumour 
xenografts in mice. The stability of the disulfide linker was shown to be crucial in determining 
therapeutic efficacy, with the most stable disulfides giving the greatest therapeutic benefit.113  
These ADCs were later adapted to contain various drug payloads, including a carbamate- and 
carbonate-linked duocarmycin as well as maytansinoid DM1.114 The carbonate-linked duocarmycin 
outperformed the carbamate, likely due to a lower linker stability enabling greater drug release in the 
tumour microenvironment. However, DM1 was predicted to form the greatest stability conjugates and 
yet this resulted in curing of solid tumours in mice. This is attributed to the fact that the cancer cell line 
assayed is highly sensitive to DM1. It could also be due to the fact that DM1 is much more potent than 
duocarymicin. So despite a lower dose of DM1 delivered to the tumour than duocarmycin, it can cause 
more cell killing. 
A disulfide linker to a DM1 payload was later used to compare the efficacy of antibody-fragment SIP 
ADC with the same linker and payload on an IgG ADC.101 It was found that the IgG ADC was the most 
stable but also the least efficacious at treating solid tumour xenografts in mice. This may be because 
SIP format ADCs are smaller and therefore better able to penetrate solid tumours allowing greater 
doses of released drug. Extracellular matrix protein tenascin-C has also been developed as a target for 
cancer treatment111 including ADCs. Conjugating anti-tenascin-C IgG antibody F16 to a doxorubicin 
derivative via a protease-cleavable Val-Cit-PAB linker led to reasonably efficient solid tumour shrinkage 
in mouse xenograft models.115 The drug was then exchanged for MMAE or MMAF. The F16-MMAE 
ADC led to efficient tumour shrinkage while F16-MMAF ADC had no effect whatsoever. This supports 
a hypothesis of extracellular drug cleavage as MMAF is not cell penetrant due to its free carboxylate 
group, whereas MMAE is highly cell penetrant.  
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Bizarrely, when the F16-MMAE IgG ADC was compared to its SIP format analogue, the IgG ADC 
performed much better in solid tumour mouse xenografts. This is in stark contrast to earlier studies in 
which the disulfide-linked anti-fibronectin-DM1 SIP ADC had performed much better than its IgG 
analogue.101 This is likely due to the fact that in both cases the IgG is more stable and the time required 
for drug delivery. In the case of anti-fibronectin-DM1 SIP ADC, the greatest tumour shrinkage was 
achieved after ~10 days, whereas for the F16-MMAE IgG ADC this required ~30 days. Reduction of 
unhindered disulfides has been shown to be a faster process than protease cleavage.22 Therefore the 
disulfide-linked DM1-SIP ADC has time to quickly release its payload before the ADC is removed from 
circulation. The disulfide-linked DM1 IgG ADC would not be able to penetrate the tumours enough to 
release a significant amount of payload within the same time period as the SIP ADC. The MMAE-IgG 
ADC has its payload released by the slower process of protease cleavage, which means that the SIP 
format ADC is not stable within the mouse for long enough to deliver a significant amount of drug to 
the tumour. The MMAE-IgG ADC can circulate for a long time and slowly release drug to the tumour. 
This hypothesis is supported by studies into different peptide linkers in the F16-MMAE IgG ADC which 
showed that the specific nature of the peptide can influence the efficacy of the ADC in tumour 
xenografts.116 
1.11 Conclusion 
ADCs have achieved great pre-clinical and clinical success, but still have far to go before becoming the 
“magic bullet” as dreamed of by Paul Ehrlich.117 In fact, while ADCs appear to offer improvements over 
existing therapies, the increase in survival seems surprisingly low for a “targeted therapy” (Table 5). 




Table 5: Summary of clinical results that led to ADCs becoming FDA approved. 
 Measure ADC Standard treatment 
Gemtuzumab 
ozogamicin118 
Event free survival 17.3 months 9.5 months 
Trastuzumab 
emtansine119 









35.8% of patients for 8 
months 
17.4% of patients for 
4.9 months 
In order to give ADCs the greatest possible chance of improving cancer patients’ lives, the largest 
possible diversity of targets, linkers and drugs should be trialled. The most neglected set of targets 
seems to be extracellular antigens to give non-internalising ADCs. No extracellular antigen-targeting 
ADCs have made it thus far to Phase II clinical trials and therefore this appears an important area to 
focus research. Most ADC linkers have been designed with an internalisation/lysosomal degradation 
pathway to drug release, so non-internalising ADCs will require new and further optimised linker 
systems. 
To study the roles extracellular-drug release can play in cancer treatment, the field will require 
chemical biology tools in order to: 
 Explore the efficacy of drugs when released into the intercellular space 
 Develop novel mechanisms of drug release from ADCs 
Therefore in the next chapter, bioorthogonal approaches to the release (decaging) of small molecules 
and proteins to study and modulate biological systems will be discussed, with a view to developing 











Bioorthogonal Decaging for Chemical Biology 
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2.1 Key Elements of Bioorthogonal Decaging Reactions 
The objective of bioorthogonal chemistry is to develop reactions which can occur in living systems 
without affecting any endogenous processes. In reality this is an ideal which is likely unachievable. 
However, many bioorthogonal reactions have been developed which affect the chosen biological 
system so little, that they allow the study of key processes in previously inconceivable ways. The 
criteria for a bioorthogonal reaction can be diverse and depend on the exact system that is to be 
studied. For example, bioorthogonal reactions can be used to study proteins simply in vitro, to more 
complex systems in vivo. Clearly, proteins in vitro constitute the least complex system and the 
requirements of the reactions are therefore less demanding. This chapter will primarily focus on 
bioorthogonal reactions developed for use in mammalian cells or even in vivo. In these cases, the pre-
requisites for a useful reaction are: 
 Rapid rate constants. Typically, biological processes of interest occur on timescales in the 
order of seconds to days, between room temperature and 37 °C and at relatively low 
concentration (pM to µM). Reactions that study these processes therefore cannot rely on high 
temperatures or high concentrations to increase their rates and must have high rate constants. 
 Low toxicity. Another key factor of the reagents in bioorthogonal reactions is that they be 
minimally toxic. If the reagents are too toxic, they will affect the organism of study so much 
that they may mask the processes which they were designed to study. 
 Excellent selectivity. If the reagents in bioorthogonal reactions cross-react with chemical 
functionalities endogenous to the organism of study, it will cause a hindrance to their reactivity 
and may alter the usual functions of the organism. Therefore the reagents involved in the 
reaction must be highly selective. 
 Synthetic tractability. The utility of bioorthogonal reagents can be limited by the ease with 
which they can be synthesised. When the synthesis of the reagents is long, complex, expensive 
and possesses limited functional group tolerance, the number of applications of these 
reagents is restricted. 
The vast majority of bioorthogonal reactions have focused on ligation – bond forming reactions 
between two molecules-of-interest. However, recently interest has been growing in the field of 
bioorthogonal decaging reactions – bond cleavage reactions that liberate molecules-of-interest for 
gain-of-function studies or drug delivery. 
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2.2 Light Mediated Decaging 
The most widely used bioorthogonal bond cleavage reaction in chemical biology is UV mediated 
decaging.122 It has been used extensively in the study of protein123 and small molecule124 function in 
biology and has even seen use in vivo.125,126 The premise of light mediated decaging is that a protecting 
group on a molecule-of-interest can absorb energy from photons, and its excited state undergoes a 
series of reactions that cause decomposition. The newly released molecule-of-interest can then 
perform its function. The most common photoremovable protecting groups are derived from o-
nitrobenzyl protection of an anionic leaving group (Scheme 6). 
 
Scheme 6: Mechanism of decaging of o-nitrobenzyl caging groups. 
The mechanism of this reaction requires the absorption of light, and in the excited state the nitro group 
behaves as a base, abstracting one proton from the neighbouring benzyl methylene.127 Subsequently, 
the nitro group behaves as a nucleophile and the molecule undergoes an intramolecular 1,8-conjugate 
addition. The cyclised intermediate can then decompose to give nitroso and hydroxyl groups. The 
newly liberated hydroxyl can push electron density onto its methylene to form an aldehyde and release 
an anionic leaving group. The nature of the leaving group covers a broad pKa range – from carboxylic 
acids and carbonates to aliphatic alcohols. A range of photoremovable protecting groups have been 
used in the activation of small molecules for diverse applications (Table 6). 
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Table 6: A selection of reactions used in the photorelease of small molecules. 
Reaction Wavelength Application 
 
~365 nm 












Peptide decaging in 
mammalian cells131 
Plant hormone decaging in 
wheat132 
Retinoic acid decaging in 
Zebrafish125 








Fluorophore decaging in 
mammalian cells134 
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Table 6: Continued… 
Reaction Wavelength Application 
 
~690 nm 




Z-CA4 decaging in mammalian 
cells136 
The majority of light mediated decaging reactions use high-energy UV light (350-365 nm) with powerful 
lamps which has problems of poor tissue penetration and cytotoxicity.136,137 Using lower energy, longer 
wavelengths of light would offer a solution to this problem. Near-IR cleavable protecting groups for 
alcohols have been developed with larger chromophores that have lower energy transitions. For 
example, a cyanine dye was adapted with a linker which would oxidatively decompose and self-
immolate to release an alcohol-bearing fluorophore or drug (Scheme 7).135  
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Scheme 7: Release mechanism of a near-IR activated protecting group. 
In another example, a silicon phthalocyanine was adapted to contain the alcohol-bearing drug Z-
CA4.136 When irradiated with near-IR light, the complex reaches an excited singlet state, which then 
undergoes intersystem crossing to a triplet state. In the presence of reducing agents – such as GSH – 
the triplet is reduced to a radical anion which can release an alcohol.  
While near-IR has the benefits of greater tissue penetration and lower toxicity, UV photoremovable 
protecting groups have seen more widespread use in more demanding applications such as genetically-
encoded amino acids. This may be because UV removable protecting groups can be smaller and 
therefore more easily incorporated as unnatural amino acids. Smaller protecting groups also have less 
of an effect on the native structure and properties of the molecule-of-interest, which may lead to 
preferable characteristics such as greater stability or solubility. This has allowed precise probing of the 
functions of single amino acids in proteins (Table 7). 
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Table 7: Examples of photocaged amino acids successfully genetically incorporated into proteins and 
their applications. 
Amino acid Transformation Applications 
Cysteine 
 
Enzyme activation in 
vitro138 
Enzyme activation in 
bacteria139,140 










Enzyme activation in 
mammalian cells143 








Protein activation in 
yeast146 
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Table 7: Continued… 
Amino acid Transformation Application 
Lysine 
 




Kinase activation in 
mammalian cells148 
2.3 Organic Small Molecule Mediated Decaging 
While genetically-encoded UV photoremovable protecting groups have allowed incredible insights into 
cell biology, they are not capable of progressing to in vivo use due to the poor tissue penetration of UV 
light. Genetically-encoded near-IR or IR photoremovable protecting groups could possibly solve this 
problem. However, the large size of the groups hinder the design of the necessary tRNA synthetase 
enzymes which are necessary for successful genetic encoding of non-canonical amino acids. This 
reason combined with the toxicity of UV light, as well as difficulty in reproducing exact conditions for 
UV decaging have led research to focus on bioorthogonal reactions of small-molecules. These should 
allow the release of molecules-of-interest after reaction with a small organic or inorganic reagent. Such 
reactions with organic molecules have seen tremendous progress in chemical biology and have even 
been used in vivo (Table 8). 
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Table 8: Examples of bioorthogonal decaging reactions with small organic molecules that have been 







ADC drug release153 












Some the most promising reagents in small organic molecule mediated decaging are trans-
cyclooctenes. Their highly strained structures lead to some interesting and rapid chemistry that has 
been applied to the release of drugs and fluorophores in mammalian cells and in vivo. For example, 
trans-cyclooctene derivatives were used in the release of a caged doxorubicin prodrug. First, a 1,3-
dipolar addition reaction with an azide leads to the formation of an unstable triazoline which 
decomposes to give an imine (Scheme 8). The unstable imine is then hydrolysed to release a self-
immolating p-aminobenzyl linker. This reaction demonstrated a second-order rate constant of 0.027 
M-1 s-1 in 1:1 MeCN:PBS which is of a similar order to slower bioorthogonal ligation reactions such as 
the Staudinger ligation.163 
 
Scheme 8: Trans-cyclooctene mediated decaging of an azide-containing carbamate. 
In another example, when amines were protected as carbamates of trans-cyclooct-2-ene-1-ol (TCO-
OH) they could be decaged after an inverse-electron Diels-Alder reaction with tetrazines (Scheme 9). 
First a [4+2] cycloaddtion occurs rapidly with a second order rate constant of 57.7 ± 5.0 M-1 s-1 in MeCN. 
Then a tautomerisation allows a 1,4-elimation, decarboxylation and release of an amine.150,164 This 
reaction has allowed the delivery of TCO-OH caged prodrugs,150 decaging of a TCO-OH caged lysine 
residue on a protein in mammalian cells152 and even the development of a TCO-OH derived linker for 
an ADC targeting tumours in mice.153 
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Scheme 9: Tetrazine mediated decaging of a TCO-OH carbamate-caged amine. 
This reaction represents the fastest reported bioorthogonal decaging reaction. When compared 
directly to photorelease of caged lysines in cells, optimised tetrazine derivatives led to greater 
conversion to the decaged free lysine of TCO-OH carbamates.165  
2.4 Metal Mediated Decaging 
While some organic decaging reactions are fast and highly applicable to living cells and mice, they have 
been used less frequently than metal mediated bioorthogonal decaging reactions. Metal complexes 
have proven to be versatile in the release of fluorophores and drugs in mammalian cells, on proteins 
and even in vivo (Table 9). 
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Table 9: Examples of bioorthogonal decaging reactions with metal complexes that have been applied 
in mammalian cells or higher organisms. 
Reaction Applications 
 




Propargyl ether fluorophore activation in 
mammalian cells173–175 and Zebrafish176 
Propargyl carbonate fluorophore activation in 
mammalian cells177 
Propargyl carbamate fluorophore activation 
in mammalian cells171,178,179 
Propargyl carbamate decaging for protein 
activation in mammalian cells180 
Sugar release on mammalian cell surface181 
Propargyl carbamate decaging of prodrugs in 
vivo182 
 
Fluorophore and prodrug activation in 
Zebrafish183 
 
Tyrosine activation on proteins in mammalian 
cells184 
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The most successful of these reactions (having been successfully implemented in mice182) is palladium 
mediated decaging of carbamates (Scheme 10). Both propargyl and allyl carbamate decaging are 
mechanistically related to the Tsuji-Trost reaction185 and have been reported together.180,182,186 
However propargyl groups have been more widely used and shown to possess superior reactivity in 
mammalian cells.180 Firstly, a Pd0 complex forms a binding interaction with the alkyne of a propargyl 
group. Pd0 can subsequently behave as a nucleophile, pushing electron density into the alkyne 
terminus. This causes the formation of an allene, and the elimination of a negatively charged leaving 
group. This leaving group can be in the form of hydroxyl or amine groups, providing that they have 
suffiently low pKa. This reaction is therefore typically restricted to the release of aromatic hydroxy 
groups173–176 and heteroaromatic amines.171,187,188 When amines or alcohols with high pKa released 
(such as alkyl amines or alcohols) then carbamates171,178–182 or carbonates177 are employed 
respectively. After addition of the Pd0 complex to a propargyl carbamate or carbonate, a carboxylate 
anion is the leaving group which can then decarboxylate to release the desired amine or alcohol. The 
release of a gas provides a large entropic driving force for the reaction. The fate of the palladium allenyl 
species is then unclear. It has been suggested that it is hydrolysed, but the evidence for this relies of 
LC-MS detection of hydroxyacetone (Scheme 10).189 A catalytic cycle of PdIV has been suggested,175,180 
however there is little evidence to support this at room temperature.189–192 Palladium mediated 
reactions that have PdIV intermediates often require high temperature, strong oxidizing reagents or 
facile oxidative addition to aryl iodides.193 
 
Scheme 10: Palladium mediated decaging of propargyl  
ethers, amines, carbonates and carbamates. 
Metal mediated bioorthogonal decaging reactions have been applied to the delivery of many different 
prodrugs (Table 10). These reactions have employed complexes of ruthenium and palladium, as well 
as nanoparticles of palladium182 and gold.183 Key to all of these reactions is that the metal complexes 
and nanoparticles can achieve reactive concentrations while being minimally toxic to the organism of 
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study. The most widely used and studied system is that of palladium mediated decaging, having been 
used with the most diverse group of prodrugs and applied in vivo.182 Palladium complexes have also 
been shown to be cell-penetrant and not cause formation of reactive-oxygen species in mammalian 
cells.180 
Table 10: Examples of metal mediated decaging reactions for drug delivery. 

















2.5 Decaging of Bifunctional Linkers 
While bioorthogonal caging groups have been used extensively to protect small molecules and 
functional groups of proteins, reports of bioorthogonally cleavable bifunctional linkers have been 
limited. In these cases, two molecules-of-interest have been ligated in such a way that they can be 
cleaved from one another with a bioorthogonal reaction. This has been most notably used in targeted 
drug delivery using bioorthogonally cleavable ADCs, whereby an antibody is ligated to a drug via a 
bioorthogonally cleavable linker.137,153,196–198 After the antibody has targeted cancerous cells, a 
2. Bioorthogonal Decaging for Chemical Biology 
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bioorthogonal reaction can be used to release the drug payload. In an early example, an antibody drug 
conjugate was synthesised bearing an anti-transferrin antibody ligated to a toxic ribosome inactivating 
protein (PAP-S1) via a UV-cleavable o-nitrobenzyl linker. The ADC was shown to be non-toxic until UV 
irradiation caused release of its payload in mammalian cells (Scheme 11).196 
 
Scheme 11: UV photorelease of a toxic payload from an anti-transferrin, o-nitrobenzyl linked ADC. 
In another example, tetrazine/TCO-OH decaging was adapted so that the TCO-OH moiety could act as 
a bifunctional linker. Attachment via the alcohol allowed a tetrazine-cleavable carbamate to be 
installed, and attachment via an activated succinimidyl ester allowed antibody conjugation (Scheme 
12).153 Despite the conjugation of a hydrophobic drug (doxorubicin) and the TCO linker, the half-life of 
the ADC was almost identical to the naked antibody. The ADC could reach ~65% decaging in only 2 
minutes in PBS, and ~25% in mouse serum after the same time. It was shown that tetrazine-cleavable 
ADCs would accumulate at a tumour xenograft in mice and that they would react with a radiolabelled 
tetrazine. If a non-radioactive tetrazine was infused first into the xenografted mice, TCO sites would 
be consumed and therefore radiolabelled tetrazine did not react with the ADC afterwards. It was 
however not shown that effective drug release was possible in tumour xenografts from a tetrazine-
cleavable ADC, nor that a clinically meaningful tumour shrinkage or increased survival of the mice was 
possible. The linker for this ADC also required a challenging 11-step synthesis, which requires 
specialised equipment for UV-irradiation in flow.153 It also thus far only allows non-selective lysine 
conjugation which is undesirable in the development of ADCs. These factors limit its applicability for 
use in other systems. 
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Scheme 12: Tetrazine mediated release of a drug payload from a TCO linked anti-TAG72 ADC. 
In another example, a near-IR cleavable cyanine caging group was adapted for conjugation to an 
antibody (Scheme 13).135,137 The ADC was shown by the inherent fluorescence of the cyanine group to 
accumulate in tumour xenografts in mice. Upon irradiation with near-IR light, the mechanism that 
causes drug release also causes decay of the cyanine. Decrease in cyanine fluorescence was shown, 
however release of the drug in mice, tumour shrinkage or increased mouse survival were not shown. 
In a second generation ADC, the linker was adapted with a more potent duocarmycin payload and 
tumour shrinkage and increased survival of the mice could be shown.197 However the tumours did not 
shrink to the point of remission. As an adjuvant therapy, the near-IR cleavable ADCs were later 
combined with antibodies ligated to photosensitizers.198 These sensitizers absorb near-IR wavelengths 
of light and cause formation of reactive-oxygen species which can kill tumours. With this combination 
therapy the tumour shrinkage was far greater and the survival of the mice was significantly longer. 
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Scheme 13: Near-IR mediated release of a drug payload from a cyanine linked ADC. 
Despite the success of palladium mediated decaging reactions in the activation of prodrugs and 
intracellular protein targets, these reactions have never been adapted to allow drug release from an 
ADC. However, palladium-cleavable bifunctional linkers have been developed for target pull-down 
assays (Scheme 14).186 These linkers were used to conjugate kinase inhibitor BIRB796 to a HaloTag 
ligand. Once the kinase inhibitor had bound to its targets in cell lysates, the HaloTag ligand was reacted 
with the HaloTag protein199 immobilised on magnetic beads. The magnetic beads were then be 
separated from the cell lysates, and palladium complexes used to cleave the linker. Mass spectrometry 
could then identify all the proteins in solution, which are the targets of kinase inhibitor BIRB796. 
 
Scheme 14: Palladium mediated release of a drug payload from an allyl carbamate- 
linked drug-Halotag conjugate for deconvolution of protein targets. 
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2.6 Conclusion 
Bioorthogonal decaging reactions have enabled key insights into biological systems that were 
previously impossible such as the functions of individual amino acids on proteins and the activation of 
prodrugs. The use of bifunctional linkers with bioorthogonal cleavage mechanisms however remain 
scarce. As palladium mediated decaging has shown great promise in chemical biology for prodrug 
activation and the intracellular activation of proteins, it seems a perfect candidate for the development 
of bifunctional, bioorthogonally cleavable linkers for the release of bioactive payloads from proteins. 
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3.1 Aims of the Project 
The purpose of this project was to develop a new linker which would allow bioorthogonal drug or 
fluorophore release. The linker was designed to be bifunctional, containing a bioorthogonally cleavable 
site, and contain a handle for facile site-selective cysteine bioconjugation (Figure 5b). This could allow 
bioorthogonally triggered, targeted drug delivery and could be a useful tool for chemical biology. 
Currently such reactions have been reported for UV decaging,200 trans-cyclooctene-tetrazine 
decaging150,153 and near-IR decaging.137 Palladium mediated decaging has been demonstrated in the 
literature to be versatile and robust, having found applications in the release of small 
molecules,175,180,182,187,188,194,195 proteins,180,184 (Figure 5a) and in target identification.186 It was 
hypothesised that palladium mediated decaging would allow for more structurally simple linkers 
without the need for complex syntheses or equipment to carry out targeted drug delivery experiments. 
 
Figure 5: a) Previous work on palladium mediated propargyl carbamate decaging has allowed the  
release of amine-containing small molecules, or the release of lysines on proteins. b) Illustration of 
palladium mediated decaging of bifunctional linkers for targeted payload delivery. 
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3.2 Results and Discussion 
The most obvious approach would be taking the literature known terminal propargyl carbamates, and 
extending via the alkyne C-H to later incorporate a bioconjugation handle (Figure 6). However simply 
extending the alkyne with methylene units could lead to steric repulsion about the alkyne and diminish 
reactivity with palladium complexes. Certain functional groups in proximity to the alkyne may be 
tolerated or even able to promote reactivity 
 
Figure 6: Potential steric inhibition of an alkyne-palladium binding interaction. 
In order to test many different carbamates, palladium complexes and conditions, a 96-well plate based 
format for rapid screening was developed (Figure 7). For this, a known decaging procedure of propargyl 
carbamate protected fluorophore 7 was adapted from the literature.181 This enabled reactions to be 
run in triplicate as well as a high throughput of organic compounds and palladium complexes. Terminal 
propargyl carbamate protected fluorophore 7 was screened against the literature known allyl2Pd2Cl2 
dimer for decaging. The solvents screened were water miscible, and used both in protein modification 
and palladium catalysis. Due to the poor water solubility of the 7-amino-4-methylcoumarin 
fluorophore (8) in water, 90% of the solvent had to be organic. The reactions were run in air to ensure 
air-stability of reagents and at room temperature to be similar to biological systems but not cause 




Figure 7: Solvent screening to establish a high-throughput fluorescence screen for reactivity between the literature known 
terminal propargyl carbamates and allyl2Pd2Cl2. 
Only 10% water was tolerated in these reactions due to the limited aqueous solubility of the coumarin 
8. The fluorophore was also insoluble in the alcohol solvents assayed, as well as the ethers but showed 
solubility in acetonitrile and DMSO. Unfortunately these solvents did not allow any reaction progress. 
Some reaction progress was observed in acetone, but acetone was too volatile and not suitable for an 
open well-plate format over an extended period of time. DMF proved to be the optimum solvent for 
these reactions and was selected for further fluorescence screening. 
The next step was to determine which functional groups would be tolerated in proximity to the alkyne 
and a range of groups were selected (Figure 8). It was found that with 0.5 equivalents of the literature 
known allyl2Pd2Cl2 (therefore 1 equivalent of palladium), the best reactivity was achieved with a 
terminal propargyl carbamate. However when increasing to 10 equivalents of allyl2Pd2Cl2, an appended 
S-trityl group 9 gives comparable reactivity. The possibility of sulfur promoting the reaction was 
exciting as this may facilitate attachment of a cysteine. However, a propargyl carbamate derivative 
bearing an N-Boc protected cysteine methyl ester (16) gave no significant reactivity when a range of 
substituted allyl2Pd2Cl2 were assayed. None of the substituted allyl2Pd2Cl2 derivatives (17-19) gave 
increased reactivity when compared to the literature known allyl2Pd2Cl2.  
10% H2O/Solvent SM is Soluble? Reaction Progress? Non-volatile Solvent? 
iPrOH, EtOH, MeOH No - - 
Dioxane, THF, DME No - - 
Acetonitrile Yes No - 
DMSO Yes No - 
Acetone Yes Yes No 
DMF Yes Yes Yes 






Figure 8: Fluorescence screening of allyl2Pd2Cl2 and substituted analogues to determine functional group tolerance of 
decaging. 200 µM solutions of caged fluorophore in 10% H2O/DMF were diluted 1:1 with solutions of palladium complexes 
at room temperature. Fluorescence intensity (λex 352 nm, λem 415 nm) was normalised to a 100 µM solution of free 
fluorophore 8 mixed with the appropriate concentration of palladium complex.  
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Allyl palladium chloride complexes are known to reduce to Pd0 after attack by nucleophiles (Scheme 
15).190 Given the large number of nucleophiles endogenous to biological systems (cysteine thiols, 
amines) it is likely that allyl2Pd2Cl2 is activated this way to react with propargyl carbamates. Therefore, 
further palladium complexes were sought with similar modes of activation. Complexes of 1,5-
cycloctadiene (COD) and palladium are known to also have a nucleophilic mode of reduction,201,202 and 
Pd(COD)Cl2 was screened against a range of propargyl carbamate derivatives (Figure 9). While it did 
not display considerable reactivity using stoichiometric concentrations, with ten equivalents it showed 
favourable reactivity and fast reaction kinetics with an S-methyl appended derivative 11. Oddly, it 
showed very little reactivity with the literature known terminal propargyl carbamate 7. The complex 
was then trialled against cysteine-containing propargyl carbamates as it was thought this could serve 
as a conjugation site to proteins. Reactivity was favourable against compounds bearing an N-Boc 
protected cysteine methyl ester 16 and N-Boc acetyl cysteine methyl ester derivatives 20, showing the 
flexibility of tolerated groups at this site. Unprotected cysteine methyl ester derivative 21 resulted in 
complete quenching of reactivity, most likely due to chelation of palladium. 
 
Scheme 15: Nucleophilic mode of reduction of palladium allyl complexes. 
As palladium is thiophilic, it seems likely that the explanation of this reactivity is a binding interaction 
between palladium and the thioether. If COD does serve as a reducing agent for the palladium 
however, the thioether would need to displace a chloride, leaving a complex with an overall positive 
charge which may not be favourable. A second complex, Pd(COD)MeCl, was trialled as a methyl ligand 
would be expected to be much less labile than a chloride. If the complex shows diminished reactivity, 
it may be evidence of a binding interaction via the displacement of chlorides. In fact, this complex did 
exhibit diminished reactivity for all thioether bearing propargyl carbamates but strangely increased 
reactivity for the terminal propargyl carbamate 7. This may be because the methyl group offers a 
reductive elimination mediated palladium reduction mechanism (to release methyl chloride) which is 
however less efficient than reduction by nucleophilic attack on COD. To investigate the effects of strain 
on the ligands of palladium, norbornadiene (NBD) was assayed in complex Pd(NBD)Cl2. The overall 
decaging conversion for cysteine appended derivatives 16 and 20 was diminished for Pd(COD)Cl2 and 
Pd(NBD)Cl2, and the rate of decaging was much lower. The steric constraints of NBD could lead to a 
slower nucleophilic addition step or slower β-hydride migration step. 







Figure 9: Fluorescence screening with Pd(COD)Cl2, Pd(COD)MeCl and Pd(NBD)Cl2.  
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Further evidence of a binding interaction is provided by the fact that insertion of an extra methylene 
between thioether and alkyne still allows reactivity (Figure 10). Greatest results for allyl2Pd2Cl2 are still 
provided by the S-trityl derivative 9. With the addition of an extra methylene spacer, reactivity is 
slightly diminished. In the case of Pd(COD)Cl2, S-methyl derivative 11 still shows the best conversion, 
and an extra methylene spacer again does not significantly inhibit the reaction. 
 
  
Figure 10: Fluorescence screening to determine effect of extra methylene insertion between thioether and alkyne. 
It is clear that thioethers offer the best reactivity for extending the alkyne into a bifunctional linker. 
With allyl ligands on palladium however, this requires large, bulky groups on the thioether which limits 
the possibilities of further modification. A group such as trityl would render any linker much less water 
soluble. With a COD ligand on palladium only small groups such as methyl are required on the 
thioether, and this allowed for further functionalisation of this group – for example with cysteines (16 
and 20). This shows the flexibility of possible modifications at this site and therefore the methyl 
thioether 11-Pd(COD)Cl2 reaction partners were selected for additional study and development. A 
summary of reactivity data is shown in Figure 11. 
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Figure 11: Summary of mechanistic data from fluorescence screening. 
In order to seek further confirmation of a thioether mediated binding mechanism, a truncated 
propargyl thioether 24 was studied by 1H NMR (Figure 12). A stoichiometric amount of Pd(COD)Cl2 was 
added to propargyl thioether 24, and only signals from the thioether were observed to shift completely 
after 10 minutes at room temperature. The alcohol protons were unshifted. This is evidence that the 
binding is mediated by the alkyne and thioether of these compounds, but not the precise nature of the 
complexes. In the mixture, there is an approximately 1:1 ratio of free COD to Pd(COD)Cl2 – or peaks 
with the same chemical shifts – with some minor signals likely from palladium COD complexes with 
displaced chlorides around 3.5-4 ppm. When substituting the thioether for ether 25, no shifts in signals 




Figure 12: 1H NMR binding experiment of propargyl thioether 24 and propargyl ether 25 with Pd(COD)Cl2. 
A 1:1 ratio of COD to Pd(COD)Cl2 would be consistent with a binding mode of two propargyl thioethers 
(24) per palladium. However, this would not be consistent with a reactive intermediate as there would 
be no mechanism to reduce PdII to Pd0. It could however be that the reaction goes via minor complexes 
in solution and that the major complexes are unreactive (Figure 13). 
 
Figure 13: Potential binding modes of Pd(COD)Cl2 with propargyl thioether 24. 
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Based on literature known reactions of palladium COD complexes201,202 a mechanism was devised 
whereby palladium can bind to the linker between thioether and alkyne. When COD is also bound to 
palladium, COD is activated to nucleophilic attack by the electron withdrawing effect of the thioether 
– enabling nucleophilic attack of water in the fluorescence screen. Evidence that this is not occurring 
without thioether binding is that Pd(COD)Cl2 does not react with terminal propargyl carbamate 7. If 
Pd(COD)Cl2 could be reduced by any other means in solution the Pd0 species could then go on to react 
with the terminal propargyl carbamate 7. After nucleophilic attack of water on COD, the alkyl palladium 
species 27 could then undergo β-hydride migration with a proximal hydrogen from the COD-derived 
ligand. The palladium hydride intermediate could then undergo reductive elimination to give a Pd0 
species. Pd0 can then nucleophilically add to the propargyl carbamate as per the standard Tsuji-Trost 
reaction mechanism.190 A mechanistic proposal is shown in Scheme 16. The fate of the palladium 
allenyl species is then unclear. It has been postulated in the literature that it undergoes hydrolysis to 
regenerate Pd0 and hydroxyacetone, but the evidence of this mechanism relies on LC-MS detection of 
hydroxyacetone.189 As hydroxyacetone has a high volatility and low mass, it makes it a challenging 
compound to detect by LC-MS and distinguish from fragments of larger organic compounds. 
 
Scheme 16: Mechanistic proposal of Pd(COD)Cl2 mediated decaging of propargyl carbamates. a) Literature known 
mechanism of reduction of Pd(COD)Br2.201,202 b) Proposed mechanism of propargyl carbamate decaging with Pd(COD)Cl2 
(charges omitted for clarity). 
To verify this mechanism and that the reaction does not go via non-specific PdII mediated hydrolysis, 
propargyl carbamates were tested against Pd(OAc)2, Zn(OAc)2 and Cu(OAc)2 (Figure 14). All compounds 
tested showed no reactivity with these complexes. Metal acetates were selected as organic soluble 
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sources of MII where the ligands are generally inert. PdII is likely still binding to the linker via the 
thioether and alkyne, but no reaction is occurring. This should mean that COD is responsible for the 
reactivity and that any reactive intermediate should involve a bound PdII ion as well as COD. 
 
 
Figure 14: Stability of propargyl carbamates to PdII, ZnII and CuII acetate. 
As reaction with Pd(COD)Cl2 allows variability of groups that can be attached to the thioether, this 
complex was chosen to further develop a palladium cleavable linker system. A linker bearing a 
triethylene glycol thioether was synthesised, as polyethylene glycol (PEG) forms straight chains in 
water. This would later allow distance between the reactive site of Pd(COD)Cl2 and any functionalities 
later added to the linker. For example, a protein may interfere with the reaction due to many chelating 
groups on its surface, and therefore it might be advantageous to have this PEG spacer. A triethylene 
glycol propargyl carbamate 28 was synthesised and the kinetics of its reaction with Pd(COD)Cl2 studied 
under pseudo-first order conditions. Reacting with between 10 and 40 equivalents of Pd(COD)Cl2, it 
was found to have a second order rate constant of 1.136 M-1 s-1 (Figure 15). 
  




Figure 15: Pseudo-first order kinetics of triethylene glycol propargyl carbamate 28. 200 µM solutions of caged fluorophore 
28 in 10% H2O/DMF were diluted 1:1 with solutions of palladium complexes at room temperature. Fluorescence intensity 
(λex 352 nm, λem 415 nm) was normalised to a 100 µM solution of free fluorophore 8 mixed with the appropriate 
concentration of Pd(COD)Cl2. Concentration of the fluorophore [Fluorophore] was assumed as Normalised FI multiplied by 
100 µM fluorophore 8. 
While this rate constant is modest, it is compatible with chemical biology applications and drug release. 
Following the second order half-life equation, t½ = 1/k[C]0, where [C]0 is the initial concentration of 
reagents (assuming both reagents are at the same concentration) this gives a half-life of approximately 
1 day at 10 µM concentrations. Following the first order half-life equation t½ = ln(2)/k1 = ln(2)/(k2∙[Pd]) 
this gives a half-life of approximately 0.7 d at 10 µM concentrations of Pd(COD)Cl2. Of course, only 
limited comparisons can be drawn between a rate constant determined in mostly organic solvent to 
the rate of the same reaction in cell culture, but this offers an approximation. Interestingly, when 
increasing the amount of Pd(COD)Cl2 beyond 40 equivalents, the observed rate constant starts to 
decrease. This is likely due to Pd(COD)Cl2 reaching such a high concentration that it starts to precipitate 
or form aggregates (Figure 16). The large error could also be significant in that the aggregation is not 
uniform across all replicates. 
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Figure 16: Decaging of triethylene glycol modified propargyl 
carbamate under pseudo-first order with 50-100 eq. Pd(COD)Cl2. 
The pegylated propargyl carbamate of 28 seeming like a good choice of linker, a pegylated doxorubicin 
prodrug cDox (35) was synthesised (Scheme 17) to verify whether this decaging could function in cell 
culture. This was achieved in 5 steps from commercially available triethylene glycol monoethyl ether 
29. A monoprotected short PEG 29 was selected as a starting point as the polarity of PEG compounds 
makes them very challenging to purify. A shorter PEG is easier to purify, and as it is already 
monoprotected with an ethyl group, this reduces the number of by-products to purify after tosylation 
to give tosylate 30 in 90% yield. The tosylate 30 could then be displaced by potassium thioacetate to 
give the thioester protected thiol 31 in 86% yield. Deprotection with sodium methoxide in methanol 
afforded the thiol which was reacted in situ with propargyl chloride 32 to give propargyl thioether 33 
in 73% yield over two steps. After reaction with p-nitrophenyl chloroformate, an activated carbonate 
34 could be isolated in 59% yield. In a final step, doxorubicin hydrochloride could be reacted with 
activated carbonate 34 to give the target doxorubicin prodrug cDox (35) in 76% yield. Doxorubicin was 
selected as a suitable drug, as it is clinically used to treat cancer and bears the required reactive amine 
in order to convert it to a propargyl carbamate prodrug. Doxorubicin exerts its anti-cancer effects by 
intercalating with and binding to the rapidly dividing DNA of cancer cells. Its amine is positively charged 
and forms strong interactions with the negatively charged DNA phosphate backbone (Scheme 17). 
When the amine is protected as a carbamate, the positive charge is lost which leads to a loss in 
potency. 
  





Scheme 17: Crystal structure of doxorubicin in complex with DNA from PDB 1D12203 and synthesis of PEGylated 
doxorubicin prodrug cDox (35). Doxorubcin causes cancer cell death by intercalating its rapidly dividing DNA thereby 
inhibiting DNA replication. The strong ionic interation between doxorubicin ammonium and DNA backbone phosphate is 
disrupted when the amine is protected as a carbamate.  
With doxorubicin prodrug cDox (35) in hand, the decaging reaction could be trialled in cell culture. 
cDox (35) was found to be significantly less toxic than doxorubicin at the same concentrations. This is 
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likely due to impaired cell membrane penetration due to the loss of an overall positive charge, and the 
ammonium of doxorubicin forms a key interaction with the negatively charged DNA phosphate 
backbone203 which would be lost in cDox (35). Given the large number of nucleophiles endogenous to 
biological systems, Pd(COD)Cl2 is not likely to be very stable. For this reason, it was decided to add 
Pd(COD)Cl2 daily in order to push the reaction further towards completion. To serve as a control, water 
soluble palladium salt Na2PdCl4 was also trialled at the same concentrations. At 48, 72 and 96 h 
Pd(COD)Cl2 was found to be more effective than Na2PdCl4 (Figure 17). This shows that either 
Pd(COD)Cl2 is more stable or more reactive than Na2PdCl4. 
  
3. Palladium Mediated Drug Release 
62 
 
Figure 17: Cell viability studies with doxorubicin prodrug cDox (35) in HEK cells. Cell viability was determined by AlamarBlue 
assay, in which viability is directly proportional to the ability of cells to reduce non-fluorescent resazurin to fluorescent 
resorfurin. Treated cells were normalised to cells cultured with an equal concentration of DMSO which were assumed to be 
100% viable. Statistical significance was determined with a two-tailed unpaired t-test. ****p = < 0.0001. ***p = 0.0002. **p 
= 0.0035. * p = 0.0318. ns = non-significant. 
As expected, the effectiveness of the drug release increases with the concentration of reagents. 
Interestingly, Na2PdCl4 still showed some efficacy in the reaction despite the fact Pd(OAc)2 showed no 
activity in the fluorescence screen (Figure 14). Both are sources of PdII without ligands capable of 
reducing the metal centre. The reason Na2PdCl4 shows efficacy is likely due to the abundance of 
reducing agents in cell media, for example ascorbic acid. In another study, it was shown that ascorbic 
acid can increase the rate of palladium decaging in vitro.180 The largest turn-on of toxicity is at 96 h 
with 10 µM Pd(COD)Cl2 per day. The reason is likely that longer timepoints allow the reaction to 
progress further, and the released doxorubicin has a longer period in which to exert its toxicity – note 
that the free doxorubicin becomes more toxic as the incubation time increases. The optimal 
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concentrations for this decaging in cell culture are presented in Figure 18, alongside brightfield 
microscopy demonstrating the cell killing. 
 
Figure 18: Summary of optimal conditions (96 h) for cellular decaging of doxorubicin prodrug cDox 35 along 
with brightfield microscopy of the cells. Statistical significance was determined with a two-tailed unpaired t-
test. ****p = < 0.0001. 
With evidence that this reaction can work well in cell culture, the linker of cDox (35) was adapted to 
contain a cysteine-selective bioconjugation handle previously developed in the group.204 These 
acrylamide bioconjugation handles react rapidly and selectively with cysteine – not lysine or any other 
nucleophilic amino acid – to give a stable bioconjugate. This is a valuable alternative to maleimide 
cysteine bioconjugation which has been shown to be unstable due to rapid retro-Michael addition. The 
bioconjugation handle could be introduced in the first step of the synthesis, and doxorubicin in the last 
step. This is important as it could allow a range of payloads to be introduced to the molecule rapidly 
in the final step. In this case, doxorubicin was selected as a payload for facile comparison with cDox 
(35). 
To demonstrate release of a payload from a protein-drug conjugate, a protein with a single reactive 
cysteine, 2Rb17c, was selected. 2Rb17c is a nanobody which is targeted to the HER2 receptor205 – the 
same target as commercially available ADC trastuzumab emtansine. HER2 is overexpressed in certain 
breast cancers and is known to rapidly internalise upon binding of an antibody.62,206,207 The cysteine of 
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2Rb17c is protected as a disulfide with GSH or cysteine in the stock solution, so 50 equivalents of tris(2-
carboxyethyl)phosphine hydrochloride (TCEP) were added to reduce any disulfide bonds. Following 
this, 50 equivalents of doxorubicin-acrylamide 36 were reacted with the free cysteine of nanobody 
2Rb17c (Figure 19a,b). The conjugate 2Rb17c-36 could then be decaged with only 10 equivalents of 
Pd(COD)Cl2 in 2 h at 37 °C (Figure 19a,c). As proteins contain many metal chelating functional groups 
(amines, thiols, acids etc.), a palladium scavenger is required to ensure that metals are not bound to 
the protein for MS analysis as this would complicate the spectra.208–210 
The optimum conditions and concentrations from the cDox (35) decaging study were used to 
investigate the toxicity of the conjugate 2Rb17c-36. The conjugate 2Rb17c-36 is much more toxic than 
cDox (35) likely due to internalisation of 2Rb17c-36 after binding with HER2 and subsequent lysosomal 
trafficking and degradation. However, when reacted with Pd(COD)Cl2, the toxicity is doubled to 
completely recover the toxicity of free doxorubicin (Figure 19d). The Pd(COD)Cl2 was added after 2 h 
to allow localisation of the conjugate on the HER2 positive cell line MCF-7. The number of copies of 
HER2 per MCF-7 cell is on the order of 103. With 5000 cells in 200 µL per well in the experiment, this 
leads to a concentration of ~10-14 M of the HER2 receptor. There is clearly a large excess of the 
conjugate 2Rb17c-36 at 10-6 M and therefore much of the decaging and toxicity should arise from 
extracellular decaging. A control experiment should be performed using a non-targeted protein (e.g. a 
nanobody with a scrambled binding region sequence) to understand if the turn-on of toxicity upon 
addition of Pd(COD)Cl2 is similar. Another useful control would be to use a HER2 negative cell line such 





Figure 19: a) Protein bioconjugation and subsequent decaging. Synthesis of protein modification reagent 36 was 
carried out by Laura Sinatra and the nanobody 2Rb17c kindly provided by the Caveliers group. b) MS of modified 
2Rb17c-36. c) MS of decaged 2Rb17c-36. d) Cell viability of MCF-7 cells after treatment with 2Rb17c-36 and 
subsequent decaging. Statistical significance was determined with a two-tailed unpaired t-test. ****p = < 0.0001. 
After decaging of the conjugate in vitro no remaining starting material 2Rb17c-36 could be detected 
by LC-MS, and the major product seemed to result from decaging followed by an elimination or 
hydrolysis. As this seems to evoke an unexpected mechanism, the conjugate was studied for stability 
to the palladium scavenger 3-mercaptopropionic acid (3-MPA). The conjugate shows complete 
stability to even 500 equivalents of 3-MPA (Figure 20), and therefore the decaging must be resulting 
from reaction with the palladium complex as in Figure 19a,c. A possible reaction mechanism is 
proposed in Scheme 18. 
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Scheme 18: Proposed mechanism for unusual product observed after decaging of 2Rb17c-36 by Pd(COD)Cl2. 
This chemical biology tool is not the first to enable release of small molecules from a bifunctional linker, 
however it has some key advantages. A tetrazine/TCO-OH mediated decaging of an antibody drug 
conjugate153 required eight steps to synthesise the linker, in a total yield of 7.6%. The synthesis is 
challenging and the reported starting material is not yet commercially available on a large scale 
(£38.75/10 mg, Aldrich CPR).211 In order to make the starting material, literature procedures require 3 
steps212,213 from 1,5-cyclooctadiene and this brings the overall yield to 4.7%. Our synthesis is 
unoptimised, yet has an overall yield of 4.6% in six steps from a commercially available starting material 
($720/10 g, Carbosynth)214 Another potential advantage of our system is that the PEG linker offers 
greater polarity than the trans-cyclooctene linker. Downsides to our system are the relative instability 
of palladium complexes in biological media with respect to tetrazines and lower reaction rates. 
A palladium cleavable bifunctional linker was reported for conjugating pharmaceutical compounds to 
HaloTag for verification of drug targets.186 This was performed in cell lysates whereas our chemistry 
could be performed in live cell cultures. Also, the tool is only designed to conjugate HaloTag and 
therefore has a limited scope of potential proteins. In another example, an ADC was prepared which 
would release its payload in response to near-IR light at 690 nm.137 This is an exciting application as 
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near-IR light has to ability to deeply penetrate biological tissues. An advantage of our approach is that 
the drug can be added in the final step, whereas in the near-IR cleavable linker the drug must be added 
after three out of five steps. Also, the sulfonated cyanine dye at its core makes purification difficult, 
and it requires three challenging reverse phase purifications. 
3.3 Conclusions and Future Work 
In this project we have successfully developed a method of targeted drug delivery using a 
bioorthogonal decaging reaction. This required the study of literature known palladium-mediated 
propargyl carbamate decaging in order to move this chemistry from simple cleavable protecting groups 
that enable prodrug synthesis, to complex linkers that allow protein bioconjugation and targeted drug 
release. The mechanism of this reaction relies on the unexpected favourable interaction of a palladium 
complex with a thioether in proximity to the propargyl carbamate. While many palladium catalysts can 
be poisoned by thioethers and sulfur-containing compounds, this reaction relies on thioethers to 
function. However, the mechanism of this reaction is not fully understood and future studies should 
focus on understanding the fate of the propargyl carbamate caging group and palladium species after 
cleavage, both mechanistically and biologically. These studies should include NMR and LC-MS 
monitoring of intermediates and products in the reaction, as well as the isolation and purification of 
these products to test in cell culture for toxicity. 
The potential of extracellular drug decaging is that it could deliver drugs to cancerous cells that have 
been targeted to antigens in their extracellular matrix. ADCs have had limited success in treating solid 
tumours, and many cancers express mutated or alternatively spliced extracellular matrix proteins. The 
ability to target ADCs to the extracellular matrix and then release their payloads with a bioorthogonal 
reaction would increase the number of antigens available for targeting and eliminate the need for an 
internalising antigen on the cell surface. While palladium complexes are unlikely to make it to the clinic 
due to their poor stability, a palladium cleavable ADC could at least elucidate whether or not a 
bioorthogonally activated, tumour extracellular matrix targeted ADC could be a viable therapeutic 
option. 
An interesting aspect of this to examine would be if a payload will still selectively accumulate in a 
cancer cell when only released in proximity to it. A palladium cleavable ADC could be synthesised which 
targets extracellular matrix proteins109 such a fibronectin112,215 or tenascin115,116 that has a fluorescent 
payload. These ADCs could then be used to treat a co-culture normal healthy cells and cancer cells 
expressing these aberrant proteins. The same ADCs could also be applied to tumour spheroids or 
patient-derived tumour samples. If the fluorophore selectively accumulates in cancerous cells as 
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opposed to healthy cells, then this could be a therapeutic avenue for future research. Also interesting 
to study would be the concentration of payload at increasing distances from a tumour (Figure 21), as 
certain ADCs attempt to increase “bystander killing”. This is when the drug once released can diffuse 
away from its target antigen and kill other cancerous cells which do not bear that antigen. It would be 
valuable to study whether bystander killing can be increased by extracellular drug release as opposed 
to intracellular drug release. 
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4.1 Aims of the Project 
Bioorthogonal decaging chemistry has focused on developing reagent pairs that individually affect 
biological systems in the smallest way possible. The purpose of this project was to find a reactive 
compound which is already used in cancer therapy in human patients, and use it as a reagent to cause 
decaging on a non-internalising ADC. A decaging reaction of this type would have several advantages: 
 The toxicity and metabolism of any compound which is regularly used to treat cancer patients 
is generally very well known. Developing novel reagents for bioorthogonal chemistry would 
require careful studies of the toxicity and metabolism. 
 If a reagent is already being used to treat a patient, an ADC that is cleaved by this reagent then 
becomes an adjuvant therapy. The non-internalising ADC would be a supplementary, 
combination therapy that still allows the first reagent to exert its effects as a drug in its own 
right. 
 Many marketed compounds used in the clinic are often commercially available, and as they 
are made on a large scale they could be more affordable and applicable when compared to, 
for example, trans-cyclooctenes and cyclooctynes. 
A key factor in the development of many marketed compounds for the treatment of cancer patients is 
metabolic stability, and therefore most chemotherapeutics are reasonably chemically inert. A selection 
of the most commonly used anti-cancer chemotherapeutics, their activity and reactivity216 are given in 
Figure 22. When looking at the reactivity of these compounds, it is clear that many of them will be 
chemically inert – especially those with long half-lives in circulation. Outliers in the reactivity of 
common chemotherapeutic drugs are the platinum DNA crosslinking agents. Cisplatin in particular has 
a very short half-life in humans (20-30 minutes),217 which is indicative of its high reactivity. 
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Figure 22: Structures, activities and reactivity of chemotherapy drugs from the most common treatment regimens. 
Moderately reactive compounds are highlighted in orange and reactive compounds in red. 
Platinum-based chemotherapy drugs are frequently used to treat cancer patients and are clearly 
reactive compounds which leads to their low half-lives. Therefore, a targeted drug delivery strategy 
was devised whereby a cancer patient could be treated with a non-internalising platinum-cleavable 
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ADC. When the ADC reaches its maximum accumulation in the tumour, cisplatin or another platinum-
based drug would be infused to cause drug release from the ADC (Figure 23). 
 
Figure 23: Cisplatin mediated release of drugs from ADCs. 
The term “bioorthogonal” could perhaps never be a fitting description for reactions with cisplatin, a 
compound known to react with water,218 DNA,219 amino acids218,220 and proteins.221 However cisplatin 
is one of the most commonly used chemotherapy drugs, being used to treat up to 20% of cancer 
patients.222 Its toxicity and effects on biological systems are therefore well known. Cisplatin was 
deemed a suitable reagent for the development of a drug decaging reaction as it is highly reactive (half-
life in humans of ~30 mins217) yet can selectively accumulate in a tumour,223 and even reach high 
concentrations (~1-2 µM in human tumours).224 
4.2 Results and Discussion 
When trying to design a decaging reaction that could be catalysed by platinum complexes, it is clear 
that platinum and gold share much of their chemistry.225,226 PtII and AuIII are isoelectronic and highly 
electronegative so this is perhaps not surprising. Therefore reactions of both platinum and gold 
complexes were searched in the literature. A literature search was performed for reactions which 
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were: heterogeneous, aqueous and rapid at room temperature in air. Later such a reaction could be 
engineered to function with cisplatin or its metabolites. Fitting these criteria, the cyclisation of 4-
pentynoic acid (37) (Scheme 19a) is well known in the literature to proceed within minutes227–229 and 
has even been demonstrated with cisplatin.230 The metal complexes catalyse a nucleophilic addition of 
an acid into an alkyne. Palladium mediated propargyl carbamate decaging relies on Pd0 acting as a 
nucleophile adding to an alkyne175,180 which causes allene formation and decarboxylation. An 
analogous mechanism using platinum or gold was devised using an acid as an internal nucleophile, 
which causes allene formation, decarboxylation and consequent drug release (Scheme 19b). 
 
Scheme 19: a) Literature known cyclisation of 4-pentynoic acid (37).227–230 b) Proposed decaging reaction. 
A model compound pentynoic acid derivative 38 using dibenzylamine as a substitute for a drug was 
synthesised, and reacted with 0.1 equivalents of NaAuCl4. This gold complex was chosen as a readily 
available, water soluble AuIII salt for model studies. The reaction was followed by 1H NMR in 25% 




Figure 24: Decaging of pentynoic acid derivative 38 followed by 1H NMR. General conditions: metal complex in D2O (0.6 mL) 
was added in one portion to alkyne (~ 10 mg) in MeOD (0.2 mL). The reaction was mixed and transferred to an NMR tube at 
room temperature in air and sealed. Conversion was monitored by 1H NMR and calculated based on the relative ratios of 
amine to amide/carbamate signals. 
The cyclisation of an acid onto alkyne can be easily followed by the alkyl proton signals in green at 
~2.50 ppm. These quickly disappear between the 14 and 28 minute timepoints. However this does not 
correspond to a similar growth in the signals of released dibenzylamine in red at ~4.25 ppm. After 
completion of the cyclisation of the acid onto the alkyne, the dibenzylamine signals slowly grow over 
the following 8 hours. This would suggest that the major mechanism of dibenzylamine release is not 
via the concerted allene-formation/elimination mechanism proposed in Scheme 19b. It is more likely 
that the cyclisation of the acid onto the alkyne occurs, but the intermediate is rapidly protonated 
before allene formation can occur. The stable cyclised intermediate 39 then contains a new, reactive 
alkene which can act as an electrophile for the carbamate carbonyl nucleophile. The carbonyl is a much 
weaker nucleophile than the acid which explains why it reacts much slower. The cyclisation of 
carbamate carbonyl onto alkene creates a cationic intermediate 40, which is then slowly hydrolysed 
to release dibenzylamine (Scheme 20). 
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Scheme 20: Proposed mechanism for the decaging of acid bearing propargyl carbamate 38. 
If this proposed mechanism is correct then it should be possible to achieve a carbamate carbonyl 
cyclisation onto an alkyne directly without the need for the acid of compound 38. A model terminal 
propargyl carbamate 41 was synthesised to study this transformation. In this case, dibenzylamine was 
replaced with morpholine to increase the water solubility of the propargyl carbamate. The decaging of 
this terminal propargyl carbamate 41 was followed by 1H NMR under the same conditions as acid 38 
(Figure 25). 
 
Figure 25: Decaging of terminal propargyl carbamate 41 monitored by 1H NMR. 
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The morpholine signals in this reaction are used to calculate the conversion as they have the best 
resolution and are well separated in starting material and product. Another option would be to 
integrate the alkyne CH but complexation of gold to the alkyne could reduce the pKa of the CH 
sufficiently to cause deuteration (Scheme 21). Also, if the alkyne were to become hydrated or 
chlorinated, the morpholine signals in the products would presumably stay at a very similar chemical 
shift as the amide bond would be intact (Scheme 21).  
 
Scheme 21: Potential side reactions arising from the use of gold complexes. 
Successful release of morpholine from carbamate 41 supports the hypothesis of carbamate carbonyl 
cyclisation onto the alkyne as the mechanism of decaging. This reaction even had slightly better 
conversion than acid 38. It is however possible the decaging was simply AuIII acting as a Lewis acid and 
binding to the carbonyl oxygen, allowing direct hydrolysis. To verify that the mechanism did proceed 
via cyclisation, an aliphatic carbamate bearing no alkyne 42 was synthesised and subjected to the same 
conditions as previous decaging reactions (Figure 26). 
 
Figure 26: Stability study of aliphatic carbamate 42 monitored by 1H NMR. 
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The aliphatic carbamate shows no sign of decomposition after 24 hours exposure to NaAuCl4. This 
provides strong evidence that the mechanism of this decaging reaction passes via a cyclised 
carbocation which slowly hydrolyses. The data collected thus far however do not elucidate the rate-
determining step of decaging. If the cyclisation step is faster than hydrolysis, then one would expect 
to see 1H NMR signals arising from the cyclised intermediate of propargyl carbamate 41 (Figure 25). 
The 1H NMR appears to show a mixture of only starting material and morpholine product, and 
therefore it could be assumed that cyclisation is the rate determining step. However, the cyclisation 
could also be rapid and reversible which could account for why there are no signals arising from a 
cyclised intermediate. Based on these mechanistic hypotheses, a similar decaging should be possible 
for amides. In fact, the intermediate cation would have mesomeric stabilisation from only one amide 
oxygen instead of two carbamate oxygens and would therefore be less stable and may hydrolyse 
faster. An amide analogue 43 of carbamate 41 was synthesised and subjected to the same decaging 
conditions (Figure 27). 
 
Figure 27: Decaging of tertiary amide 43 monitored by 1H NMR. 
Gratifyingly, the decaging of amide 43 had significantly better conversion than carbamate 41. The 
decaging of amide 43 is also faster than carbamate 41 (20% at 15 min and 13% at 14 min respectively). 
This suggests that hydrolysis of the cyclised cationic intermediate is the rate determining step as amide 




Scheme 22: Proposed decaging mechanism of carbamate 41 and amide 43. 
However it is very clear from these NMRs that even when the starting material alkyne CH signal is fully 
consumed, this does not lead to complete formation of the desired decaged product (Figure 27) – 
suggesting perhaps that the alkyne CH can be deuterated or the alkyne subject to side-reactions in the 
presence of the gold complex as proposed in Scheme 21. This is supported by the fact that after 
overnight reaction, no alkyne CH is remaining, and the propargylic methylene signals are a triplet and 
not doublet of triplets (Figure 27). Other potential side-reactions arising from the use of gold 
complexes could be alkyne hydration231 and alkyne chlorination232 (Scheme 21). Some signals in the 
2.7-3.2 ppm region (Figure 27) suggest that these could be derived from the methylene groups in the 
starting material – perhaps after a side-reaction or cyclisation with the alkyne. However the integration 
of these peaks is insignificant when compared to the methylene signals in the starting material. It was 
also of interest to verify if this reaction would proceed with secondary amides. A secondary amide 
analogue 44 of tertiary amide 42 was synthesised and subjected to the same decaging conditions 
(Figure 28). 
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Figure 28: Decaging of secondary amide 44 monitored by 1H NMR. 
With tertiary amides such as 43, the carbonyl oxygen acts as a nucleophile to attack the alkyne. In a 
secondary amide such as 44, the amide nitrogen can also act as a nucleophile and attack the alkyne to 
give a stable cyclised product, thereby outcompeting the carbonyl oxygen and leading to a lower 
decaging conversion (Scheme 23).233 
 
Scheme 23: Proposed mechanism of gold mediated cyclisation of secondary amide 44. 
These reactions developed first with the gold complex NaAuCl4 were then tested for efficacy with 
platinum complexes including cisplatin (Table 11). As cisplatin has such a low half-life in circulation in 
humans, it was hoped that metabolites of cisplatin may also eventually be catalytically active in cellular 
or animal models. To act as a model for cisplatin metabolites, both K2PtCl4 and K2PtCl6 were trialled 
against these reactions. These offer “naked” sources of PtII and PtIV respectively which can be more 




Table 11: Summary of conversions for decaging reactions with gold and platinum 
complexes. 
Catalyst Compound Structure Conversion % (time) 
0.1 eq. NaAuCl4∙2H2O 41 
 
12% (4 min) 
20% (24 h) 
0.1 eq. NaAuCl4∙2H2O 42 
 
No change (24 h) 




0.1 eq. NaAuCl4∙2H2O 43 
 
20% (6 min) 
21% (15 min) 
37% (13h 14 min) 
0.1 eq. K2PtIVCl6 43 
 
Traces (8 min) 
40% (13 h 7 min) 
0.1 eq. K2PtIICl4 43 
 
4% (10 min) 
9% (4 h 21 min) 
0.1 eq. cisplatin 43 
 
3% (overnight) 
0.1 eq. NaAuCl4∙2H2O 44 
 
12% (14 h 35 min) 
2% (10 min) 




0.1 eq. K2PtIVCl6 44 
 
11% (14 h 45 min) 
General procedure: Carbamates and amides (~10 mg) were dissolved in MeOD (0.2 
mL) and gold or platinum complexes (0.1 eq.) were added in D2O (0.6 mL) at room 
temperature in air. The reactions were transferred to an NMR tube then sealed. 
Amides are generally much more metabolically stable than carbamates, and there are already several 
carbamate decaging reactions in the literature.150,152,180 Therefore amide decaging was chosen as the 
most promising reaction for further development. In our initial results tertiary amides had shown much 
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better decaging conversions than secondary amides. Therefore drugs were sought which contained a 
secondary amine functionality which could be caged with 4-pentynoic acid (37) to give a tertiary amide. 
Doxorubicin would be an ideal candidate as it is readily available in large quantities and its inherent 
fluorescence may later allow the tracking of platinum-cleavable antibody-doxorubicin conjugates. 
Unfortunately it bears only a primary amine, so methods were sought to synthesise a doxorubicin 
prodrug bearing a secondary amine. Fortunately, a doxorubicin analogue which had been reacted with 
acetone was known in the literature.234 It was reported that the free base form of doxorubicin could 
be refluxed in anhydrous acetone to form cyclised product pDox (45). In the presence of water, 
doxorubicin analogue pDox (45) would decompose rapidly to release acetone and doxorubicin. 
However when acetylated the rate of decomposition of pDoxAc (48) was greatly reduced. It was 
hypothesised that if doxorubicin analogue pDox (45) could be converted to an amide with 4-pentynoic 
acid (37), then this could be decaged to release doxorubicin (Scheme 24a). Thus, doxorubicin prodrug 
pDoxAm (46) was synthesised to test its ability as a platinum cleavable doxorubicin prodrug. As 
negative controls, primary amide DoxAm (47) and acetylated pDoxAc (48) were synthesised as they 
should not react with platinum complexes efficiently to release doxorubicin (Scheme 24b). 
 
Scheme 24: a) Mechanism of doxorubicin release from pDox (45) b) Synthesis of pDoxAm (46)  
and structures of DoxAm (47) and pDoxAc (48).  
The toxicity of doxorubicin prodrug pDoxAm (46) and negative controls DoxAm (47) and pDoxAc (48) 




Figure 29: Toxicity of doxorubicin and derivatives in HeLa 
cells after 3 days as determined by Alamar Blue assay. 
Unfortunately, the difference in toxicity between pDoxAm (46) and Dox was small (~2x). This would 
mean a very narrow margin in which to determine if the decaging reaction is working or not. 
Interestingly, while pDoxAc (48) and pDoxAm (46) were of similar toxicity, DoxAm (47) was much less 
toxic. This is likely due to ring strain in pDox (45) leading to weaker amides that are more easily 
hydrolysed. 5-Fluorouracil (5-FU) is a drug that is frequently used in decaging studies,171,183,187 so this 




Figure 30: Toxicity screening of 5-FU and 5-FU-am (49). 
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In this case, the toxicity of 5-FU and 5-FU-am (49) are almost exactly the same. Presumably again this 
is due to the amide of 5-FU-am (49) being unstable and hydrolysed to release 5-FU. This led to a search 
for aliphatic secondary amine drugs which could be converted into stable amides. 
Monomethylauristatin E (MMAE) is a common ADC payload16 which exerts its anti-cancer activity by 
inhibiting tubulin polymerisation. One of its most important interactions with tubulin comes from a 
salt bridge between its positively charged ammonium and a negatively charged aspartate side chain.95 
MMAE bears an aliphatic secondary amine which was caged with 4-pentynoic acid (37) to give MMAE-
am (50) and tested for toxicity (Figure 31). MMAE-am (50) was expected to be less toxic than MMAE 







Figure 31: Binding mode of MMAE to its target tubulin including its important interaction with a positively charged 
ammonium and a negatively charged aspartate side chain. MMAE-am (50) was expected to disrupt this interaction and 
therefore lead to lower toxicity. Toxicity screening of MMAE and MMAE-am (50) in HeLa cells.  
Optimal concentrations are highlighted in red. 
Encouragingly MMAE-am (50) was much less toxic than MMAE. Caging with 4-pentynoic acid (37) gives 
an approximately 10x difference in toxicity at the optimal concentration (1.6 nM). Hence, 1.6 nM 
MMAE-am was incubated for the same amount of time in cell culture with non-toxic concentrations 
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of platinum salts K2PtIICl4 and K2PtIVCl6 (Figure 32). Unfortunately, cisplatin and satraplatin were too 
toxic to achieve high concentrations in cell culture, and their non-toxic concentrations were deemed 
too low to achieve a reaction. 
 
Figure 32: Decaging assay of K2PtIICl4 (Pt(II)) and K2PtIVCl6 (Pt(IV)) given twice daily at intervals of 8 h and 16 h as an aqueous 
solution for a total of 72 h. Optimal concentrations are highlighted in red. Concentration of MMAE-am (50) = 1.6 nM. 
Statistical significance was determined with a two-tailed unpaired t-test. ***p = 0.0001. **p = 0.0023. 
Pleasingly, with increasing non-toxic concentrations of K2PtIICl4 and K2PtIVCl6 in the presence of MMAE-
am (50) a large increase in toxicity is observed with 8 µM K2PtIICl4 and 4 µM K2PtIVCl6. Cisplatin and 
satraplatin were too toxic to achieve high concentrations. They would require sub-micromolar 
concentrations to not affect cell viability, meaning a very high reaction rate would be required in order 
to react efficiently with a nanomolar concentration of prodrug. It is also interesting to note that 
overconfluence of cells (> 100%) is observed for controls where cells are only treated with platinum 
complexes. It has been reported in the literature that platinum complexes can result in greater 
consumption of oxidative species by certain enzymes.235 The study did not extend to live cell cultures 
and therefore this effect could not be observed for cancerous cells. However, low concentrations of 
K2PtIICl4 and K2PtIVCl6 leading to a reduction of oxidative stress on cancer cells could offer an 
explanation of this effect. 
Around this time, a decaging reaction was reported of gold nanoparticles with a propargylated 5-FU 
compound pFU (51). This was reported to be an efficient, bioorthogonal reaction which was even 
demonstrated in Zebrafish.183 pFU (51) was tested for toxicity and decaging to verify whether it could 
potentially be reactive with platinum complexes despite not bearing the 4-pentynoic acid (37) caging 




Figure 33: Structure, toxicity and decaging of pFU (51) in the presence of platinum complexes K2PtIICl4 (Pt(II)) and K2PtIVCl6 
(Pt(IV)) as an aqueous solution for a total of 72 h. Optimal concentrations are highlighted in red. Statistical significance was 
determined with a two-tailed unpaired t-test. ***p = 0.0002. **p = 0.0018. ns = non-significant. 
Pleasingly, pFU (51) and 5-FU have a large difference in toxicity and showed efficient decaging with 16 
µM K2PtIICl4. Surprisingly no increase in toxicity could be seen with K2PtIVCl6 despite it having been 
successful with MMAE-am (50) (Figure 32). With evidence that this platinum mediated decaging 
reaction can function in cell culture, an ADC linker was designed that should be able to release a drug 
payload in the presence of platinum complexes and perhaps cisplatin (Figure 34). 
 
Figure 34: General structure of proposed targeted bioconjugates for the  
platinum mediated release of drug MMAE. 
The linker bears the drug MMAE as a secondary amine toxic payload, and the alkyne is extended with 
two PEG units before a cysteine-selective acrylamide bioconjugation handle. An ether was deemed the 
safest choice of linker to extend the alkyne as ethers are not known to bind strongly with platinum 
complexes or undergo many platinum mediated reactions. The PEG also offers a spacer between the 
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protein surface and metal reagent as well as increased water solubility. The linker could be synthesised 
in 8 steps from commercially available 2-(2-aminoethoxy)ethanol (52) (Scheme 25). 
 
Scheme 25: Synthesis of platinum-cleavable bioconjugation linker 59. 
2-(2-Aminoethoxy)ethanol (52) was initially Boc protected to afford 53 in order to allow selective O-
propargylation to give 54. This was then N-methylated with nBuLi and MeI and subsequently the alkyne 
was lithiated with nBuLi and reacted with oxetane activated by Lewis acid BF3∙Et2O to give alcohol 55. 
Alcohol 55 was first oxidised to an aldehyde with Dess-Martin periodinane (DMP), and then the 
aldehyde to an acid via Pinnick oxidation to afford 56. The crude acid 56 was coupled with MMAE using 
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HATU to give 57, Boc deprotected in HCl/dioxane and finally reacted with activated ester 58 to give 
the desired product 59. The acrylamide bioconjugation handle is unstable to Pinnick oxidation, and the 
presence of MMAE eliminates the possibility of intermediate purification by flash chromatography on 
silica as it renders the compounds too polar. Due to possible loss of product with repeated preparative 
HPLC purifications, it was decided that the product should only be purified after the final step. There 
were predictably many impurities in the chromatogram, and it required two successive purification 
procedures. With a pure sample of bioconjugation reagent 59 in hand, it was possible to selectively 
modify a model protein. A mutated Ubiquitin K63C (Ub) was selected as a small protein available in 
large quantities and at high concentration. This was reacted with an almost stoichiometric amount of 
acrylamide reagent 59 to give Ub-59 with a small amount of Ub (Figure 35). 
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Figure 35: LC-MS analysis of the modification of Ubiquitin K63C (Ub) with acrylamide 59 to give Ub-59. The reaction was 
incomplete, however the retention times of starting material and product were sufficiently resolved that the product peak 
in the HPLC could be integrated to exclusively monitor the product. Ub was kindly provided by Dr Ester Jiménez-Moreno. 
Samples of the reaction mixture were injected without further preparation and LC-MS run under denaturing conditions. 
While conversion was not complete, the starting material Ub and the product Ub-59 were very well 
separated in the chromatogram. It was thought that this separation would be sufficient to allow 
monitoring of a decaging reaction with cisplatin. Reactions with palladium complexes on proteins 
typically require palladium scavenger 3-mercaptopropionic acid (3-MPA).208,209,236,237 Therefore a 
screen of concentrations of 3-MPA was performed to verify that the conjugate Ub-59 was stable to 
thiols (Figure 36). 
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Figure 36: Stability study of conjugate Ub-59 with varying concentrations of platinum scavenger 3-MPA. 
The conjugate Ub-59 appeared stable to all concentrations of palladium scavenger 3-MPA tested. 
Interestingly, free Ub can be seen to form disulfide bonds with 3-MPA to form Ub-MPA (Mass 
calculated 8668, found 8669). 1000 equivalents of scavenger 3-MPA was selected as a suitable 
concentration to study cisplatin mediated decaging of conjugate Ub-59 as it should offer maximum 
scavenging of metals while not compromising protein stability. To study decaging, 10 equivalents of 
cisplatin in DMSO were added to conjugate Ub-59 and after 1 hour the reaction was quenched with 
1000 equivalents of scavenger 3-MPA (Figure 37). DMSO was required as a co-solvent due to the 
limited water solubility of cisplatin. 
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Figure 37: Unsuccessful decaging of conjugate Ub-59 with cisplatin. The final DMSO concentration in the reaction was 1%. 
The chaotic mass spectrum clearly indicated that the conditions of this experiment required further 
optimisation. While the mass of Ub can be seen (mass calculated 8562, found 8565) it is almost within 
the baseline of the spectrum. It was thought that the reaction would not be efficient enough to work 
with fewer than 10 equivalents of cisplatin, and therefore the equivalents of scavenger 3-MPA were 




Figure 38: Successful decaging of conjugate Ub-59 with cisplatin. The final DMSO concentration in the reaction was 1%. 
Some evidence of decaging can be seen by MS, however masses of the products are unexpected. One 
should correspond to fragmentation of MMAE (mass 9324), whereas others should correspond to 
MMAE release followed by further reaction of the linker (mass 8848, 8871, 8889, Figure 39). 
Decarboxylation seems a particularly likely reaction to give the major products (mass calculated 8889, 
found 8889) as decarboxylation reactions are well known in the literature for gold complexes.238–240 
The peaks are not easily explained mechanistically but should correspond to further degradation of 
the linker (Figure 39). 
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Figure 39: Potential explanations for product peaks observed after cisplatin decaging of conjugate Ub-59. 
The mechanism as to how these compounds could form is unclear, and further decaging studies should 
be performed to investigate. Firstly, other platinum complexes such as K2PtIICl4 and K2PtIVCl6 should be 
reacted with conjugate Ub-59 to see if the same products form. Small molecule analogues of Ub-59 
should also be synthesised to study the decaging by 1H NMR, isolating all products for full 
characterisation. To see if conversion in the reaction between cisplatin and Ub-59 could be increased, 





Figure 40: LC-MS analysis of attempted further optimisation of cisplatin mediated decaging of conjugate Ub-59. 
Unfortunately, leaving the reaction with 10 equivalents for longer (4 h) appeared to result in protein 
degradation as evidenced by the decrease in protein peaks in the chromatogram. The mass spectrum 
appears to only show Ub and Ub dimer (Ub2) which suggests that conjugate Ub-59 degrades the fastest. 
After reaction of conjugate Ub-59 with greater equivalents of cisplatin (20 eq.), protein peaks are still 
significant in the chromatogram. However integration of all protein peaks in the chromatogram leads 
to a mass spectrum in which no major protein peaks can be seen. This is likely due to non-specific 
binding of platinum to the proteins greatly reducing the intensity of any given species. 
An IgG antibody was also selected for conjugation with acrylamide 59. The F16* antibody111,115,241 
targets an alternatively spliced isoform of tenascin-C, a extracellular-matrix glycoprotein often 
overexpressed in tumours. As this is a non-internalising antibody, it was thought that this could later 
allow application to a solid-tumour model to test cisplatin mediated drug decaging. The F16* antibody 
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is a full IgG, but all interchain disulfide cysteines in the heavy chain have been mutated to serines. This 
leaves one reactive interchain disulfide cysteine per light chain (Figure 41). 
 
Figure 41: Native IgG antibody compared to mutated IgG antibody F16*, kindly provided by the group of Prof Dario Neri. 
Heavy chains are highlighted in dark blue and purple, light chains in light blue and glycosylation in grey. 
The reduced F16* antibody can therefore easily be reacted with electrophiles to produce an ADC with 
a DAR of 2. In this case, the fully reduced F16* antibody was reacted with 40 equivalents of acrylamide 




Figure 42: LC-MS analysis of  the modification of IgG antibody F16* with acrylamide 59. Samples of the reaction mixture 
were injected without further preparation and LC-MS run under denaturing conditions. 
In the starting material (antibody F16*) the light chain (mass calculated 22693, found 22700) and the 
heavy chain are clearly visible. Interestingly, the dimer of the light chain is also visible from the 
formation of a light chain-light chain disulfide. After reaction with 40 equivalents of acrylamide 59 for 
1 hour there is full conversion to the product F16*-59 (mass calculated 23787, found 23785) and 
negligible quantities of light chain dimer. Small molecule peaks in the chromatogram derived from 
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acrylamide 59 can be seen at 13.60 and 14.11 min of the reaction mixture. Dialysis of the reaction 
mixture was performed (Figure 43) using a dialysis device with a 3 kDa molecular weight cut-off. This 
allows small molecules of less than 3 kDa to diffuse across the membrane into a buffer solution while 




Figure 43: Chromatograms of F16* IgG antibody, crude reaction mixture of F16*-59 and purified F16*-59 after dialysis with 
a Slide-A-Lyzer™ MINI Dialysis Device into PBS (3 x). 
The chromatograms show a decrease in the presence of small molecules to negligible levels after 
dialysis of the reaction mixture. This is important as any biological evaluation of the non-internalising, 
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cisplatin cleavable ADC would be effected by the presence of any MMAE-containing small molecules. 
With this purified ADC in hand, these biological studies will be performed first in cell culture with 
cancer cell lines, and then perhaps in mice. 
4.3 Conclusions and Future Work 
In this project, we have taken the concept of a cisplatin-mediated decaging reaction, developed 
mechanistic hypotheses as to how this may work, and successfully developed these hypotheses into 
decaging reactions that function with prodrugs in cell culture, as well as enabling the synthesis of a 
platinum-cleavable ADC. While our original mechanistic hypothesis of an acid-to-alkyne cyclisation was 
incorrect, careful study allowed this false-positive result to be turned into a functioning reaction that 
offers many advantages over other bioorthogonal decaging reactions. In order to fully understand the 
reaction, further study will be required as to the fate of the alkyne-bearing protecting groups after 
cleavage to ensure that they are non-toxic. The simplest method to achieve this would be to derivatise 
the terminal alkynes to make them non-volatile, and isolate any products after decaging. To further 
study platinum-cleavable linkers, Ub-59 should be treated with platinum complexes such as K2Pt2Cl4 
and K2Pt2Cl6 to see if their greater reactivity allows the detection of MMAE and protein degradation 
products by LC-MS. The ADC F16*-59 should also be fully analysed by native MS as well as analytical 
size-exclusion chromatography to ensure that it is a single species and that bioconjugation does not 
result in excessive aggregation. 
As cisplatin is known to accumulate in tumours it would also be interesting to see if this accumulated 
cisplatin could be used to cause drug decaging. For this, a 3D model of tumours would be necessary. 
In a collaboration with the Godinho Ferreira lab, patient derived samples of tumours will be implanted 
into Zebrafish embryos where they continue to grow for a short time.242 First the Zebrafish will be 
incubated with cisplatin solutions to cause platinum accumulation in the tumour. The fish could then 
be washed, and incubated with pFU (51) to see if this then causes more tumour shrinkage than if the 
fish had just been incubated with cisplatin or pFU (51) alone (Figure 44). While this is very different 
from the final goal of non-internalising cisplatin-cleavable ADCs, it will tell us whether or not platinum 
mediated chemistry of cisplatin is feasible in a solid tumour with residual accumulated platinum. 
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Figure 44: Proposed Zebrafish studies to be carried out in the lab of Dr Miguel Godinho Ferreira by Dr João Diogo Osório de 
Castro Conde. 
Finally with the pure conjugate F16*-59, cancer cell cultures such as HeLa can be grown and first 
incubated with the ADC. Afterwards platinum complexes can be added to the culture to see if cell 
killing occurs. This would indicate that drug release is possible from an ADC in cell culture. Cellular 
studies with the F16* ADCs are not known in the literature and typically only mouse models are used. 
However it would still be useful to see whether or not drug release and cell killing can be induced from 
F16*-59 in cell culture, as if F16*-59 has low toxicity it would indicate that it is not being digested. It 
would also be interesting to see it would be possible to incubate cancerous cells with the ADC, wash 
out the excess ADC and then cause decaging with platinum complexes. This would indicate that drugs 
delivered to the close environment of cancerous cells can be much more efficacious than those in 
solution, and help elucidate whether a cisplatin cleavable ADC could be a therapeutic option in cancer. 
If these cellular decaging experiments seem promising, then tumour-xenograft models in mice will be 
performed. Firstly mice bearing tumours will be treated with the ADC F16*-59. Once the ADC F16*-59 
has accumulated to the maximum possible at its target site, cisplatin will be infused to see if this causes 
drug release and tumour shrinkage. In a second experiment, mice bearing tumours will be treated with 
cisplatin so that platinum complexes accumulate in the tumour. Afterwards the ADC F16*-59 will be 
infused, and it will be interesting to see if the residual platinum complexes will be sufficient to cause 














5.1 General Experimental Details 
Solvents, Reagents and Materials 
All reactions were carried out under a positive pressure of argon dried over CaCl2 unless otherwise 
stated. Oven dried glassware was heated to 140 °C and cooled under high vacuum. All reagents were 
purchased from commercial sources and were used as received. Distilled MeCN, DCM, MeOH, Et2O 
and toluene were freshly distilled over CaH2 under an atmosphere of argon. Distilled THF was pre-dried 
over CaH2 and then distilled over LiAlH4/Ph3CH. Dry DMF was obtained from commercial sources and 
used directly. DIPEA and TEA were distilled over CaH2 and stored under argon over 4 Å mol. sieves. 
Unless otherwise stated, water for HPLC or LC-MS was HPLC grade and water for synthesis was 
deionised. Flash column chromatography was performed on Material Harvest 60 Å silica and 
preparative TLC was performed on Merck PLC 60 F254 plates. Analytical TLC was visualized by UV at 
254 nm, ninhydrin or KMnO4 stain as appropriate. 
Characterisation 
IR spectrometry was carried out on a Perkin Elmer Spectrum One ATR FT-IR and melting points on a 
Stanford Research Systems OptiMelt. NMR spectra were recorded on Bruker 400-AVIII, DPX-400 or 
500-AVIII HD Smart Probe as appropriate. The residual solvent peaks were used as an internal 
reference for chemical shift (1H NMR CHCl3 δ 7.27 ppm, DMSO δ 2.50 ppm, D2O δ 4.79 ppm, MeOD δ 
3.31 ppm; 13C NMR CDCl3 δ 77.0 ppm, DMSO δ 39.5 ppm). Data are presented as follows: chemical 
shift (ppm), multiplicity (br. = broad, s = singlet, d = doublet, t = triplet, q = quartet, hept = heptet, m = 
multiplet), coupling constant J, and integration. High resolution mass spectra were obtained with a 
Thermo Fischer Orbitrap or Waters Xevo LC-MS and ionized by electrospray (ESI). Absorbance and 
fluorescence spectra or endpoints were measured in a BMG Clariostar in Greiner 300 µL 96-well, U-
bottom, clear polypropylene plates. 
General method of fluorescence assay for decaging optimisation 
200 M solutions of 7-amino-4-methylcoumarin (8) (fluorophore) and caged-fluorophore derivatives 
were prepared in 10% deionised H2O/DMF (v/v). Solutions of palladium catalysts were prepared to 
give twice their desired final concentration [Pd] in 10% deionised H2O/DMF (v/v). 50 L aliquots of 
caged fluorophore solutions were pipetted into a 96-well plate, and diluted with either 50 L solvent 
or 50 L palladium catalyst solution. Reaction progress was monitored at 23 °C by the fluorescence of 
7-amino-4-methylcoumarin: abs (max) 352 nm, em (max) 415 nm, bandwidth 8 nm. The gain and focus 
5. Experimental (Appendix) 
104 
of the plate reader were automatically adjusted before each assay based on 100 µM 7-amino-4-methyl 
coumarin. All reactions were performed in triplicate. 
General method of NMR screening for gold and platinum decaging optimisation 
Amides or carbamates (~10 mg) were dissolved in MeOD (0.2 mL), and gold or platinum complexes 
dissolved in D2O (0.6 mL). Sonication was required for complexes with limited aqueous solubility such 
as cisplatin. The solution of gold or platinum complex was then added to the solution of amide or 
carbamate and this marked as time t = 0 min. The reactions were monitored at various timepoints as 
well as after overnight reaction. After overnight reaction the conversion remains constant as the gold 
and platinum complexes have decomposed. All reactions were performed in air at room temperature. 
Cell Studies 
HEK (ATCC® CRL-1573™), MCF-7 (ATCC® HTB-22™) and HeLa (HeLa ATCC® CCL-2™) cells, kindly 
provided by the David Klenerman (Department of Chemistry, University of Cambridge, UK), Maria 
Mota (Instituto de Medicina Molecular, João Lobo Antunes, Portugal) and Shankar Balasubramanian 
(Department of Chemistry, University of Cambridge UK) groups respectively, were grown in a 
humidified incubator at 37 °C under 5% CO2 with 90% humidity, and split at approximately 80% 
confluence using Trypsin-EDTA solution 0.25%. HEK cells were grown in DMEM supplemented with 
heat-inactivated FBS, 100 units/mL penicillin, 100 μg/mL streptomycin and 0.25 μg/mL amphotericin 
B. MCF-7 and HeLa cells were grown in high glucose DMEM (+ pyruvate) supplemented with 10% heat-
inactivated FBS, 100 units/mL penicillin and 100 μg/mL streptomycin, 1% non-essential amino acids, 2 
mM GlutaMax™ and 10 mM HEPES. Cell viability experiments with MCF-7 and HeLa cells were 
performed without the presence of HEPES. All cell lines were grown to 80% confluency before seeding 
in 200 µL at 5000 (HEK), 3000 (MCF-7) and 5000 (HeLa) cells/well into a Corning Costar 96-well clear, 
flat bottom plate. AlamarBlue assays to determine toxicity were performed by adding 20 µL 
AlamarBlue solution to each well, and incubating (4 h for HEK cells, 6 h for MCF-7 and 6 h for HeLa). 
Determination of cell viability was as per supplier’s guidelines. Briefly, for HEK and MCF-7 studies 
fluorescence was then measured at λex 530-560 nm and λem 590 nm. The residual fluorescence of 
AlamarBlue in cell media was subtracted from each well as a background. Cell viability was calculated 
as 100 x Fcells / FDMSO, where F is the fluorescence of a given well, cells refers to treated cells being 
studied and DMSO refers to a 1% DMSO control defined as 100% viable. For HeLa studies, absorbance 
was measured at 570 nm and 600 nm. The residual absorbance of cell media at 570 nm and 600 nm 
was subtracted from each well as a background. Cell viability was calculated as 100 x (ε600 nm ∙ A570 nm – 
ε570 nm ∙ A600 nm)cells / (ε600 nm ∙ A570 nm – ε570 nm ∙ A600 nm)DMSO. All experiments were performed in triplicate. 
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ε refers to the molar extinction coefficient at the given wavelength, A refers to the absorbance of a 
well at the given wavelength, cells refers to treated cells and DMSO refers to a 1% DMSO control 
defined as 100% viable. 
HPLC 
HPLC was performed on a HPLC: Agilent Technologies 1100 Series G1313A system with a semi-
preparative ColumnL YMC-Pack Pro C18, 250 x 10 mm L.D., S-5 µm, 12 nm, AS12S05-2510WT. Crude 
product was dissolved in 1:1 MeCN/H2O and sterile filtered at 0.2 µm with EMD Millipore™ 
polyethersulfone syringe filters. 100 µL crude product aliquots were injected into the column and flow 
was maintained at 3.000 mL min-1 with solvent mixtures of MeCN/H2O + 0.1% TFA. UV-vis absorbance 
was monitored at 254 nm to indicate when to begin manual collection of fractions. MeCN was 
evaporated from the fractions under a flow of compressed air, and the remaining H2O/TFA solution 
flash frozen in liquid nitrogen then lyophilised. 
LC-MS method for analysis of protein conjugation 
For Chapter 3: 
LC-MS was performed on a Xevo G2-S TOF mass spectrometer coupled to an Acquity UPLC system 
using an Acquity UPLC BEH300 C4 column (1.7 µm, 2.1% 50 mm). Solvents A (H2O with 0.1% formic 
acid) and B (71% acetonitrile, 29% H2O, and 0.1% formic acid) were used as the mobile phase at a flow 
rate of 0.2 mL min–1. The gradient used was: 0-25 min 72% A/B-100% B, 25-27 min 100% B, 27-45 min 
72% A/B. The electrospray source was operated with a capillary voltage of 2.0 kV and a cone voltage 
of 40 V. Nitrogen was used as the desolvation gas at a total flow of 850 L h–1. Total mass spectra were 
reconstructed from the ion series using the MaxEnt algorithm preinstalled on MassLynx software 
(version 4.1 from Waters) according to the manufacturer’s instructions. To obtain the ion series 
described, the major peak(s) of the chromatogram were selected for integration and further analysis. 
For Chapter 4: 
LC-MS was performed on a Waters Acquiry UPLC system equipped with a single quadrupole mass 
detector using an Acquity UPLC protein BEH C4 column, 300 Å, (1.7 mm, 2.1 × 50 mm). Solvents A (H2O 
with 0.01% formic acid) and B (71% MeCN, 29% H2O and 0.075% formic acid) were used as the mobile 
phase at a flow rate of 0.2 mL min–1. The gradient used was: 0-12 min 28-71.2% A/B, 12-13 min 71.2-
100% A/B, 13-16 min 100% A/B, 16-16.5 min 100%-28% A/B, 16.5-20 min 28% A/B. The electrospray 
source was operated with a capillary voltage of 3.0 kV and a cone voltage of 20 V. Nitrogen was used 
as the desolvation gas at a total flow of 800 L h–1 with cone volume at 1 L h-1. Desolvation temperature 
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was set to 400 °C. Total mass spectra were reconstructed from the ion series using the MaxEnt 
algorithm preinstalled on MassLynx software (version 4.1 from Waters) according to the 
manufacturer’s instructions. To obtain the ion series described, the major protein peak(s) of the 
chromatogram were selected for integration and further analysis. 
Protein sequences 
2Rb17c205 (Calculated mass: 14861.46) 
EVQLQESGGG LVQPGGSLRL SCAASGFIFS NDAMTWVRQA PGKGLEWVSS INWSGTHTNY ADSVKGRFTI 
SRDNAKRTLY LQMNSLKDED TALYYCVTGY GVTKTPTGQG TQVTVSSHHH HHHSPSTPPT PSPSTPPC 
Ubiquitin K63C (Calculated mass: 8566.77) 
SAQIFVKTLT GKTITLEVEP SDTIENVKAK IQDKEGIPPD QQRLIFAGKQ LEDGRTLSDY NIQCESTLHL VLRLRGG 
F16*115 
Light Chain (Calculated mass: 22693.2) 
SSELTQDPAV SVALGQTVRI TCQGDSLRSY YASWYQQKPG QAPVLVIYGK NNRPSGIPDR FSGSSSGNTA 
SLTITGAQAE DEADYYCNSS VYTMPPVVFG GGTKLTVLGQ PKAAPSVTLF PPSSEELQAN KATLVCLISD 
FYPGAVTVAW KADSSPVKAG VETTTPSKQS NNKYAASSYL SLTPEQWKSH KSYSCQVTHE GSTVEKTVAP TECS 
Heavy Chain (Calculated mass: 48489.5) 
EVQLLESGGG LVQPGGSLRL SCAASGFTFS RYGMSWVRQA PGKGLEWVSA ISGSGGSTYY ADSVKGRFTI 
SRDNSKNTLY LQMNSLRAED TAVYYCAKAH NAFDYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA 
LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN VNHKPSNTKV 
DKKVEPKSSD KTHTSPPSPA PELLGGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG 
VEVHNAKTKP REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 
PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN 
VFSCSVMHEA LHNHYTQKSL SLSPGK 
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5.2 Synthetic Procedures for Chapter 3 
Propargyl (7-amino-4-methylcoumarin)carbamate (7) 
 
7-amino-4-methylcoumarin (8) (50 mg, 1 eq., 0.285 mmol) was dissolved in dry DMF (1.5 mL) in an 
oven dried flask. K2CO3 (118 mg, 1.5 eq., 0.428 mmol) was added and the solution chilled to 0 ˚C. 
Propargyl chloroformate (0.04 mL, 1.5 eq., 0.428 mmol) was then added dropwise and the reaction 
stirred for 30 min before pouring over icewater (25 mL). The precipitate was filtered and washed with 
icewater (4 x 3 mL) then EtOH (3 x 3 mL) to give the desired product a yellow solid (22 mg, 0.0855 
mmol, 30%). The product was used without further purification. The data were in accordance with 
literature.181 
1H NMR (400 MHz, DMSO-d6) δ 10.36 (br. s, 1H; NH), 7.71 (d, J = 8.56 Hz, 1H; Haromatic(5)), 7.49 - 7.57 (m, 
1H; Haromatic(8)), 7.41 (d, J = 8.56 Hz, 1H; Haromatic(6)), 6.25 (s, 1H; Haromatic(3)), 4.82 (s, 2H; OCH2), 3.57 - 3.64 




7-amino-4-methylcoumarin (8) (100 mg, 1 eq., 0.570 mmol) and triphosgene (85 mg, 0.5 eq., 0.285 
mmol) were dissolved in freshly distilled toluene (20 mL) and refluxed for 0.5 h in oven dried glassware. 
The reaction mixture was then evaporated in vacuo to give the desired product which was used 
without further purification. 
1H NMR (400 MHz, DMSO-d6)  7.41 (d, J = 8.56 Hz, 1H; H5), 6.57 (dd, J = 1.47, 8.56 Hz, 1H; H6), 6.41 (d, 
J = 1.47 Hz, 1H; H8), 5.90 (s, 1H; H3), 2.30 (s, 3H; CH3) 
MS(ESI): calcd. for C11H8NO3Na [M+H]+ 202.0499, found 202.0492 
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Propargyl trityl thioether (9a) 
 
K2CO3 (750 mg, 3 eq., 5.43 mmol) was dried under high vacuum for 2 h before adding dry DMF (5 mL), 
followed by 80% propargyl bromide in toluene (0.6 mL, 3 eq., 5.43 mmol). Triphenylmethane thiol (500 
mg, 1 eq., 1.81 mmol) was then added in one portion at room temperature and the reaction stirred at 
room temperature for 6 h. The reaction was then diluted in Et2O (80 mL) and washed with icewater (2 
x 30 mL), then icewater/brine (30 mL). The organics were dried over MgSO4, and evaporated in vacuo 
to give the desired product as a light yellow solid (457 mg, 1.45 mmol, 80%).  
Rf (petrol) 0.19 
m.p. 127.5-130.5 ˚C 
IR (ATR) / cm-1: 3299, 3065, 1593, 1485, 1441 
1H NMR (400 MHz, CDCl3)  7.44 (d, J = 7.58 Hz, 6H; Haromatic), 7.30 - 7.35 (m, 6H; Haromatic), 7.23 - 7.29 
(m, 3H; Haromatic), 2.83 (d, J = 2.5 Hz, 2H; CH2), 2.19 (t, J = 2.5 Hz, 1H; C≡CH) 
13C NMR (101 MHz, CDCl3)  144.0, 129.5, 128.1, 126.8, 79.1, 71.8, 67.2, 20.2 




Propargyl trityl thioether (9a) (100 mg, 1 eq., 0.318 mmol) was added to an oven dried flask and 
dissolved in freshly distilled THF (5 mL). The solution was cooled to -78 ˚C before adding 2.5 M nBuLi in 
hexanes (0.14 mL, 1.1 eq., 0.350 mmol) dropwise. After 20 min stirring at -78 ˚C, (CH2O)n (30 mg, 3 eq., 
0.715 mmol) that had been previously dried under high vacuum overnight was added in one portion. 
After a further 20 min stirring, the reaction was warmed to room temperature and stirred for 4 h. The 
reaction mixture was poured over ice (30 mL) and extracted with EtOAc (2 x 50 mL). The organics were 
washed with icewater/brine (30 mL), dried over MgSO4, filtered and evaporated. The crude material 
was purified by preparative TLC (2 mm, 25% EtOAc/petrol) to give the desired product as a yellow waxy 
solid (88 mg, 0.255 mmol, 80%).  
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Rf (25% EtOAc/petrol) 0.23 
IR (ATR) / cm-1: 3377, 3056, 2924, 1594, 1486, 1444 
1H NMR (400 MHz, CDCl3)  7.46 (d, J = 7.7 Hz, 6H; Haromatic), 7.34 (t, J = 7.7 Hz, 6H; Haromatic), 7.23 - 7.29 
(m, 3H; Haromatic), 4.18 - 4.22 (m, 2H; SCH2), 2.88 - 2.92 (m, 2H; CH2O), 1.59 (br. s., 1H; OH) 
13C NMR (101 MHz, CDCl3)  144.1, 129.6, 128.0, 126.9, 81.9, 81.2, 67.2, 51.2, 20.5 
MS(ESI): calcd. for C23H20O32SNa [M+Na]+ 367.1127, found 367.1129 
 
4-(Tritylthio)but-2-ynl (7-amino-4-methylcoumarin)carbamate (9) 
 
Isocyanate 8a (57 mg, 1 eq., 0.283 mmol) and alcohol 9b (98 mg, 1 eq., 0.283 mmol) were dissolved in 
freshly distilled THF (5 mL) at room temperature in an oven dried flask. Dibutyltin dilaurate (0.01 mL, 
0.06 eq., 16.9 mol) was added, and the reaction stirred for 1 h. The product was precipitated by 
dropwise addition of water (15 mL) and filtered. The precipitate was washed with MeOH (3 x 3 mL), 
Et2O (3 x 3 mL) and petrol (3 x 3 mL), then dried in vacuo to give the desired product as an off-white 
powder (110 mg, 0.201 mmol, 71%). 
m.p. 184.5-188.0 ˚C 
IR (ATR) / cm-1: 3278, 3084, 1739, 1697, 1625, 1591, 1531 
1H NMR (400 MHz, DMSO-d6)  10.34 (s, 1H; NH), 7.71 (d, J = 8.60 Hz, 1H; H5), 7.53 (d, J = 1.96 Hz, 1H; 
H8), 7.41 (dd, J = 1.96, 8.60 Hz, 1H; H6), 7.30 - 7.39 (m, 12H; Haromatic), 7.23 - 7.29 (m, 3H; Haromatic), 6.25 
(s, 1H; H3), 4.73 - 4.77 (m, 2H; OCH2), 2.89 - 2.94 (m, 2H; SCH2), 2.39 (s, 3H; CH3) 
13C NMR (101 MHz, DMSO-d6)  160.4, 154.3, 153.6, 152.9, 144.1, 142.9, 129.5, 128.6, 127.4, 126.6, 
115.0, 114.7, 112.5, 105.0, 82.5, 78.7, 67.4, 53.1, 20.2, 18.5 
MS(ESI): calcd. for C34H27NO432SNa [M+Na]+ 568.1553, found 568.1549 
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tert-Butyl prop-2-yn-1-yl thioether (10a) 
 
NaOH (106 mg, 1.2 eq., 2.66 mmol) was dissolved in MeOH (4.5 mL) before chilling to 0 ˚C and 80% 
propargyl bromide in toluene (0.37 mL, 1.5 eq., 3.33 mmol) was added. tBuSH (0.25 mL, 1 eq., 2.22 
mmol) was then added in one portion and the reaction warmed to room temperature. After 3 h 
stirring, the reaction mixture was evaporated in vacuo, the residues diluted in water (30 mL) and 
extracted with DCM (3 x 20 mL). The organics were dried over MgSO4 and evaporated in vacuo to give 
the desired product as a yellow oil (185 mg, 1.44 mmol, 65%). The data were in accordance with the 
literature.243 




Alkyne 10a (185 mg, 1 eq., 1.44 mmol) was dissolved in freshly distilled THF (10 mL) and chilled to -78 
˚C in an oven dried flask. 2.5 M nBuLi in hexanes (0.63 mL, 1.1 eq., 1.59 mmol) was then added 
dropwise. (CH2O)n (65 mg, 1.5 eq., 2.16 mmol) was added after 10 min. The reaction was warmed to 
room temperature and stirred for 1 h before pouring over sat. aq. NH4Cl (20 mL) and extracting with 
Et2O (3 x 20 mL). The organics were dried over MgSO4 and evaporated in vacuo. The crude material 
was purified by flash chromatography with 50% Et2O/petrol on silica (26 g) to give the desired product 
as a light yellow oil (71 mg, 0.448 mmol, 31%). The data were in accordance with the literature.244 
Rf (50% Et2O/petrol) 0.31 





4-(tert-Butylthio)but-2-yn-1-yl (7-amino-4-methylcoumarin)carbamate (10) 
 
7-amino-4-methylcoumarin (8) (50 mg, 1 eq., 0.285 mmol) and triphosgene (42 mg, 0.5 eq., 0.143 
mmol) were dissolved in freshly distilled toluene (10 mL) in and refluxed for 0.5 h in oven dried 
glassware before evaporating in vacuo. The crude isocyanate was then dissolved in freshly distilled THF 
(5 mL) at room temperature and alcohol 10b (68 mg, 1.5 eq., 0.428 mmol) was added followed by 
dibutyltin dilaurate (0.01 mL, 0.06 eq., 20.4 µmol). After 1 h, the reaction was chilled to 0 ˚C and water 
(15 mL) was added dropwise to precipitate the product. The precipitate was filtered and washed with 
MeOH (3 mL), Et2O (2 x 3 mL) and petrol (3 mL), then dried in vacuo to give the desired product as an 
off-white powder (34 mg, 0.0938 mmol, 33%). 
m.p. 175.1-176.3 °C 
IR (ATR) / cm-1: 3263, 3058, 2963, 1721, 1686, 1620 
1H NMR (400 MHz, DMSO-d6)  7.69 (d, J = 8.74 Hz, 1H; H5), 7.52 (d, J = 2.06 Hz, 1H; H8), 7.39 (dd, J = 
2.06, 8.74 Hz, 1H; H6), 6.24 (d, J = 1.28 Hz, 1H; H3), 4.82 (t, J = 2.10 Hz, 2H; OCH2), 3.44 (t, J = 2.10 Hz, 
2H; SCH2), 2.38 (d, J = 1.28 Hz, 3H; ArCH3), 1.30 (s, 9H; (CH3)3) 
13C NMR (126 MHz, DMSO-d6)  160.4, 154.3, 153.6, 153.0, 142.9, 126.5, 115.0, 114.7, 112.5, 105.0, 
85.2, 77.0, 53.3, 43.5, 30.9, 18.5, 16.4 




Sodium methanethiolate (500 mg, 1.5 eq., 7.13 mmol) was suspended in dry DMF (5 mL) in an oven 
dried flask, and chilled in a room temperature water bath. 80% propargyl bromide in toluene (0.53 mL, 
1 eq., 4.76 mmol) was added dropwise, and the reaction stirred for 5 h. The reaction mixture was then 
poured over icewater basified to > pH 10 with sat. Na2CO3 solution (100 mL), and diluted with Et2O 
(100 mL). The organics were washed with icewater basified to > pH 10 with sat. Na2CO3 solution (2 x 
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80 mL), then icewater/brine (50 mL), dried over MgSO4 and then further dried over 4 Å mol. sieves. 
This solution was transferred via cannula to an oven dried flask, and then chilled to -78 ˚C. 2.5 M nBuLi 
in hexanes (2.85 mL, 1.5 eq., 7.13 mmol) was then added dropwise, and the reaction stirred for 10 min 
before (CH2O)n (428 mg, 3.0 eq., 14.3 mmol) was added. The reaction was allowed to warm to room 
temperature and stirred for 1 h. The reaction mixture was washed with icewater (100 mL), and the 
aqueous layer was further extracted with Et2O (100 mL). The organics were washed with brine (50 mL), 
dried over MgSO4 and evaporated. The crude oil was purified by flash chromatography with 50% 
Et2O/petrol on silica (49 g) to give the desired product as a malodorous, cloudy, viscous oil (146 mg, 
1.25 mmol, 26%).  
Rf (50% Et2O/petrol) 0.26 
1H NMR (400 MHz, CDCl3)  4.32 (s, 2H; OCH2), 3.26 - 3.31 (m, 2H; SCH2), 2.24 (s, 3H; CH3) 
13C NMR (126 MHz, CDCl3) δ 81.7, 81.0, 51.1, 21.7, 15.3 
MS(ESI): calcd. for C5H8O32SNa [M+Na]+ 139.0188, found 139.0188 
 
4-(Methylthio)but-2-ynl (7-amino-4-methylcoumarin)carbamate (11) 
 
Isocyanate 8a (40 mg, 1 eq., 0.199 mmol) and alcohol 24 (29 mg, 1.26 eq., 0.251 mmol) were dissolved 
in freshly distilled THF (5 mL) at room temperature. Dibutyltin dilaurate (0.01 mL, 0.08 eq., 17.4 mol) 
was added, and the reaction stirred for 1 h. The reaction mixture was evaporated to ~¾ its volume, 
and the product precipitated by dropwise addition of water (4 mL). The precipitate was washed with 
water (4 x 3 mL), MeOH (3 x 3 mL), Et2O (3 x 3 mL) and petrol (3 x 3 mL), then dried in vacuo to give 
the desired product as a white powder (38 mg, 0.121 mmol, 61%).  
Decomp. 208 ˚C 
IR (ATR) / cm-1: 3276, 3172, 3100, 1738, 1687, 1627, 1593, 1534 
1H NMR (400 MHz, DMSO-d6)  10.37 (br. s, 1H; NH), 7.71 (d, J = 8.51 Hz, 1H; H5), 7.53 (d, J = 1.36 Hz, 
1H; H8), 7.41 (dd, J = 1.36, 8.51 Hz, 1H; H6), 6.25 (s, 1H; H3), 4.85 - 4.88 (m, 2H; OCH2), 3.41 - 3.44 (m, 
2H; SCH2), 2.39 (s, 3H; CH3), 2.16 (s, 3H; SCH3) 
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13C NMR (101 MHz, DMSO-d6)  160.5, 154.3, 153.6, 152.9, 142.8, 126.5, 115.0, 114.7, 112.5, 105.0, 
83.8, 77.6, 53.3, 20.9, 18.5, 15.0 




A solution of 2.5 M nBuLi in hexanes (1.17 mL, 1.2 eq., 2.92 mmol) in freshly distilled THF (12 mL) was 
chilled to -78 ˚C in an oven dried flask, and 3-dimethylamino-1-propyne (0.26 mL, 1 eq., 2.44 mmol) 
added dropwise. After 1 h, (CH2O)n (146 mg, 2 eq., 4.88 mmol) was added in one portion and the 
reaction allowed to warm to room temperature. After 1 h, the reaction was quenched with brine (20 
mL) and extracted with EtOAc (3 x 20 mL). The organics were dried over MgSO4 and evaporated in 
vacuo to give the desired product as a yellow oil (219 mg, 1.93 mmol, 80%). The data were in 
accordance with the literature.245 
1H NMR (400 MHz, CDCl3)  4.27 (t, J = 2.15 Hz, 2H; OCH2), 3.25 (t, J = 2.15 Hz, 2H; NCH2), 2.29 (s, 6H; 
CH3) 
 
4-(Dimethylamino)but-2-ynl (7-amino-4-methylcoumarin)carbamate (12) 
 
7-amino-4-methylcoumarin (8) (60 mg, 1 eq., 0.339 mmol) and triphosgene (50 mg, 0.5 eq., 0.169 
mmol) were dissolved in freshly distilled toluene (10 mL) and refluxed for 0.5 h in oven dried glassware 
before evaporating in vacuo. The crude isocyanate was then suspended in freshly distilled THF (5 mL) 
at room temperature and alcohol 12a (57 mg, 1.5 eq., 0.508 mmol) was added followed by dibutyltin 
dilaurate (0.01 mL, 0.06 eq., 20.4 mol). After 1 h, the product was precipitated by the dropwise 
addition of water (10 mL), chilling to 0 ˚C, and dropwise addition of Na2CO3 until pH 10. Futher water 
(5 mL) was added dropwise and the suspension stirred for 10 min. The precipitate was filtered and 
washed with MeOH (3 mL), Et2O (2 x 3 mL) and petrol (3 mL), then dried in vacuo to give the desired 
product as an off-white powder (37 mg, 0.117 mmol, 35%). 
5. Experimental (Appendix) 
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Decomp. 178 ˚C 
IR (ATR) / cm-1: 3277, 2954, 2931, 2856, 1736,, 1687, 1624, 1591, 1530 
1H NMR (500 MHz, DMSO-d6)  7.71 (d, J = 8.78 Hz, 1H; H5), 7.54 (d, J = 1.91 Hz, 1H; H8), 7.41 (dd, J = 
1.91, 8.78 Hz, 1H; H6), 6.25 (s, 1H; H3), 4.85 - 4.88 (m, 2H; OCH2), 3.25 - 3.30 (m, 2H; NCH2), 2.39 (s, 3H; 
CH3), 2.17 (s, 6H; N(CH3)2) 
13C NMR (126 MHz, DMSO-d6)  160.5, 154.3, 153.6, 153.0, 143.0, 126.6, 115.0, 114.8, 112.5, 105.0, 
82.9, 80.1, 53.2, 47.6, 44.1, 18.5 
MS(ESI): calcd. for C15H20N2O4Na [M+Na]+ 315.1215, found 315.1322 
 
Propargyl trityl ether (13a) 
 
Propargyl alcohol (1.75 mL, 1 eq., 30.0 mmol) was dissolved in distilled DCM (15 mL) with 4 Å mol. 
sieves. DMAP (73 mg, 0.02 eq., 0.600 mmol) and pyridine (2.45 mL, 1.01 eq., 30.0 mmol) were added, 
followed by triphenylmethyl chloride (9.2 g, 1.1 eq., 33.0 mmol) in one portion and the reaction stirred 
at room temperature for 18 h. The reaction was then poured onto ice (200 mL) and then acidified to < 
pH 2 with 3 M HCl. The aqueous mixture was then extracted with EtOAc (3 x 150 mL). The organics 
were washed with icewater/brine (200 mL), dried over MgSO4 and evaporated in vacuo. The crude 
material was dry-loaded onto silica (30 g) with EtOAc, and purified by flash chromatography with a 
gradient of 1-5% Et2O/petrol, on silica (188 g) to give the product as a white powder (4.04 g, 13.5 mmol, 




Propargyl trityl ether (13a) (2.0 g, 1 eq., 6.70 mmol) and (CH2O)n (604 mg, 3 eq., 20.1 mmol) were dried 
separately under high vacuum overnight, before dissolving 13a in distilled THF (40 mL) and chilling the 
solution to -78 ˚C in an oven dried flask. 2.5 M nBuLi in hexanes (2.95 mL, 1.1 eq., 7.37 mmol) was then 
added dropwise, and the reaction stirred at -78 ˚C for 10 mins. (CH2O)n was then added in one portion, 
and the reaction stirred for 2 h before warming to room temperature and stirring for a further 1 h. The 
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reaction was poured over ice (100 mL) and extracted with EtOAc (3 x 100 mL). The organics were 
washed with icewater/brine (50 mL), dried over MgSO4 and evaporated in vacuo. The crude material 
was dry-loaded onto silica (10 g) and purified by flash chromatography with 30% EtOAc/petrol on silica 
(193 g) to give product as a white powder (1.71 g, 5.23 mmol, 78%). The data were in accordance with 
literature.247 
1H NMR (400 MHz, CDCl3)  7.51 (d, J = 7.5 Hz, 6H; Haromatic), 7.35 (t, J = 7.5 Hz, 6H; Haromatic), 7.28 (t, J = 
7.09 Hz, 3H; Haromatic), 4.29 (s, 2H; CH2), 3.87 (s, 2H; CH2) 
 
4-(Trityloxy)but-2-ynl (7-amino-4-methylcoumarin)carbamate (13) 
 
Isocyanate 8a (40 mg, 1 eq., 0.199 mmol) and alcohol 13b (72 mg, 1.1 eq., 0.219 mmol) were dissolved 
in freshly distilled THF (5 mL) at room temperature in an oven dried flask. Dibutyltin dilaurate (0.01 
mL, 0.08 eq., 16.9 mol) was added, and the reaction stirred for 1 h. The product was precipitated by 
dropwise addition of water (15 mL) and filtered. The precipitate was washed with MeOH (3 x 3 mL), 
Et2O (3 x 3 mL) and petrol (3 x 3 mL), then dried in vacuo to give the desired product as a white powder 
(77 mg, 0.145 mmol, 73%). 
m.p. 192.1-194.9 ˚C 
IR (ATR) / cm-1: 3281, 1734, 1697, 1619, 1582, 1534 
1H NMR (400 MHz, DMSO-d6)  10.38 (s, 1H; NH), 7.71 (d, J = 8.86 Hz, 1H; H5), 7.55 (d, J = 1.70 Hz, 1H; 
H8), 7.42 (dd, J = 1.70, 8.86 Hz, 1H; H6), 7.33 - 7.40 (m, 12H; Haromatic), 7.24 - 7.32 (m, 3H; Haromatic), 6.25 
(s, 2H; H3), 4.84 - 4.87 (m, 2H; OCH2), 3.77 - 3.80 (m, 2H; OCH2), 2.39 (s, 3H; CH3) 
13C NMR (101 MHz, DMSO-d6)  160.4, 154.3, 153.6, 152.9, 143.5, 142.9, 128.5, 127.7, 126.6, 115.0, 
114.7, 112.5, 105.0, 87.4, 83.6, 80.8, 67.5, 53.0, 25.6, 18.5 
MS(ESI): calcd. for C34H27NO5Na [M+Na]+ 552.1781, found 552.1763 
 
  




Methyl propargyl ether (0.85 mL, 1 eq., 10.0 mmol) was dissolved in freshly distilled THF (30 mL) in an 
oven dried flask. The solution was cooled to 0 ˚C, and 2.5 M nBuLi in hexanes (4.4 mL, 1.1 eq., 11.0 
mmol) was added dropwise. The reaction was stirred for 30 min at 0 ˚C before (CH2O)n (0.45 g, 1.5 eq., 
15.0 mmol) was added in one portion. After 1 h at 0 ̊ C, the reaction was diluted with sat. NH4Cl solution 
(50 mL) and extracted with EtOAc (3 x 80 mL). The organics were washed with icewater/brine (50 mL), 
dried over MgSO4 and evaporated in vacuo to yield the product as a light yellow liquid (738 mg, 7.37 
mmol, 74%). The data were in accordance with the literature.248 
1H NMR (400 MHz, CDCl3)  4.27 - 4.33 (m, 2H; OCH2), 4.10 - 4.16 (m, 2H; OCH2), 3.38 (s, 3H; OCH3), 
2.74 (br. s, 1H; OH) 
 
4-Methoxybut-2-ynl (7-amino-4-methylcoumarin)carbamate (14) 
 
Isocyanate 8a (40 mg, 1 eq., 0.199 mmol) and alcohol 25 (25 mg, 1.26 eq., 0.249 mmol) were dissolved 
in freshly distilled THF (5 mL) at room temperature in an oven dried flask. Dibutyltin dilaurate (0.01 
mL, 0.08 eq., 16.9 mol) was added, and the reaction stirred for 1 h. The precipitate was filtered 
washed with water (4 x 3 mL), MeOH (4 x 3 mL), Et2O (3 x 3 mL) and petrol (3 x 3 mL), then dried in 
vacuo to give the desired product as an off-white powder (27 mg, 0.0896 mmol, 45%).  
Decomp. 186 ˚C 
IR (ATR) / cm-1: 2928, 2323, 1726, 1689, 1618 
1H NMR (500 MHz, DMSO-d6)  10.37 (br. s, 1H; NH), 7.70 (d, J = 8.78 Hz, 1H; H5), 7.53 (d, J = 1.91 Hz, 
1H; H8), 7.40 (dd, J = 1.91, 8.78 Hz, 1H; H6), 6.24 (d, J = 0.92 Hz, 1H; H3), 4.89 (br. t, J = 1.80 Hz, 1H; 
OCH2), 4.16 (br. t, J = 1.80 Hz, 1H; OCH2), 3.27 (s, 3H; OCH3), 2.39 (d, J = 0.92 Hz, 3H; CH3) 
13C NMR (126 MHz, DMSO-d6)  160.5, 154.2, 153.6, 152.9, 142.8, 126.6, 115.0, 114.8, 112.5, 105.0, 
83.6, 81.6, 59.4, 57.4, 53.1, 18.5 
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MS(ESI): calcd. for C16H15NO5Na [M+Na]+ 324.0842, found 324.0827 
 
Hex-2-yn-1-yl (7-amino-4-methylcoumarin)carbamate (15) 
 
Triphosgene (85 mg, 1 eq., 0.285 mmol) was dissolved in DCM (10 mL) previously dried over 4 Å mol. 
sieves and then chilled to 0 ̊ C. 2-hexyn-1-ol (0.09 mL, 3 eq., 0.856 mmol) was added dropwise followed 
by pyridine (0.07 mL, 3 eq., 0.856 mmol). The reaction was allowed to warm to room temperature and 
stirred for 3 h before evaporating in vacuo. The crude solids were triturated with freshly distilled Et2O 
(3 x 4 mL) and the filtrate evaporated in vacuo to give the crude chloroformate. This was added 
dropwise to a suspension of 7-amino-4-methylcoumarin (8) (50 mg, 1 eq., 0.285 mmol) and K2CO3 (59 
mg, 1.5 eq., 0.428 mmol) in dry DMF (1 mL). To ensure complete addition, the chloroformate flask was 
rinsed with further dry DMF (0.5 mL). The reaction was stirred at 0 ˚C for 30 min then icewater (5 mL) 
was added slowly dropwise before pouring the mixture over icewater (20 mL). The precipitate was 
filtered and washed with icewater (4 x 3 mL) then EtOH (3 x 3 mL) to give the desired product as an 
off-white powder (27 mg, 0.0902 mmol, 32%).  
Decomp. 208 ˚C 
IR (ATR) / cm-1: 3276, 2958, 1734, 1688, 1622, 1590, 1528 
1H NMR (400 MHz, DMSO-d6) δ 10.32 (br. s, 1H; NH), 7.70 (d, J = 8.56 Hz, 1H; Haromatic(5)), 7.53 (s, 1H; 
Haromatic(8)), 7.41 (d, J = 8.56 Hz, 1H; Haromatic(6)), 6.24 (s, 1H; Haromatic(3)), 4.80 (s, 2H; OCH2), 2.39 (s, 3H; 
CH3), 2.23 (t, J = 6.9 Hz, 2H; CH2CH2), 1.48 (sxt, J = 6.9 Hz, 2H; CH2CH3), 0.94 (t, J = 6.9 Hz, 3H; CH2CH3) 
13C NMR (126 MHz, DMSO-d6) δ 165.2, 159.0, 158.4, 157.8, 147.7, 131.2, 119.7, 119.5, 117.2, 109.7, 
92.5, 80.2, 58.2, 26.6, 25.1, 23.2, 18.4 




5. Experimental (Appendix) 
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Propargyl chloride (0.2 mL, 1 eq., 2.68 mmol) was dissolved in freshly distilled Et2O (10 mL) and chilled 
to -78 ˚C in an oven dried flask. 2.5 M nBuLi in hexanes (0.96 mL, 0.91 eq., 2.44 mmol) was then added 
quickly dropwise. After 10 min, (CH2O)n (96 mg, 1.2 eq., 3.22 mmol) was added in one portion. The 
reaction was warmed to room temperature and stirred for 1 h before pouring over sat. aq. NH4Cl (20 
mL) and extracting with Et2O (3 x 20 mL). The organics were dried over MgSO4 and evaporated in vacuo 
to give the desired product as an orange oil (209 mg, 2.00 mmol, 72%). The data were in accordance 
with the literature.249 
Rf (1% MeOH/DCM) 0.27 
1H NMR (400 MHz, CDCl3)  4.23 - 4.26 (m, 2H), 4.13 (t, J = 1.92 Hz, 2H) 
 
Methyl N-(tert-butoxycarbonyl)-S-(4-hydroxybut-2-yn-1-yl)-L-cysteinate (16a) 
 
KOAc (1.514 g, 3.5 eq., 15.0 mmol) was suspended in acetone (100 mL) and propargyl chloride 32 (0.67 
g, 1.5 eq., 6.44 mmol) added. BocCysOMe (1.01 g, 1 eq., 4.29 mmol) was then added and the reaction 
stirred at room temperature for 20 h. The reaction was then evaporated in vacuo, and purified by flash 
chromatography with 40% EtOAc/petrol on silica (60 g) to give the desired product as a light orange 
oil (1.01 g, 3.33 mmol, 78%).  
Rf (50% EtOAc/petrol) 0.16 
IR (ATR) / cm-1: 3382, 2978, 1742, 1698, 1511 
1H NMR (400 MHz, CDCl3)  5.41 - 5.53 (m, 1H; NH), 4.53 - 4.70 (m, 1H; αCH), 4.23 (br. s, 1H; OH), 3.74 
(s, 3H; CH3), 3.21 - 3.39 (m, 2H; SCH2), 2.95 - 3.18 (m, 2H; βCH2), 1.41 (s, 9H; (CH3)3) 
13C NMR (101 MHz, CDCl3)  171.6, 155.3, 82.8, 80.6, 80.4, 53.3, 52.6, 50.8, 33.8, 28.3, 20.2 







7-amino-4-methylcoumarin (8) (35 mg, 1 eq., 0.200 mmol) and triphosgene (30 mg, 0.5 eq., 0.100 
mmol) were dissolved in freshly distilled toluene (10 mL) and refluxed for 0.5 h in oven dried glassware 
before evaporating in vacuo. The crude isocyanate was then dissolved in freshly distilled THF (3 mL) at 
room temperature and alcohol 16a (85 mg, 1.4 eq., 0.280 mmol) in further THF (2 mL) was added 
followed by dibutyltin dilaurate (0.01 mL, 0.08 eq., 16.9 µmol). After 1 h, the reaction was evaporated 
in vacuo and re-dissolved in DCM (10 mL). 10% aqueous KF (10 mL) was added and stirred for 10 min 
before the layers were separated. The aqueous layer was extracted with DCM (2 x 10 mL) and the 
organics were dried over MgSO4, filtered and evaporated in vacuo. The crude solids were triturated 
with MeOH (3 x 3 mL), Et2O (3 x 3 mL) and petrol (3 x 3 mL) to give the desired product as an off-white 
powder (41 mg, 0.0821 mmol, 41%).  
m.p. 137-139 °C  
IR (ATR) / cm-1: 3284, 3082, 2986, 1741, 1683, 1624 
1H NMR (500 MHz, DMSO-d6)  10.39 (s, 1H; NH), 7.72 (d, J = 8.85 Hz, 1H; H5), 7.54 (d, J = 1.83 Hz, 1H; 
H8), 7.41 (dd, J = 1.83, 8.85 Hz, 1H; H6), 6.25 (d, J = 0.92 Hz, 1H; H3), 4.92 (t, J = 1.83 Hz, 1H; OCH2), 4.55 
(t, J = 1.83 Hz, 1H; OCH2), 4.12 - 4.17 (m, 1H; αCH), 3.64 - 3.66 (m, 3H; CO2CH3), 2.78 - 2.95 (m, 2H; 
SCH2), 2.67 - 2.74 (m, 1H; SCH2), 2.55 - 2.62 (m, 1H; SCH2), 2.40 (s, 3H; ArCH3), 1.40 (s, 9H; (CH3)3) 
13C NMR (126 MHz, DMSO-d6)  171.2, 160.0, 155.3, 153.8, 153.2, 152.4, 142.3, 126.1, 114.8, 114.2, 
112.0, 104.3, 82.1, 81.2, 78.4, 56.1, 52.4, 51.9, 30.6, 28.1, 25.3, 18.0 
MS(ESI): calcd. for C24H28N2O8SNa [M+Na]+ 527.1459, found 527.1443 
 
  




PdCl2 (200 mg, 1 eq., 1.13 mmol) was suspended in concentrated HCl (~37%, 0.5 mL) and gently 
warmed until fully dissolved. The solution was cooled to room temperature and then diluted with 
absolute ethanol (15 mL). The solution was filtered, and the residues washed with further ethanol (2 
mL). To the filtrate 1,5-cyclooctadiene (0.3 mL, 2.16 eq., 2.44 mmol) was added and the reaction was 
stirred for 5 min before being left to stand for 10 min. The yellow precipitate was filtered and washed 
with Et2O (3 x 3 mL) to give the desired product as a bright yellow powder (216 mg, 0.756 mmol, 67%). 
The data were in accordance with the literature.250,251 
1H NMR (400 MHz, CDCl3) δ 6.35 – 6.27 (m, 4H; CHalkenyl), 2.98 – 2.85 (m, 4H; CHalkyl), 2.63 – 2.51 (m, 
4H; CHalkyl) 
 
Methyl S-(4-hydroxybut-2-yn-1-yl)-L-cysteinate (20a) 
 
Alcohol 16a (1.01 g, 1 eq., 3.33 mmol) was dissolved in DCM (10 mL) and TFA (1 mL) added. After 3 h, 
the reaction was evaporated in vacuo and purified by flash chromatography with 5% TEA/8% 
MeOH/DCM on silica (10 g), then 5% MeOH/EtOAc on silica (30 g) then 8% MeOH/EtOAc on silica (60 
g) to give the desired product (542 mg, 2.66 mmol, 80%). The product could not be fully separated 
from triethylamine salts and was used crude.  
Rf (8% MeOH/EtOAc) 0.19 
1H NMR (400 MHz, CDCl3) δ 4.26 (t, J = 2.20 Hz, 2H; OCH2), 3.80 (dd, J = 4.85, 7.23 Hz, 1H; αH), 3.76 (s, 
3H; CH3), 3.32 (td, J = 2.13, 4.35 Hz, 2H; SCH2), 3.11 (dd, J = 4.76, 13.90 Hz, 1H; βH), 2.98 (dd, J = 7.14, 




Methyl N-acetyl-S-(4-hydroxybut-2-yn-1-yl)-L-cysteinate (20b) 
 
Alcohol 20a (191 mg, 1 eq., 0.940 mmol) was dissolved in DCM (10 mL) and TEA (0.2 mL, 1.5 eq., 1.41 
mmol) was added, followed by AcCl (0.08 mL, 1.2 eq., 1.13 mmol) at room temperature. After 4 h the 
reaction was evaporated in vacuo and purified by flash chromatography with 1% HCOOH/EtOAc to give 
the desired product as a light yellow oil (53 mg, 0.216 mmol, 23%).  
Rf (1% HCOOH/EtOAc) 0.33 
1H NMR (500 MHz, CDCl3) δ 6.57 (br. d, J = 6.70 Hz, 1H; NH), 4.92 - 4.97 (m, 1H; αH), 4.28 - 4.31 (m, 2H; 
OCH2), 3.81 (s, 3H; OCH3), 3.40 (td, J = 1.98, 16.78 Hz, 1H; βH), 3.31 - 3.34 (m, 1H; βH), 3.28 - 3.30 (m, 
1H; SCH), 3.09 (dd, J = 5.65, 14.19 Hz, 1H; SCH), 2.10 (s, 3H; COCH3) 
13C NMR (126 MHz, CDCl3)  171.3, 170.9, 83.3, 80.4, 52.9, 52.5, 50.9, 33.1, 23.2, 20.4 
IR (ATR) / cm-1: 3275, 2954, 1740, 1655, 1537 
MS(ESI): calcd. For C10H16O4N32S [M+H]+ 246.0795, found 246.0791 
 
Methyl N-acetyl-S-(4-(((7-amino-4-methylcoumarin)carbamoyl)oxy)but-2-yn-1-yl)-L-cysteinate (20) 
 
7-amino-4-methylcoumarin (8) (50 mg, 1 eq., 0.285 mmol) and triphosgene (42 mg, 0.5 eq., 0.143 
mmol) were dissolved in freshly distilled toluene (10 mL) and refluxed for 0.5 h in oven dried glassware 
before evaporating in vacuo. The crude isocyanate was then dissolved in freshly distilled THF (3 mL) at 
room temperature and alcohol 20b (77 mg, 1.1 eq., 0.314 mmol) added in further THF (2 mL) followed 
by dibutyltin dilaurate (0.01 mL, 0.06 eq., 16.9 µmol). After 1 h, the reaction was evaporated in vacuo 
and re-dissolved in DCM (10 mL). 10% aqueous KF (10 mL) was added and stirred for 10 min before the 
layers were separated. The aqueous layer was extracted with DCM (2 x 10 mL) and the organics were 
dried over MgSO4, filtered and evaporated in vacuo. The crude solids were triturated with MeOH (3 x 
5. Experimental (Appendix) 
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3 mL), Et2O (3 x 3 mL) and petrol (3 x 3 mL) to give the desired product as a yellow powder (46 mg, 
0.103 mmol, 36%).  
Decomp. 184 °C 
1H NMR (500 MHz, DMSO-d6)  10.35 (br. s, 1H; NHCO2), 8.41 (d, J = 7.90 Hz, 1H; NHCO), 7.71 (d, J = 
8.54 Hz, 1H; H5), 7.53 (d, J = 1.83 Hz, 1H; H8), 7.40 (dd, J = 2.14, 8.54 Hz, 1H; H6), 6.25 (d, J = 0.92 Hz, 
1H; H3), 4.85 - 4.87 (m, 2H; OCH2), 4.47 - 4.56 (m, 1H; αH), 3.64 (s, 3H; OCH3), 3.48 - 3.52 (m, 2H; SCH2), 
3.05 (dd, J = 5.34, 13.89 Hz, 1H; βH), 2.86 (dd, J = 8.70, 13.89 Hz, 1H; βH), 2.39 (d, J = 0.61 Hz, 3H; 
ArCH3), 1.87 (s, 3H; COCH3) 
13C NMR (126 MHz, DMSO-d6)  171.7, 169.9, 160.5, 154.3, 153.6, 153.0, 142.9, 126.5, 115.0, 114.7, 
112.5, 105.0, 83.4, 78.1, 53.2, 52.6, 52.0, 32.9, 22.7, 19.4, 18.5 
IR (ATR) / cm-1: 3279, 1739, 1687, 1625 
MS(ESI): calcd. For C21H23O7N2S [M+H]+ 447.1220, found 447.1205 
 
Methyl S-(4-hydroxybut-2-yn-1-yl)-L-cysteinate hydrochloride (21a) 
 
In an oven dried flask, freshly distilled MeOH (10 mL) was chilled to 0 °C and AcCl (0.06 mL) added. The 
reaction was warmed to room temperature, and then re-chilled to 0 °C before amine 19a (80 mg, 1 
eq., 0.394 mmol) was added. After 5 min the reaction was evaporated in vacuo to give the desired 
product as a clear oil (88 mg, 0.367 mmol, 93%) which was used without further purification. 
 
Methyl S-(4-(((7-amino-4-methylcoumarin)carbamoyl)oxy)but-2-yn-1-yl)-L-cysteinate (21) 
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7-amino-4-methylcoumarin (8) (50 mg, 1 eq., 0.285 mmol) and triphosgene (42 mg, 0.5 eq., 0.143 
mmol) were dissolved in freshly distilled toluene (10 mL) and refluxed for 0.5 h in oven dried glassware 
before evaporating in vacuo. The crude isocyanate was then dissolved in freshly distilled THF (3 mL) at 
room temperature and alcohol 21a (88 mg, 1.29 eq., 0.367 mmol) in further THF (2 mL) was added 
followed by dibutyltin dilaurate (0.01 mL, 0.06 eq., 16.94 µmol). After 1 h, the reaction was evaporated 
in vacuo and re-dissolved in DCM (10 mL). 10% aqueous KF (10 mL) was added and stirred for 10 min 
before the aqueous layer was basified to pH > 10 with sat. aq. Na2CO3 and the layers were separated. 
The aqueous layer was extracted with DCM (2 x 10 mL) and the organics were dried over MgSO4, 
filtered and evaporated in vacuo. The crude solids were triturated with MeOH (3 x 3 mL), Et2O (3 x 3 
mL) and petrol (3 x 3 mL) to give the desired product as a dark yellow powder (52 mg, 0.129 mmol, 
45%). 
m.p. 109-111 °C 
1H NMR (500 MHz, DMSO-d6)  9.33 (s, 1H; NHCO2), 7.64 (d, J = 8.54 Hz, 1H; H5), 7.57 (d, J = 2.14 Hz, 
1H; H5), 7.26 (dd, J = 1.98, 8.70 Hz, 1H; H8), 6.89 (d, J = 7.93 Hz, 1H; H6), 6.20 (d, J = 0.92 Hz, 1H; H3), 
5.16 (t, J = 5.95 Hz, 1H; NH), 4.56 - 4.64 (m, 1H; NH), 4.07 - 4.10 (m, 2H; OCH2), 3.70 (s, 3H; OCH3), 3.45 
- 3.49 (m, 2H; SCH2), 3.13 (dd, J = 4.88, 13.73 Hz, 1H; βH), 3.04 (dd, J = 7.32, 13.73 Hz, 1H; βH), 2.38 (d, 
J = 0.61 Hz, 3H; CH3CO) 
13C NMR (126 MHz, DMSO-d6)  172.0, 160.6, 154.6, 154.5, 153.7, 144.1, 126.4, 114.4, 114.0, 111.8, 
104.3, 83.7, 80.1, 52.8, 52.5, 49.5, 33.4, 19.8, 18.4 
IR (ATR) / cm-1: 3381, 2922, 1717, 1677, 1618 




PdCl2 (100 mg, 1 eq., 0.564 mmol) was suspended in concentrated HCl (~37%, 0.25 mL) and gently 
warmed until fully dissolved. The solution was cooled to room temperature and then diluted with 
absolute ethanol (7.5 mL). The solution was filtered, and the residues washed with further ethanol (1 
mL). To the filtrate was added norbornadiene (0.12 mL, 2.16 eq., 1.22 mmol) and the reaction was 
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stirred for 5 min before being left to stand for 10 min. The yellow precipitate was filtered and washed 
with Et2O (3 x 3 mL) to give the desired product as a bright yellow powder (94 mg, 0.349 mmol, 
62%).251,252  
1H NMR (400 MHz, DMSO-d6)  6.74 (t, J = 1.92 Hz, 4H; CHalkenyl), 3.56 – 3.52 (m, 2H; CHbridgehead), 1.87 
(t, J = 1.56 Hz, 2H; CHbridging) 
 
But-3-yn-1-yl trityl thioether (22a) 
 
K2CO3 (1.5 g, 3 eq., 10.9 mmol) was suspended in DMF (10 mL) in an oven dried flask. 4-bromo-1-
butyne (577 mg, 1.2 eq., 4.34 mmol) was added followed by triphenylmethane thiol (1 g, 1 eq., 3.62 
mmol) in one portion. After 6 h stirring at room temperature, the reaction was diluted in Et2O (100 mL) 
and washed with water basified to pH > 10 with sat. aq. Na2CO3 (2 x 50 mL), then brine (50 mL). The 
organics were dried over MgSO4, filtered and dry-loaded directly onto silica (5 g). The crude material 
was purified by flash chromatography on silica (50 g) with 5% Et2O/petrol to give the desired product 
as a white powder (886 mg, 2.73 mmol, 75%).  
Rf (5% Et2O/petrol) 0.41 
m.p. 73.5-76.5 °C 
IR (ATR) / cm-1: 3292, 3057, 3030, 2932, 1594, 1488, 1443 
1H NMR (400 MHz, CDCl3)  7.46 (d, J = 7.32 Hz, 6H), 7.32 (t, J = 7.32 Hz, 6H), 7.22 - 7.29 (m, 3H), 2.41 
(t, J = 7.45 Hz, 2H), 2.15 (dt, J = 2.55, 7.45 Hz, 2H), 2.00 (t, J = 2.55 Hz, 1H) 
13C NMR (101 MHz, CDCl3)  144.7, 129.6, 127.9, 126.7, 82.6, 69.2, 66.8, 30.8, 18.5 





Propargyl thioether 22a (645 mg, 1 eq., 1.96 mmol) was dissolved in freshly distilled THF (20 mL) in an 
oven dried flask and chilled to -78 °C. 1.6 M nBuLi in hexanes (1.5 mL, 1.2 eq., 2.36 mmol) was then 
added dropwise. After 10 mins, (CH2O)n (88 mg, 1.5 eq., 2.95 mmol) was then added in one portion 
and the reaction warmed to room temperature. After 1 h the reaction was quenched with sat. aq. 
NH4Cl (30 mL) and the phases separated. The aqueous layer was further extracted with EtOAc (2 x 30 
mL). The organics were dried over MgSO4, filtered and evaporated directly onto silica (5 g) and purified 
by flash chromatography on silica (50 g) with a gradient of 25-50% EtOAc/petrol to give the desired 
product as a yellow amorphous solid (677 mg, 1.89 mmol, 99%). 
Rf (40% EtOAc/petrol) 0.33 
m.p. 99.2-101.5 °C  
IR (ATR) / cm-1: 3365, 3057, 3018, 2929, 2870, 1594, 1488, 1443 
1H NMR (400 MHz, CDCl3)  7.43 (d, J = 7.40 Hz, 6H; Haromatic), 7.30 (t, J = 7.40 Hz, 6H; Haromatic), 7.23 (t, J 
= 7.40 Hz, 3H; Haromatic), 4.19 - 4.23 (m, 2H; OCH2), 2.37 (t, J = 7.50 Hz, 2H; SCH2), 2.18 (tt, J = 1.70, 7.20 
Hz, 2H; CH2CC), 1.58 - 1.64 (m, 1H; OH) 
13C NMR (101 MHz, CDCl3)  144.7, 129.6, 127.9, 126.7, 84.5, 79.3, 66.8, 51.3, 30.9, 18.8 
MS(ESI): calcd. for C24H22O32SNa [M+Na]+ 381.1284, found 381.1293 
 
5-(Tritylthio)pent-2-yn-1-yl (7-amino-4-methylcoumarin)carbamate (22) 
 
7-amino-4-methylcoumarin (8) (50 mg, 1 eq., 0.285 mmol) and triphosgene (42 mg, 0.5 eq., 0.143 
mmol) were dissolved in freshly distilled toluene (10 mL) and refluxed for 0.5 h in oven dried glassware 
before evaporating in vacuo. The crude isocyanate was then dissolved in freshly distilled THF (5 mL) at 
room temperature and alcohol 22b (123 mg, 1.2 eq., 0.342 mmol) added followed by dibutyltin 
dilaurate (0.01 mL, 0.08 eq., 16.9 µmol). After 1 h, the reaction was evaporated in vacuo to ~½ volume 
and chilled to 0 °C. Water (10 mL) was added dropwise and the precipitate filtered. The crude solids 
were triturated with MeOH (2 x 3 mL), Et2O (2 x 3 mL) and petrol (2 x 3 mL) to give the desired product 
as an off-white powder (63 mg, 0.191 mmol, 67%). 
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m.p. 188.8-190.0 °C 
IR (ATR) / cm-1: 3277, 3176, 3085, 3057, 2926, 2956, 2854, 1738, 1697, 1624 
1H NMR (400 MHz, DMSO-d6)  10.33 (s, 1H; NH), 7.69 (d, J = 8.86 Hz, 1H; H5), 7.53 (d, J = 2.04 Hz, 1H; 
H8), 7.40 (dd, J = 1.87, 8.69 Hz, 1H; H6), 7.30 - 7.36 (m, 12H; Htrityl), 7.22 - 7.27 (m, 3H; Htrityl), 6.25 (s, 1H; 
H2), 4.78 (s, 2H; OCH2), 2.39 (s, 3H; CCH3), 2.18 - 2.28 (m, 4H; SCH2/CCCH2) 
13C NMR (101 MHz, DMSO-d6)  160.5, 154.2, 153.6, 153.0, 144.7, 142.9, 129.5, 128.5, 127.2, 126.5, 
115.0, 114.7, 112.5, 105.0, 85.9, 76.2, 66.7, 53.3, 30.8, 18.5, 18.4 




K2CO3 (1.77 g, 2.5 eq., 12.8 mmol) was dissolved in water (20 mL) and 4-bromo-1-butyne (750 mg, 1.1 
eq., 5.64 mmol) was added. Sodium methanethiolate (359 mg, 1 eq., 5.13 mmol) was then added at 
room temperature and the reaction stirred for 5 h. The reaction was extracted with Et2O (3 x 20 mL) 
and the organics dried over MgSO4, then filtered directly onto 4 Å mol. sieves in an oven dried flask. 
The solution was then filtered via cannula into an oven dried flask and chilled to -78 °C. 1.6 M nBuLi in 
hexanes (4.81 mL, 1.5 eq., 7.69 mmol) was added dropwise followed by (CH2O)n (308 mg, 2 eq., 10.3 
mmol) after 10 min. The reaction was warmed to room temperature and stirred for 1 h before 
quenching with sat. aq. NH4Cl (30 mL) and separating. The organics were dried over MgSO4, filtered 
and evaporated. The crude material was purified by flash chromatography on silica (30 g) with 50% 
Et2O/petrol to give the desired product as a clear oil (262 mg, 2.01 mmol, 39%) which contains traces 
of Et2O and petrol. 
Rf (50% Et2O/Petrol) 0.24 
IR (ATR) / cm-1: 3345, 2917, 2865, 1431 
1H NMR (500 MHz, CDCl3)  4.27 (br. s., 2H; OCH2), 2.68 (t, J = 7.02 Hz, 2H; SCH2), 2.54 (t, J = 6.71 Hz, 
2H; CH2CC), 2.16 (s, 3H; SCH3), 1.88 (br. s, 1H; OH) 
13C NMR (126 MHz, CDCl3)  84.4, 79.4, 51.2, 33.1, 19.7, 15.6 
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MS(ESI): calcd. for C6H11O32S [M+H]+ 131.0525, found 131.0530 
5-(Methylthio)pent-2-yn-1-yl (7-amino-4-methylcoumarin)carbamate (23) 
 
7-amino-4-methylcoumarin (8) (50 mg, 1 eq., 0.285 mmol) and triphosgene (42 mg, 0.5 eq., 0.143 
mmol) were dissolved in freshly distilled toluene (10 mL) and refluxed for 0.5 h in oven dried glassware 
before evaporating in vacuo. The crude isocyanate was then dissolved in freshly distilled THF (5 mL) at 
room temperature and alcohol 23a (56 mg, 1.5 eq., 0.428 mmol) was added followed by dibutyltin 
dilaurate (0.01 mL, 0.08 eq., 16.9 µmol). After 1 h, the reaction was evaporated in vacuo to ~½ volume 
and chilled to 0 °C. Water (10 mL) was added dropwise and the precipitate filtered. The crude solids 
were triturated with MeOH (2 x 3 mL), Et2O (2 x 3 mL) and petrol (2 x 3 mL) to give the desired product 
as a white powder (63 mg, 0.190 mmol, 66%). 
m.p. 175.6-177.8 °C 
IR (ATR) / cm-1: 3277, 3174, 3100, 2956, 2920, 1735, 1687, 1625 
1H NMR (400 MHz, DMSO-d6)  10.33 - 10.37 (m, 1H; NH), 7.70 (d, J = 8.86 Hz, 1H; H5), 7.53 (d, J = 1.70 
Hz, 1H; H8), 7.40 (dd, J = 1.70, 8.52 Hz, 1H; H6), 6.24 (s, 1H; H2), 4.80 - 4.82 (m, 2H; OCH2), 2.59 - 2.65 
(m, 2H; SCH2/CCCH2), 2.52 - 2.58 (m, 2H; SCH2/CCCH2), 2.39 (s, 3H; CCH3), 2.09 (s, 3H; SCH3) 
13C NMR (101 MHz, DMSO-d6)  160.4, 154.2, 153.6, 153.0, 142.9, 126.5, 115.0, 114.7, 112.5, 104.9, 
86.6, 76.0, 53.4, 32.4, 19.4, 18.5, 15.1 
MS(ESI): calcd. for C17H18O4N32S [M+H]+ 332.0951, found 332.0960 
 
2-(2-(2-Ethoxyethoxy)ethoxy)ethyl tosylate (30) 
 
Triethylene glycol monoethylether 29 (25 mL, 1 eq., 143 mmol) was dissolved in TEA (100 mL, 5 eq., 
720 mmol) and chilled to 0 °C. TsCl (30 g, 1.1 eq., 157 mmol) was added over 5 min and the reaction 
allowed to warm to room temperature after 15 min and stirred for 5 h. The reaction mixture was 
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poured slowly over a mixture of ice (200 mL) and conc. HCl (150 mL) and then extracted with Et2O (3 x 
100 mL). The combined organics were washed with brine (100 mL) and sat. aq. NaHCO3 (100 mL), dried 
over MgSO4, filtered and evaporated to give the desired product as a light yellow oil (42.759 g, 129 
mmol, 90%). The data were in accordance with the literature.253 
1H NMR (400 MHz, CDCl3) δ 7.79 (d, J = 8.05 Hz, 2H; Haryl), 7.34 (d, J = 8.05 Hz, 2H; Haryl), 4.14 - 4.17 (m, 
2H; SO2CH2), 3.66 - 3.70 (m, 2H; SO2CH2CH2), 3.54 - 3.63 (m, 8H; OCH2CH2O), 3.51 (q, J = 7.06 Hz, 2H; 




Tosylate 30 (2.0 g, 1.0 eq., 6.02 mmol) was dissolved in acetone (50 mL) and degassed by five 
evacuation/refill cycles. KSAc (1.37 g, 2.0 eq., 12.0 mmol) was then added in one portion and the 
reaction stirred for 20 h.  The reaction was evaporated then diluted in sat. aq. NaHCO3 (60 mL) and 
extracted with DCM (4 x 30 mL) and evaporated in vacuo. This gave the desired product as an orange 
oil (1.22 g, 5.17 mmol, 86%) which was used crude without further purification.  
1H NMR (400 MHz, CDCl3) δ 3.55 - 3.65 (m, 10H; OCH2), 3.51 (q, J = 7.06 Hz, 2H; OCH2CH3), 3.08 (t, J = 




A 1 M solution of NaOMe was prepared by dissolving Na (553 mg, 24.1 mmol) in freshly distilled MeOH 
(24 mL). An portion of this solution (6.3 mL, 2.06 eq., 6.28 mmol) was added to thioester 32 (721 mg, 
1 eq., 3.05 mmol) in an oven dried flask and the reaction stirred at room temperature for 1.5 h. 
Propargyl alcohol 32 (478 mg, 1.5 eq., 4.58 mmol) was then added in one portion and the reaction 
stirred for a further 20 h. The reaction was then evaporated and purified by flash chromatography with 
a gradient of 50-70% EtOAc/petrol on silica (80 g) to give the desired product as an orange oil (581 mg, 
2.21 mmol, 73%).  
Rf (50% EtOAc/petrol) 0.10 
129 
IR (ATR) / cm-1: 3407, 2866 
1H NMR (500 MHz, CDCl3) δ 4.29 - 4.31 (m, 2H; OCH2C≡C), 3.74 (t, J = 6.71 Hz, 2H; SCH2CH2O), 3.66 - 
3.69 (m, 6H; OCH2), 3.60 - 3.63 (m, 2H; CH2OCH2CH3), 3.55 (q, J = 7.02 Hz, 2H; OCH2CH3), 3.39 (t, J = 
1.98 Hz, 2H; SCH2C≡C), 2.91 (t, J = 6.71 Hz, 2H; SCH2CH2O), 1.89 - 1.95 (m, 1H; OH), 1.24 (t, J = 7.02 Hz, 
3H; OCH2CH3) 
13C NMR (126 MHz, CDCl3) δ 81.7, 81.6, 70.8, 70.6, 70.6, 70.4, 69.8, 66.7, 51.1, 30.7, 20.1, 15.1 
MS(ESI): calcd. for C12H22O432S [M+H]+ 263.1259, 263.1256 
 
3,6,9-Trioxa-12-thiahexadec-14-yn-16-yl (7-amino-4-methylcoumarin)carbamate (28) 
 
7-amino-4-methylcoumarin (8) (50 mg, 1 eq., 0.285 mmol) and triphosgene (42 mg, 0.5 eq., 0.143 
mmol) were dissolved in freshly distilled toluene (10 mL) and refluxed for 0.5 h in oven dried glassware 
before evaporating in vacuo. The crude isocyanate was then dissolved in freshly distilled THF (5 mL) at 
room temperature and alcohol 33 (97 mg, 1.3 eq., 0.371 mmol) was added followed by dibutyltin 
dilaurate (0.01 mL, 0.06 eq., 17.1 µmol). After 1 h, the reaction was evaporated in vacuo. The crude 
viscous oil was treated with petrol (15 mL) and then evaporated again. The crude waxy solid was 
triturated with petrol (5 x 3 mL) and Et2O (5 x 3 mL) then dried in vacuo to give the desired product as 
a light brown waxy solid (100 mg, 0.216 mmol, 87%).  
IR (ATR) / cm-1: 3278, 3173, 3094, 2868, 17.36, 1687 
1H NMR (400 MHz, DMSO-d6) δ 10.37 (s, 1H; NH), 7.71 (d, J = 8.69 Hz, 1H; H5), 7.54 (d, J = 1.36 Hz, 1H; 
H8), 7.41 (dd, J = 1.36, 8.69 Hz, 1H; H6), 6.25 (s, 1H; H3), 4.86 (s, 2H; OCH2C≡C), 3.61 (t, J = 6.47 Hz, 2H; 
SCH2CH2O), 3.37 - 3.54 (m, 12H; O(CH2)2O+SCH2C≡C+OCH2CH3), 2.78 (t, J = 6.47 Hz, 2H; SCH2CH2O), 2.39 
(s, 3H; ArCH3), 1.09 (t, J = 6.98 Hz, 3H; OCH2CH3) 
13C NMR (101 MHz, DMSO-d6) δ 160.4, 154.3, 153.6, 153.0, 142.9, 126.5, 115.0, 114.7, 112.5, 105.0, 
84.2, 77.6, 70.3, 70.3, 70.2, 70.0, 69.6, 66.0, 53.3, 30.9, 19.4, 18.5, 15.6 
MS(ESI): calcd. for C23H30NO732S [M+H]+ 464.1743, found 464.1752 
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3,6,9-Trioxa-12-thiahexadec-14-yn-16-yl (4-nitrophenyl) carbonate (34) 
 
Alcohol 33 (200 mg, 1 eq., 0.762 mmol) was dissolved in freshly distilled DCM (12 mL) in an oven dried 
flask and p-nitrophenylchloroformate (231 mg, 1.5 eq., 1.14 mmol) was added. DIPEA (0.27 mL, 2.0 
eq., 1.52 mmol) was added dropwise and the reaction stirred for 20 h. The reaction was evaporated 
and purified by flash chromatography with 50% EtOAc/petrol on silica (60 g). Crude fractions were 
evaporated, the material dissolved in DCM (50 mL) and washed with dilute aq. NaHCO3 (30 mL). The 
aqueous layer was extracted with DCM (25 mL) and the combined organics dried over MgSO4, filtered 
and evaporated in vacuo to give the desired product as a light yellow oil (192 mg, 0.449 mmol, 59%).  
Rf (50% EtOAc/Petrol) 0.30 
IR (ATR) / cm-1: 2869, 1768 
1H NMR (400 MHz, CDCl3) δ 8.30 (d, J = 9.20 Hz, 2H; Haromatic), 7.42 (d, J = 9.20 Hz, 2H; Haromatic), 4.92 (t, 
J = 1.70 Hz, 2H; OCH2C≡C), 3.73 (t, J = 6.56 Hz, 2H; SCH2CH2O), 3.63 - 3.69 (m, 6H; OCH2), 3.58 - 3.63 (m, 
2H; CH2OCH2CH3), 3.53 (q, J = 7.07 Hz, 2H; OCH2CH3), 3.41 (t, J = 1.87 Hz, 2H), 2.88 (t, J = 6.56 Hz, 2H; 
SCH2CH2O), 1.22 (t, J = 7.07 Hz, 3H; OCH2CH3) 
13C NMR (101 MHz, CDCl3) δ 155.3, 152.0, 145.5, 125.3, 121.8, 85.2, 75.2, 70.8, 70.7, 70.6, 70.4, 69.8, 
66.6, 57.1, 31.1, 20.0, 15.2 





Carbonate 34 (48 mg, 1.3 eq., 112 µmol) was dissolved in DMF and doxorubicin hydrochloride (50 mg, 
1.0 eq., 86.2 µmol) was added. DIPEA (37 µL, 2.5 eq., 216 µmol) was then added in one portion and 
the reaction stirred for 3 h then diluted with EtOAc (75 mL), washed with water (2 x 30 mL) and brine 
(30 mL). The organics were dried over MgSO4, filtered and evaporated in vacuo. The crude material 
was purified by flash chromatography with 5% MeOH/DCM on silica (30 g) to give the desired product 
as a red waxy solid (55 mg, 65.6 µmol, 76%).  
Rf (5% MeOH/DCM) 0.38 
IR (ATR) / cm-1: 3441, 2931, 1721 
1H NMR (500 MHz, CDCl3) δ 13.98 (s, 1H; H6/11), 13.25 (s, 1H; H6/11), 8.05 (d, J = 7.63 Hz, 1H; H1), 7.80 
(dd, J = 7.63, 8.24 Hz, 1H; H2), 7.41 (d, J = 8.24 Hz, 1H; H3), 5.52 – 5.48 (m, 1H; H1’), 5.43 (d, J = 8.54 Hz, 
1H; NH), 5.31 – 5.27 (m, 1H; H7), 4.78 (d, J = 3.05 Hz, 2H; H14), 4.68 (d, J = 15.4 Hz, 1H; H9), 4.59 (d, J = 
13.9 Hz, 2H; OCH2C≡C), 4.12 (q, J = 6.7 Hz, 1H; H5’), 4.10 (s, 3H; OCH3), 3.84 - 3.92 (m, 1H; H3’),3.63 - 
3.73 (m, 10H; SCH2CH2O + CH2O + H4’ + H3’), 3.59 - 3.63 (m, 2H; CH2OCH2CH3), 3.54 (q, J = 7.02 Hz, 2H; 
OCH2CH3), 3.34 (br. s., 2H; C≡CCH2S), 3.31 (d, J = 2.2 Hz, 2H; C4’/9OH), 3.27 (dd, J = 18.9, 2.0 Hz, 1H; H10), 
3.02 (s, 2H; C14OH), 2.97 (d, J = 14.6 Hz, 1H; H10), 2.85 (dt, J = 2.14, 6.70 Hz, 2H; SCH2CH2O), 2.50 - 2.55 
(m, 1H; C4’/9OH), 2.36 (d, J = 14.65 Hz, 1H; H8), 2.19 (dd, J = 3.66, 14.65 Hz, 1H; H8), 1.82 - 1.87 (m, 2H; 
H2’), 1.31 (d, J = 6.41 Hz, 3H; C6’-CH3), 1.22 (t, J = 7.02 Hz, 3H; OCH2CH3) 
13C NMR (126 MHz, CDCl3) δ 213.9, 187.1, 186.7, 161.1, 156.2, 155.7, 154.8, 135.8, 135.5, 133.6, 133.6, 
120.9, 119.9, 118.5, 111.6, 111.4, 100.7, 82.7, 77.6, 76.6, 70.7, 70.7, 70.5, 70.3, 69.7, 69.6, 69.3, 67.4, 
66.7, 65.6, 56.7, 53.0, 47.2, 35.6, 34.0, 31.5, 30.0, 20.0, 16.9, 15.1 
MS(ESI): calcd. for C40H49NO1632SNa [M+Na]+ 854.2664, found 854.2648 
 
Synthesis of Compounds 36a-e and 36 performed by Laura Sinatra 
5. Experimental (Appendix) 
132 
tert-Butyl (2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)carbamate (36a) 
 
A solution of Boc2O (207 mg, 1.5 eq., 1.13 mmol) in EtOH (0.5 mL) was added to 2-(2-2-2-
aminoetriethoxy)ethanol (150 mg, 1.0 eq., 0.753 mmol) in EtOH (1.0 mL). The reaction mixture was 
stirred at room temperature for 18 h and the solvent was evaporated in vacuo. The residue was 
dissolved in DCM (20 mL) then washed with 1 M HCl (20 mL), sat. aq. NaHCO3 (20 mL) and brine (20 
mL). The organic layer was dried over MgSO4, filtered and evaporated in vacuo. The crude material was 
purified by flash chromatography on silica with 0-10% MeOH/DCM to give the desired product as a 
pale yellow oil (186 mg, 0.473 mmol, 63%). The data were in accordance with the literature.253 
Rf (5% MeOH/DCM) 0.41 
1H NMR (400 MHz, CDCl3) δ 3.75 – 3.68 (m, 4H; OCH2CH2O), 3.68 – 3.60 (m, 8H; OCH2CH2O), 3.53 (dd, 
J = 5.5, 4.5 Hz, 2H; OCH2CH2N), 3.31 (dd, J = 5.5, 4.5 Hz, 2H; CH2NH), 1.44 (s, 9H; C(CH3)3) 
 
2,2-Dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azahexadecan-16-yl 4-methylbenzenesulfonate (36b) 
 
Carbamate 36a (180 mg, 1.0 eq., 0.617 mmol) was dissolved in freshly distilled DCM (1.0 mL) in an 
oven dried flask. TEA (422 µL, 5.0 eq., 3.05 mmol) and DMAP (3.66 mg, 0.05 eq., 0.0305 mmol) were 
added and the reaction was cooled to 0 °C. TsCl (173 mg, 1.5 eq., 0.926 mmol) was added slowly, the 
reaction allowed to warm to room temperature and stirred for 20 h. Then the reaction was diluted 
with DCM (20 mL) and washed with 1 M HCl (20 mL). The aqueous layer was extracted with DCM (3 x 
20 mL). The organic layers were combined, washed with brine (50 mL), dried over MgSO4, filtered and 
evaporated in vacuo. The crude product was purified by flash chromatography on silica with 0-5% 
MeOH/DCM to give the desired product as light yellow oil (257 mg, 0.574 mmol, 93 %). The data were 
in accordance with the literature.253 
Rf (5% MeOH/DCM) 0.46 
1H NMR (400 MHz, CDCl3) δ 7.80 (d, J = 8.3 Hz, 2H; Haryl), 7.34 (d, J = 8.1 Hz, 2H; Haryl), 4.16 (dd, J = 9.7, 
1.1 Hz, 2H; SO2CH2), 3.70 (dd, J = 5.6, 4.1 Hz, 2H; SO2CH2CH2), 3.60 (m, J = 1.7 Hz, 8H; OCH2CH2O), 3.53 
(t, J = 5.2 Hz, 2H; OCH2CH2N), 3.30 (q, J = 5.5 Hz, 2H; CH2NH), 2.45 (s, 3H; ArCH3), 1.44 (s, 9H; C(CH3)3) 
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S-(2,2-Dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azahexadecan-16-yl) ethanethioate (36c) 
 
Tosylate 36b (182 mg, 1.0 eq., 0.407 mmol) was dissolved in acetone (6 mL) and degassed by five 
evacuation/refill cycles. KSAc (278 mg, 6.0 eq., 2.44 mmol) was added in one portion and the reaction 
stirred for 20 h at room temperature. The reaction was then evaporated in vacuo, the crude material 
diluted in sat. aq. NaHCO3 (30 mL) and extracted with DCM (3 x 30 mL). The organic layers were 
combined, washed with 5% NaOH (2x 50 mL) and evaporated in vacuo. The crude product was purified 
by flash chromatography on silica with 5% MeOH/DCM to give the desired product as a yellow oil (139 
mg, 0.394 mmol, 97%).  
Rf (5% MeOH/DCM) 0.46 
1H NMR (400 MHz, CDCl3) δ 3.66 – 3.57 (m, 10H, OCH2CH2O), 3.54 (t, J = 5.1 Hz, 2H, OCH2CH2N), 3.31 
(q, J = 5.4 Hz, 2H, CH2NH), 3.09 (t, J = 6.5 Hz, 2H, CH2SCH3), 2.33 (s, 3H, CH2SCH3), 1.43 (s, 9H, C(CH3)3) 
13C NMR (75 MHz, DMSO-d6) δ 195.6, 156.1, 70.7, 70.7, 70.5, 70.4, 69.9, 40,5, 30.7, 29.0, 28.6 
IR (ATR) / cm-1: 3354, 2977, 2869, 1690, 1513 
MS(ESI): calcd. for C15H29NO632SNa [M+Na]+ 374.1613, found 374.1599 
 
tert-Butyl (16-hydroxy-3,6,9-trioxa-12-thiahexadec-14-yn-1-yl)carbamate (36d) 
 
Thioester 36c (120 mg, 1.0 eq., 0.341 mmol) was dissolved in freshly distilled MeOH (2 mL). A 1 M 
solution of NaOMe was prepared by dissolving Na (553 mg, 24.05 mmol) in freshly distilled MeOH (24 
mL). A portion of this solution (0.59 mL, 2.0 eq., 0.683 mmol) was added to thioester 36c in an oven 
dried flask and the reaction stirred for 1.5 h. Propargyl chloride 32 (48 mg, 1.35 eq., 0.460 mmol) was 
then added in one portion and the reaction stirred for further 20 h. The reaction was then evaporated 
in vacuo and purified by flash chromatography on silica with 0-33% MeOH/DCM to give the desired 
product as a yellow oil (109 mg, 0.290 mmol, 85%). 
Rf (5% MeOH/DCM) 0.40 
5. Experimental (Appendix) 
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1H NMR (400 MHz, CDCl3) δ 5.18 (s, 1H, OH), 4.29 – 4.27 (m, 2H, OCH2C≡C), 3.74 (t, J = 6.5 Hz, 2H, 
SCH2CH2O), 3.68 – 3.60 (m, 8H, OCH2CH2O), 3.55 (q, J = 5.1 Hz, 2H, OCH2CH2N), 3.38 (t, J = 2.2 Hz, 2H, 
SCH2C≡C), 3.36 – 3.28 (m, 2H, CH2NH), 2.88 (t, J = 6.5 Hz, 2H, CH2SCH2), 1.45 (s, 9H, C(CH3)3) 
13C NMR (75 MHz, DMSO-d6) δ 156.3, 81.8, 81.7, 79.4, 71.0, 70.8, 70.7, 70.4, 66.0, 51.2, 40.5, 31.0, 
28.6, 20.3, 15.4 
IR (ATR) / cm-1: 3368, 2868, 1691, 1515  




Alcohol 36d (60 mg, 1.0 eq., 0.159 mmol) was dissolved in 20% TFA in DCM (1 mL) and stirred for 3 h. 
Afterwards the solvent was evaporated in vacuo and the crude product was dissolved in dry DMF 
(0.75 mL) in an oven dried flask. DIPEA (31 µL, 2.0 eq, 0.32 mmol) was added to the solution. 3-
benzoylacrylic acid (28 mg, 1.0 eq., 0.16 mmol) and HBTU (72 mg, 1.2 eq., 0.19 mmol) were dissolved 
in dry DMF (0.75 mL) and DIPEA (31 µL, 2.0 eq., 0.318 mmol) was added. This solution was stirred for 
15 min and added dropwise to the crude amine in DMF at 0 °C. The reaction was allowed to warm to 
room temperature and stirred for 18 h. The solvent was evaporated in vacuo and coevaporated 3 times 
with toluene. The crude product was dissolved in DCM (20 mL) and washed with 1 M HCl (3x 20 mL), 
NaHCO3 sat. (3x 20 mL) and brine (3x 20 mL). The organic layer was dried over MgSO4, filtered and 
evaporated in vacuo. The crude material was purified by flash chromatography on silica with 0-5% 
MeOH/DCM to give the desired product as brown waxy oil (15.1 mg, 35.2 µmol, 22% over two steps).  
Rf (5% MeOH/DCM) 0.26 
1H NMR (400 MHz, CDCl3) δ 8.06 – 8.03 (m, 2H; Haryl), 7.98 (d, J = 15.1 Hz, 1H; HC=CH), 7.65 – 7.59 (m, 
1H; Haryl), 7.51 (dd, J = 8.4, 7.0 Hz, 2H; Haryl), 7.31 (s, 1H; NH), 7.04 (d, J = 15.1 Hz, 1H; HC=CH), 4.28 (t, J 
= 2.1 Hz, 2H; OCH2C≡C), 3.74 (t, J = 6.6 Hz, 2H; SCH2CH2O), 3.71 – 3.64 (m, 10H; OCH2CH2O), 3.62 (dd, J 
= 7.4, 3.3 Hz, 2H; SCH2C≡C), 3.32 (t, J = 2.1 Hz, 2H; CH2NH), 2.86 (t, J = 6.6 Hz, 2H; CH2SCH2), 2.39 (s, 1 
H; OH) 
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13C NMR (75 MHz, DMSO-d6) δ 189.9, 164.4, 136.9, 135.6, 133.7, 133.0, 128.9, 128.8, 81.8, 81.4, 70.8, 
70.6, 70.5, 70.2, 70.1, 69.6, 51.0, 39.9, 30.8, 20.1 
IR (ATR) / cm-1: 3279, 3070, 2917, 2867, 1646, 1596, 1579, 1535  
MS(ESI): calcd. for C22H29NO632SNa [M+Na]+ 458.1608, found 458.1597 
 
(E)-N-(16-Hydroxy-3,6,9-trioxa-12-thiahexadec-14-yn-1-yl)-4-oxo-4-phenylbut-2-enamide 
doxorubicin carbamate (36) 
 
Alcohol 36e (15 mg, 1.0 eq., 34.4 µmol) was dissolved in DCM (1 mL) and p-nitrophenylchloroformate 
(11 mg, 1.57 eq., 54.1 µmol) was added in an oven dried flask. DIPEA (18 µL, 3.0 eq., 0.103 mmol) was 
added dropwise and the reaction stirred for 20 h. Then it was diluted with DCM (20 mL) and washed 
with dilute aq. NaHCO3 (20 mL). The aqueous layer was extracted with DCM (2 x 20 mL) and the 
combined organic layer was dried over MgSO4, filtered and evaporated under reduced pressure. The 
residue was dissolved in dry DMF (1 mL) and doxorubicin hydrochloride (20 mg, 1.0 eq., 0.035 mmol) 
and DIPEA (18 µL, 3.0 eq., 0.11 mmol) were then added in one portion and the reaction stirred for 18 h. 
Afterwards DMF was coevaporated with toluene (3 x 5 mL). The crude product was purified by flash 
chromatography on silica with 0-5% MeOH/DCM and then purified by preparative TLC (1 mm, 5% 
MeOH/DCM) to give the desired product as a red waxy solid (15 mg, 15.1 µmol, 43% over two steps).  
Rf (5% MeOH/DCM) 0.21 
1H NMR (400 MHz, CDCl3) δ 13.97 (s, 1H, H6/11), 13.27 (s, 1H, H6/11), 8.08 – 8.00 (m, 3H, H1, Haryl), 7.96 
(d, J = 15.0 Hz, 1H, HC=CH), 7.79 (dd, J = 8.5, 7.7 Hz, 1H, Haryl), 7.60 (t, J = 7.4 Hz, 1H, HAryl), 7.50 (t, J = 
7.6 Hz, 2H, Haryl), 7.39 (dd, J = 8.6, 1.1 Hz, 1H, Haryl), 7.22 (s, 1 H, NH), 7.05 (d, J = 15.1 Hz, 1H, HC=CH), 
5.64 (d, J = 8.6 Hz, 1H, NH), 5.57 – 5.49 (m, 1H, H1), 5.31 (s, 1H, H7), 4.77 (s, 2H, H14), 4.70 (s, 1H, H9), 
4.65 (d, J = 19.5 Hz, 2H, OCH2C≡C), 4.50 (d, J = 15.4 Hz, 2H), 4.22 (s, 1H, H5’), 4.08 (s, 3H, OCH3), 3.87 (s, 
1H, H3’), 3.78 – 3.54 (m, 16H, SCH2CH2O + CH2O + H4’ + H3’), 3.31 (d, J = 2.5 Hz, 2H, C≡CCH2S), 3.27 (d, J 
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= 2.0 Hz, 1H, H10), 3.15 (d, J = 6.3 Hz, 1H, H10), 2.86 – 2.80 (m, 2H, SCH2CH2O), 2.36 (d, J = 14.6 Hz, 1H, 
H8), 2.22 – 2.12 (m, 1H, H8), 1.90 – 1.80 (m, 2H, H2’), 1.31 (d, J = 6.5 Hz, 3H, C6’-CH3) 
13C NMR (75 MHz, DMSO-d6) δ 213.90, 189.70, 187.16, 186.77, 164.48, 161.07, 156.24, 155.72, 154.84, 
154.75, 136.92, 135.75, 135.56, 135.37, 133.70, 133.62, 133.09, 128.84, 120.96, 119.86, 118.43, 
111.62, 111.44, 100.80, 82.76, 70.86, 70.55, 70.42, 70.26, 70.20, 69.56, 69.30, 67.98, 67.48, 65.57, 
56.70, 52.94, 47.33, 39.92, 35.67, 34.03, 30.75, 30.06, 29.71, 25.62, 20.03, 17.00 
IR (ATR)  / cm-1: 3694, 3327, 2925, 2335, 2191, 2064, 1974,1721, 1646, 1579  
MS(ESI): calcd. for C50H56N2O1832S [M+H]+ 1027.3141, found 1027.3108  
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5.3 Synthetic Procedures for Chapter 4 
tert-Butyldimethyl(pent-4-yn-1-yloxy)silane (38a) 
 
4-pentyn-1-ol (1.00 g, 1.00 eq., 11.9 mmol) was dissolved in DCM (20 mL) and TBSCl (1.88 g, 1.05 eq., 
12.5 mmol) was added followed by imidazole (1.62 g, 2.00 eq., 23.8 mmol). The reaction was stirred 
for 2 h at room temperature, then poured over water (50 mL) and acidified to pH < 2 with 3 M HCl. The 
layers were separated and the aqueous layer further extracted with DCM (2 x 30 mL). The organics 
were dried over MgSO4 and evaporated in vacuo to give the desired product as a clear oil (2.15 g, 10.9 
mmol, 91%). The data were in accordance with the literature.254 
1H NMR (400 MHz, CDCl3) δ 3.70 (t, J = 6.0 Hz, 2H; OCH2), 2.27 (td, J = 7.1, 2.7 Hz, 2H; CH2C≡CH), 1.93 




Alkyne 38a (7.79 g, 1.0 eq., 39.3 mmol) was dissolved in freshly distilled THF (50 mL) in an oven dried 
flask and chilled to -78 °C. 1.6 M nBuLi in hexanes (29.5 mL, 1.2 eq., 47.2 mmol) was added dropwise 
and the reaction stirred for 10 min. (CH2O)n (1.53 g, 1.3 eq., 51.1 mmol) was added and the reaction 
allowed to warm to room temperature, then stirred for 1 h. The reaction was then poured over sat. 
aq. NH4Cl (150 mL) and separated. The aqueous layer was extracted wtih EtOAc (2 x 100 mL). The 
combined organics were dried over MgSO4 and evaporated in vacuo. The crude material was purified 
by flash chromatography with 1% TEA, 20% EtOAc/petrol on silica (150 g) to give the product (8.65 g, 
37.4 mmol, 96%) as a light yellow oil. The data were in accordance with the literature.254 
Rf (20% EtOAc/petrol) 0.18 
1H NMR (400 MHz, CDCl3) δ 4.28 – 4.21 (m, 2H; HOCH2), 3.68 (t, J = 6.0 Hz, 2H; TBSOCH2), 2.30 (tt, J = 7.1, 2.2 Hz, 
2H; CH2C≡CH2), 1.77 – 1.65 (m, 2H; OCH2CH2), 1.49 – 1.44 (m, 1H; OH), 0.89 (s, 9H; C(CH3)3), 0.05 (s, 6H; 
Si(CH3)2) 
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6-((tert-Butyldimethylsilyl)oxy)hex-2-yn-1-yl dibenzylcarbamate (38c) 
 
Alcohol 38b (200 mg, 1.0 eq., 0.875 mmol) was dissolved in freshly distilled MeCN (12 mL) in an oven 
dried flask and DSC (336 mg, 1.5 eq., 1.31 mmol) added in one portion at room temperature. DIPEA 
(0.46 mL, 3.0 eq., 2.63 mmol) was added dropwise and the reaction stirred for 5 h. Bn2NH (0.42 mL, 
2.5 eq., 2.19 mmol) was added dropwise and the reaction stirred a further 2 h then evaporated in 
vacuo. The crude oil was diluted in 3 M HCl (50 mL) and extracted with EtOAc (2 x 50 mL). The organics 
were washed with brine (30 mL), dried over MgSO4 and evaporated in vacuo. The crude material was 
purified by flash chromatography with 1% TEA, 10% EtOAc/petrol on silica (50 g) to give the product 
(304 mg, 0.673 mmol, 77%) as a clear oil.  
Rf (10% EtOAc/petrol) 0.32 
IR (ATR) /cm-1: 2952, 2929, 1702, 1605 
1H NMR (400 MHz, CDCl3) δ 7.37 – 7.20 (m, 10H; Haromatic), 4.81 (t, J = 2.2 Hz, 2H; CO2CH2), 4.43 (d, J = 
12.7 Hz, 4H; N(CH2)2), 3.69 (t, J = 6.1 Hz, 2H; TBSOCH2), 2.33 (tt, J = 7.1, 2.2 Hz, 2H; CH2C≡CH2), 1.79 – 
1.67 (m, 2H; OCH2CH2), 0.89 (s, 9H; C(CH3)3), 0.05 (s, 6H; Si(CH3)2) 
13C NMR (101 MHz, CDCl3) δ 156.17, 137.16, 128.59, 128.17, 127.74, 127.46, 86.93, 74.82, 61.54, 54.11, 
49.31, 48.88, 31.50, 25.93, 18.33, 15.26, -5.33 
MS(ESI): calcd. for C27H37NO3Si [M+H]+ 452.2616, found 452.1862 
 
6-Hydroxyhex-2-yn-1-yl dibenzylcarbamate (38d) 
 
Silane 38c (207 mg,  1.0 eq., 0.458 mmol) was dissolved in freshly distilled MeOH (15 mL) and chilled 
to 0 °C. AcCl (8 drops) was added, and the reaction stirred for 0.5 h. The reaction was evaporated in 
vacuo and purified by flash chromatography with 40% EtOAc/petrol on silica (50 g) to give the desired 
product (150 mg, 0.445 mmol, 97%) as a clear oil.  
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Rf (40% EtOAc/petrol) 0.18 
IR (ATR) /cm-1: 3438, 3032, 2943, 1690 
1H NMR (400 MHz, CDCl3) δ 7.36 – 7.19 (m, 10H; Haromatic), 4.79 (t, J = 2.2 Hz, 2H; CO2CH2), 4.42 (d, J = 
13.8 Hz, 4H; NCH2), 3.75 (t, J = 6.5 Hz, 2H; HOCH2), 2.37 (tt, J = 6.5, 2.2 Hz, 2H; C≡CCH2), 1.82 – 1.73 (m, 
2H; OCH2CH2) 
13C NMR (101 MHz, CDCl3) δ 156.17, 137.12, 128.60, 128.16, 127.69, 127.48, 86.43, 75.41, 61.57, 54.02, 
49.39, 48.92, 31.02, 15.38 
MS(ESI): calcd. For C21H25NO3 [M+H]+ 338.1756 , found 338.1757 
 
6-((Dibenzylcarbamoyl)oxy)hex-4-ynoic acid (38) 
 
Alcohol 38d (95 mg, 1.0 eq., 0.282 mmol) was dissolved in DCM (10 mL) and pyridine (68.3 µL, 3.0 eq., 
0.845 mmol) was added followed by DMP (179 mg, 1.5 eq., 0.422 mmol). The reaction was stirred for 
2 h at room temperature before diluting with 1:1 10% aq. Na2S2O3/sat. aq. Na2CO3 (10 mL) and stirring 
for 30 min. The layers were separated and the aqueous layer extracted with DCM (2 x 10 mL). The 
organics were washed with water (10 mL), dried over MgSO4 and evaporated in vacuo. The crude 
material was dissolved in tBuOH (4 mL) and diluted with 50 mM pH 7.4 NaPi (4 mL). 2-methyl-2-butene 
(0.3 mL, 10 eq., 2.82 mmol) was added followed by NaClO2 (60 mg, 2.0 eq., 0.563 mmol) and the 
reaction stirred for at room temperature. After 2 h, the reaction was evaporated then diluted with 3 
M HCl (20 mL) and extracted with DCM (3 x 15 mL). The organics were dried over MgSO4 and 
evaporated in vacuo. The crude material was purified by flash chromatography with 60% EtOAc/petrol 
on silica (30 g) to give the product (76 mg, 0.217 mmol, 77%) as a white powder. 
Rf (80% EtOAc/petrol) 0.10 
IR (ATR) /cm-1: 3030, 2350, 1705 
1H NMR (400 MHz, CDCl3) δ 7.38 – 7.17 (m, 10H; Haromatic), 4.79 (t, J = 2.0 Hz, 2H; OCH2), 4.42 (d, J = 14.8 
Hz, 4H; NCH2), 2.64 – 2.51 (m, 4H; (CH2)2CO2H) 
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13C NMR (101 MHz, CDCl3) δ 176.95, 156.13, 137.06, 128.61, 128.16, 127.71, 127.50, 84.78, 75.71, 
53.90, 49.40, 48.92, 32.97, 14.46 
MS(ESI): calcd. For C21H22NO4 [M+H]+ 352.1549, found 352.1550 
 
Propargyl morpholine-4-carboxylate (41) 
 
DIPEA (0.27 mL, 1.5 eq., 1.55 mmol) was dissolved in freshly distilled DCM (5 mL) in an oven dried flask 
and propargyl chloroformate (0.15 mL, 1.5 eq., 1.55 mmol) was added, followed by dropwise 
morpholine (90.4 µL, 1.0 eq., 1.03 mmol) at room temperature. After 1 h, the reaction was diluted with 
3 M HCl (20 mL) and extracted with DCM (3 x 10 mL). The organics were dried over MgSO4 and 
evaporated in vacuo. The crude material was purified by flash chromatography with 30% EtOAc/petrol 
on silica (50 g) to give the product (138 mg, 0.816 mmol, 79%) as a white powder. 
Rf (30% EtOAc/petrol) 0.19 
m.p. 42.5-44.4 °C 
IR (ATR) /cm-1: 3676, 3244, 2988, 2975, 2902, 1716, 1690 
1H NMR (400 MHz, CDCl3) δ 4.70 (d, J = 2.4 Hz, 2H; OCH2), 3.65 (s, 4H; O(CH2)2), 3.52 – 3.44 (m, 4H; 
N(CH2)2), 2.47 (t, J = 2.4 Hz, 1H; C≡CH) 
13C NMR (101 MHz, CDCl3) δ 154.39, 78.29, 74.64, 66.48, 53.07, 44.32, 43.99 
MS(ESI): calcd. for C8H12NO3 [M+H]+ 170.0817, found 170.0818 
 
iso-Butyl morpholine-4-carboxylate (42) 
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iso-Butyl chloroformate (0.23 mL, 1.5 eq., 1.72 mmol) was dissolved in freshly distilled DCM (6 mL) in 
an oven dried flask and DIPEA (0.3 mL, 1.5 eq., 1.72 mmol) was added. Morpholine (0.1 mL, 1 eq., 1.25 
mmol) was then added dropwise and the reaction stirred for 1 h at room temperature. The reaction 
was diluted with 3 M HCl (20 mL) and extracted with DCM (3 x 10 mL). The organics were dried over 
MgSO4 and evaporated in vacuo. The crude material was purified by flash chromatography with 20% 
EtOAc/petrol on silica (50 g) to give the product (194 mg, 1.04 mmol, 90%) as a clear oil. 
Rf (20% EtOAc/petrol) 0.15 
IR (ATR) /cm-1: 3677, 2963, 2901, 1698 
1H NMR (400 MHz, CDCl3) δ 3.87 (dd, J = 6.7, 0.9 Hz, 2H; OCH2), 3.65 (t, J = 4.8 Hz, 4H; O(CH2)2), 3.50 – 
3.42 (m, 4H; N(CH2)2), 1.92 (hept, J = 6.7 Hz, 1H; CH(CH3)2), 0.92 (dd, J = 6.7, 0.9 Hz, 6H; (CH3)2) 
13C NMR (101 MHz, CDCl3) δ 155.59, 71.65, 66.61, 44.00, 27.97, 19.08 




4-pentynoic acid (37) (150 mg, 1.0 eq., 1.53 mmol) was dissolved in DCM (20 mL) and morpholine (134 
µL, 1.0 eq., 1.53 mmol) was added followed by DCC (284 mg, 0.9 eq., 1.38 mmol) and the reaction 
stirred for 6 h at room temperature. The reaction was filtered, and the filtrate evaporated then purified 
by flash chromatography with 50% EtOAc/petrol on silica (50 g) to give the desired product (132 mg, 
0.789 mmol, 57%) as a white powder. 
Rf (50% EtOAc/petrol) 0.10 
m.p. 83.0-84.6 °C 
IR (ATR) /cm-1: 3676, 3223, 2967, 2919, 1636 
1H NMR (400 MHz, CDCl3) δ 3.68 – 3.64 (m, 4H; O(CH2)2), 3.63 – 3.60 (m, 2H; NCH2), 3.50 – 3.43 (m, 2H; 
NCH2), 2.57 – 2.52 (m, 4H; (CH2)2C≡C), 1.98 – 1.95 (m, 1H; C≡CH) 
13C NMR (101 MHz, CDCl3) δ 169.52, 83.35, 68.83, 66.88, 66.57, 45.79, 42.02, 31.97, 14.45 
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4-pentynoic acid (37) (100 mg, 1.0 eq., 1.02 mmol) was dissolved in DCM (10 mL) and TEA (0.43 mL, 
3.0 eq., 3.06 mmol) was added, followed by EDC∙HCl (195 mg, 1.0 eq., 1.02 mmol) at room 
temperature. The reaction was stirred for 1 h before 2-methoxyethylamine (88.6 µL, 1.0 eq., 1.02 
mmol) was added dropwise. The reaction was stirred for a further 6 h before diluting with 3 M HCl (20 
mL) and extracting with DCM (3 x 10 mL). The organics were dried over MgSO4, filtered and evaporated 
in vacuo. The crude material was purified by flash column chromatography with 75% EtOAc/petrol on 
silica (50 g) to give the desired product (32 mg, 0.206 mmol, 20%) as a clear oil. 
Rf (75% EtOAc/petrol) 0.14 
IR (ATR) /cm-1: 3288, 2926, 1650, 1545 
1H NMR (400 MHz, CDCl3) δ 6.07 (br. s, 1H; NH), 3.43 (d, J = 2.7 Hz, 4H; OCH2 + NCH2), 3.32 (s, 3H; 
OCH3), 2.50 (td, J = 7.3, 2.2 Hz, 2H; C≡CH), 2.38 (t, J = 7.3 Hz, 2H), 1.96 (t, J = 2.7 Hz, 1H; C≡CH) 
13C NMR (101 MHz, CDCl3) δ 170.95, 82.94, 71.14, 69.19, 58.72, 39.21, 35.27, 14.85 




Doxorubicin hydrochloride (100 mg, 1 eq., 172.42 µmol) was suspended in chloroform (20 mL) and TEA 
(10 drops) added until fully dissolved. Water (10 mL) was then added and the layers separated. The 
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aqueous layer was extracted with chloroform (10 mL) and the combined organics evaporated in vacuo. 
Acetone (30 mL) and 4 Å mol. sieves were added and the reaction refluxed for 3 h. The reaction was 
cooled to room temperature then chilled to 0 ˚C before adding TEA (72 µL, 3 eq., 517.26 µmol). 4-
pentynoic acid (37) (51 mg, 3 eq., 517.26 µmol) was dissolved in CDCl3 and TEA (72 µL, 3 eq., 517.26 
µmol) was added followed by SOCl2 (19 µL, 1.5 eq., 258.63 µmol). The reaction was monitored by 1H 
NMR until complete formation of anhydride after 2 h. The crude anhydride in CDCl3 was added to pDox 
(45) in acetone at 0 ˚C. The reaction was allowed to come to room temperature and stirred for 18 h, 
then formic acid (5 drops) was added and the reaction dry-loaded directly onto silica (2 g). The crude 
product was purified by flash chromatography on silica (50 g) with 10% MeOH/DCM, then on silica (30 
g) with 0-10% MeOH/DCM, then again on silica (50 g) w(ith 4-10% MeOH/DCM to give the desired 
product (11 mg, 16.57 µmol, 10%) as a red powder. 
1H NMR (500 MHz, CDCl3) δ 14.02 (s, 1H; OHphenol), 13.26 (s, 1H; OHphenol), 8.04 (dd, J = 7.7, 1.1 Hz, 1H; 
H1/3), 7.80 (dd, J = 8.6, 7.7 Hz, 1H; H2), 7.41 (dd, J = 8.6, 1.1 Hz, 1H; H1/3), 5.53 (t, J = 8.1 Hz, 1H; H1’), 
5.32 (dd, J = 4.1, 2.1 Hz, 1H; H7), 4.75 (s, 2H; CH2OH), 4.56 (s, 1H; 9-OH), 4.30 (qd, J = 6.7, 2.2 Hz, 1H; 
H5’), 4.09 (s, 3H; OMe), 3.99 – 3.89 (m, 2H; H3’/4’), 3.31 (dd, J = 18.8, 2.1 Hz, 1H; H10), 3.05 (d, J = 18.8 
Hz, 1H; H10), 2.51 – 2.45 (m, 3H; NHCOCH2 + H8), 2.41 – 2.30 (m, 2H; CH2C≡C), 2.23 – 2.16 (m, 1H; H8), 
2.10 – 2.03 (m, 1H; H2’), 1.87 (t, J = 2.4 Hz, 1H; C≡CH), 1.80 (ddd, J = 14.2, 10.5, 4.0 Hz, 1H; H2’), 1.70 
(s, 3H; CMe2), 1.57 (s, 3H; CMe2), 1.41 (d, J = 6.7 Hz, 3H; 5’-Me) 
13C NMR (126 MHz, CDCl3) δ 213.41, 187.18, 186.83, 167.01, 161.10, 156.18, 155.61, 135.87, 135.48, 
133.48, 133.34, 120.87, 119.87, 118.49, 111.76, 111.62, 100.45, 95.26, 83.29, 72.33, 70.14, 68.74, 
65.45, 63.95, 56.71, 50.95, 35.40, 34.07, 33.82, 31.65, 29.71, 26.89, 23.90, 16.79, 14.18 




5. Experimental (Appendix) 
144 
Doxorubicin hydrochloride (50 mg, 1 eq., 86.21 µmol) and 4-pentynoic acid (37) (17 mg, 2 eq., 172.42 
µmol) were dissolved in DCM (12 mL) and TEA (60.1 µL, 5 eq., 431.05 µmol) was added followed by 
TBTU (55 mg, 2 eq., 172.42 µmol). The reaction was stirred at room temperature for 6 h. The reaction 
was diluted with DCM (20 mL) and washed with water (20 mL). The aqueous layer was washed with 
DCM (10 mL), and the combined organics dried over MgSO4, filtered and evaporated in vacuo directly 
onto silica (2 g). The crude product was purified by flash chromatography on silica (50 g) with 7-10% 
MeOH, 1% HCOOH/DCM. The product containing fractions were dry-loaded onto silica (1 g) and 
purified by flash chromatography on silica (50 g) with 5-10% MeOH/DCM to give the desired product 
(42 mg, 67.35 µmol, 78%) as a bright red amorphous solid. 
IR (ATR) /cm-1: 3297, 2925, 2854, 1724, 1618, 1579 
1H NMR (400 MHz, CDCl3) δ 13.95 (s, 1H; OHphenol), 13.20 (s, 1H; OHphenol), 8.02 (dd, J = 8.1, 1.1 Hz, 1H; 
H1/3), 7.77 (t, J = 8.1 Hz, 1H; H2), 7.38 (dd, J = 8.1, 1.1 Hz, 1H; H1/3), 6.00 (d, J = 8.4 Hz, 1H; NH), 5.49 (d, 
J = 4.1 Hz, 1H; H1’), 5.28 – 5.22 (m, 1H; H7), 4.75 (s, 2H; CH2OH), 4.51 (s, 1H; 9-OH), 4.20 – 4.11 (m, 2H; 
H5’), 4.06 (s, 3H; OMe), 3.65 (s, 1H; H3’), 3.25 (dd, J = 18.9, 1.9 Hz, 1H; H10), 2.97 (d, J = 18.9 Hz, 1H; H10), 
2.50 – 2.42 (m, 2H; NHCOCH2), 2.37 – 2.28 (m, 3H; CH2C≡C + H8), 2.16 (dd, J = 14.8, 4.1 Hz, 1H; H8), 1.98 
(t, J = 2.6 Hz, 1H; C≡CH), 1.86 (dd, J = 13.3, 5.2 Hz, 1H; H2’), 1.77 (td, J = 13.3, 4.1 Hz, 1H; H2’), 1.29 (d, J 
= 6.6 Hz, 3H; 5’-Me) 
13C NMR (101 MHz, CDCl3) δ 213.88, 187.05, 186.59, 170.28, 160.99, 156.18, 155.60, 135.78, 135.45, 
133.58, 133.52, 120.78, 119.85, 118.42, 111.55, 111.36, 100.70, 82.84, 69.72, 69.45, 69.43, 67.16, 
65.56, 56.65, 45.28, 35.67, 35.28, 33.95, 29.90, 29.70, 16.85, 14.92 




Doxorubicin hydrochloride (100 mg, 1 eq., 172.42 µmol) was suspended in chloroform (20 mL) and TEA 
(10 drops) was added until fully dissolved. Water (10 mL) was then added and the layers separated. 
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The aqueous layer was extracted with chloroform (10 mL) and the combined organics evaporated in 
vacuo. Acetone (30 mL) and 4 Å mol. sieves were added and the reaction refluxed for 3 h. The reaction 
was cooled to room temperature. then chilled in ice before adding TEA (48 µL, 2 eq., 344.84 µmol) 
followed by acetic anhydride (26 mg, 1.5 eq., 258.63 µmol). The reaction was allowed to come to room 
temperature and stirred for 18 h, then formic acid (5 drops) was added and the reaction dry-loaded 
directly onto silica (2 g). The crude product was purified by flash chromatography on silica (50 g) with 
10% MeOH/DCM, then on silica (30 g) with 0-10% MeOH/DCM, then again on silica (50 g) with 4-10% 
MeOH/DCM to give the product (13 mg, 20.78 µmol, 12%) as a red powder. 
IR (ATR) /cm-1: 3476, 2925, 2855, 1724, 1618, 1579 
1H NMR (400 MHz, CDCl3) δ 13.98 (s, 1H; OHphenol), 13.21 (s, 1H; OHphenol), 8.01 (dd, J = 7.8, 1.1 Hz, 1H; 
H1/3), 7.78 (t, J = 8.1 Hz, 1H; H2), 7.39 (dd, J = 8.6, 1.1 Hz, 1H; H1/3), 5.53 – 5.49 (m, 1H; H1’), 5.31 – 5.26 
(m, 1H; H7), 4.74 (s, 2H; CH2OH), 4.55 (s, 1H; 9-OH), 4.32 – 4.23 (m, 1H; H5’), 4.08 (s, 3H; OMe), 3.93 – 
3.89 (m, 1H; H3’/4’), 3.89 – 3.83 (m, 2H; H3’/4’), 3.26 (dd, J = 18.9, 1.9 Hz, 1H; H10), 3.05 – 2.95 (m, 2H; 
H10), 2.38 (d, J = 14.8 Hz, 1H; H8), 2.22 – 2.13 (m, 1H; H8), 2.11 – 2.02 (m, 1H; H2’), 1.97 (s, 3H; Ac), 1.79 
(ddd, J = 13.9, 10.3, 3.9 Hz, 1H; H2’), 1.69 (s, 3H; CMe2), 1.56 (s, 3H; CMe2), 1.39 (d, J = 6.7 Hz, 3H; 5’-
Me) 
13C NMR (101 MHz, CDCl3) δ 213.43, 187.13, 186.74, 166.61, 161.08, 156.16, 155.53, 135.90, 135.40, 
133.51, 133.32, 120.77, 119.86, 118.51, 111.63, 111.53, 100.42, 95.03, 72.19, 70.06, 65.45, 64.00, 
56.71, 51.78, 35.33, 34.02, 31.55, 29.70, 26.86, 23.88, 23.56, 16.79 




5-Fluorouracil (50 mg, 1.0 eq., 384.38 µmol), EDC∙HCl (81 mg, 1.1 eq., 422.82 µmol) and 4-pentynoic 
acid (37) (45 mg, 1.2 eq., 461.26 µmol) were dissolved in DMF (1 mL). TEA (0.21 mL, 4.0 eq., 1.54 mmol) 
was added and the reaction stirred at room temperature for 20 h. The reaction was evaporated, then 
diluted in EtOAc and washed with dilute NaHCO3 (10 mL), 3 M HCl (10 mL) and brine (10 mL). The 
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organics were dried over MgSO4, filtered and evaporated in vacuo. The crude material was purified by 
filtration over silica (5 g) in EtOAc to give the product (22 mg, 104.69 µmol, 27%) as a white powder. 
IR (ATR) /cm-1: 3251, 3083, 2921, 1743, 1693, 1681 
1H NMR (500 MHz, CDCl3) δ 8.90 (s, 1H; NH), 8.30 (d, J = 6.6 Hz, 1H; H6), 3.39 (t, J = 6.9 Hz, 2H; CH2CO), 
2.63 (td, J = 6.9, 2.7 Hz, 2H; CH2CC), 2.00 (t, J = 2.7 Hz, 1H; Halkyne) 
13C NMR (126 MHz, CDCl3) δ 170.16 , 156.31 (d, J = 28.6 Hz), 147.66 , 141.44 (d, J = 245.0 Hz), 121.43 
(d, J = 36.8 Hz), 81.83 , 69.48 , 38.33 , 29.68 , 14.01 




4-pentynoic acid (37) (1.4 mg, 2.0 eq., 13.9 µmol) was dissolved in DMF (0.5 mL) and HBTU (5.3 mg, 
2.0 eq., 13.9 µmol) was added followed by DIPEA (6 µL, 5.0 eq., 34.8 µmol) at room temperature. After 
10 min, MMAE (5 mg, 1.0 eq., 6.96 µmol) was added in one portion. The reaction was stirred for 6 h 
then evaporated in vacuo. The crude product was dissolved in DCM (10 mL) and washed with 3 M HCl 
(5 mL), water basified to ~pH 8 with sat. aq. NaHCO3 solution (5 mL) and water (5 mL). The organics 
were dried over MgSO4, filtered and evaporated in vacuo. The crude material was purified by 
preparative HPLC with a gradient of 50-95% H2O/MeCN + 0.1% TFA for 0-15 min, then 95% for 15-20 
min, then 95-50% for 20-22 min to give the desired product (4 mg, 5.01 µmol, 72%). 
MMAE Rt = 4.3 min – peak confirmed by high-res mass spec 
 
147 




MS(ESI): calcd. for C44H72O8N5 [M+H]+ 798.5375, found 798.5354 
MS(ESI): calcd. for C44H71O8N5Na [M+Na]+ 820.5194, found 820.5166 
MMAEam decaging (5 h) Rt = 3.5 min – peak confirmed by high-res mass spec 
MMAE-am (2.1 mg, 1.0 eq., 2.63 µmol) was reacted with NaAuCl4 (10.5 mg, 10 eq., 26.3 µmol) in 1:1 
MeCN:H2O for 5 h. A 0.5 mL aliquot was taken and the reaction quenched by addition of vitamin A (2.6 
mg, 22 eq., 14.8 µmol). This reduces the gold complexes to a brown precipitate, which can then be 
filtered before HPLC. 








5-Fluorouracil (400 mg, 1.0 eq., 3.08 mmol) was dissolved in dry DMF and DBU (460 µL, 1.0 eq., 3.08 
mmol) was added at room temperature followed by 80% propargyl bromide in toluene (343 µL, 1.0 
eq., 3.08 mmol). The reaction was stirred at room temperature for 20 h then evaporated in vacuo at 
50 °C. The crude product was purified by flash column chromatography on silica (100 g) with a gradient 
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of 50-75% EtOAc/petrol to give the desired product (136 mg, 0.808 mmol, 26%) as a white powder. 
The data were in accordance with the literature.187  
1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 5.4 Hz, 1H; Haromatic), 4.56 (d, J = 2.6 Hz, 2H; CH2), 2.55 (d, J = 2.6 
Hz, 1H; C≡CH) 
 
tert-Butyl (2-(2-hydroxyethoxy)ethyl)carbamate (53) 
 
2-(2-aminoethoxy)ethan-1-ol 52 (5 mL, 1.0 eq., 49.8 mmol) was dissolved in THF (100 mL) and Boc2O 
(12.0 g, 1.1 eq., 54.8 mmol) was added in one portion at 0 °C. NaHCO3 (8.37 g, 2.0 eq., 99.7 mmol) 
dissolved in water (60 mL) was then added dropwise to the reaction over 10 min. The reaction was 
warmed to room temperature and stirred for 3 days then evaporated to ~½ volume in vacuo. EtOAc 
(100 mL) was added and washed with 3 M HCl (50 mL). The aqueous layer was extracted with EtOAc 
(50 mL) and the combined organics were washed with brine (50 mL), dried over MgSO4, filtered and 
evaporated in vacuo to give the desired product (7.93 g, 49.8 mmol, 78%) as a clear oil. The data were 
in accordance with the literature.255 
1H NMR (400 MHz, CDCl3) δ 4.90 (br. s, 1H; NH), 3.76 – 3.71 (m, 2H; CH2OH), 3.59 – 3.52 (m, 4H; OCH2), 
3.36 – 3.28 (m, 2H; NCH2), 1.45 (s, 9H; (CH3)3) 
 
tert-Butyl (2-(2-(prop-2-yn-1-yloxy)ethoxy)ethyl)carbamate (54) 
 
Alcohol 53 (1.0 g, 1.0 eq., 4.87 mmol) was dissolved in freshly distilled THF (25 mL) in an oven dried 
flask and chilled to 0 °C. 60% NaH in mineral oil (779 mg, 4.0 eq., 19.49 mmol) was added, followed by 
80% propargyl bromide in toluene (0.65 mL, 1.5 eq., 7.31 mmol) and the reaction allowed to warm to 
room temperature. After 2.5 h, the reaction was quenched with sat. aq. NH4Cl (50 mL) and separated. 
The aqueous layer was extracted with EtOAc (2 x 30 mL) and the combined organics dried over MgSO4, 
filtered and evaporated in vacuo. The crude product was purified by flash chromatography on silica 
(200 g) with 35% EtOAc/petrol to give the desired product (563 mg, 2.31 mmol, 48%) as a clear oil. The 
data were in accordance with the literature.256 
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Rf (30% EtOAc/petrol) 0.20 
1H NMR (400 MHz, CDCl3) δ 4.96 (s, 1H; NH), 4.21 – 4.17 (m, 2H; CH2C≡C), 3.70 – 3.66 (m, 2H; OCH2), 
3.65 – 3.60 (m, 2H; OCH2), 3.53 (t, J = 5.4 Hz, 2H; NCH2CH2), 3.31 (q, J = 5.4 Hz, 2H; NCH2), 2.43 (td, J = 
2.4, 0.8 Hz, 1H; C≡CH), 1.43 (s, 9H; (CH3)3) 
 
tert-Butyl (2-(2-((6-hydroxyhex-2-yn-1-yl)oxy)ethoxy)ethyl)methylcarbamate (55) 
 
Alkyne 54 (239 mg, 1.0 eq., 0.982 mmol) was dissolved in freshly distilled THF (15 mL) in an oven dried 
flask then chilled to -78 °C. 1.6 M nBuLi in hexanes (0.92 mL, 1.5 eq., 1.47 mmol) was added dropwise 
and stirred for 10 min. MeI (0.61 mL, 10 eq., 9.82 mmol) was added dropwise and the reaction warmed 
to room temperature. After 2 h the reaction was quenched with sat. aq. NH4Cl (30 mL) and extracted 
with EtOAc (3 x 10 mL). The combined organics were dried over MgSO4, filtered and evaporated in 
vacuo to give crude methylated product (237 mg, 0.921 mmol, 94%). The crude material was dissolved 
in freshly distilled THF (15 mL) and chilled to -78 °C. 1.6 M nBuLi in hexanes (1.15 mL, 2.0 eq., 1.84 
mmol) was added dropwise and stirred for 10 min. Trimethylene oxide (120 µL,2.0 eq., 1.84 mmol) 
was added followed by BF3∙Et2O (0.23 mL, 2.0 eq., 1.84 mmol), then the reaction was warmed to room 
temperature and stirred for 2 h. The reaction was quenched with sat. aq. NH4Cl (30 mL) and extracted 
with EtOAc (3 x 10 mL). The combined organics were dried over MgSO4, filtered and evaporated in 
vacuo. The crude material was purified by flash chromatography on silica (50 g) with 80% EtOAc/petrol 
to give the desired product (119 mg, 0.377 mmol, 41%) as a clear oil. 
Rf (80% EtOAc/petrol) 0.29 
1H NMR (400 MHz, CDCl3) δ 4.16 (t, J = 2.2 Hz, 2H; OCH2C≡C), 3.73 (t, J = 6.7 Hz, 2H; CH2OH), 3.66 – 3.49 
(m, 7H; NH + OCH2), 3.38 (br. s, 2H; NCH2), 2.90 (s, 3H; NCH3), 2.33 (tt, J = 6.7, 2.2 Hz, 2H; C≡CCH2CH2), 
1.75 (tt, J = 6.7 Hz, 2H; CH2CH2CH2), 1.43 (s, 9H; (CH3)3) 
13C NMR (101 MHz, CDCl3) δ 155.77, 86.28, 79.42, 76.39, 70.30, 69.58, 68.91, 61.56, 58.95, 48.37, 
35.32, 31.18, 28.45, 15.31 
MS(ESI): calcd. for C16H29NO5Na [M+Na]+ 338.1938, found 338.1935 
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Perfluorophenyl (E)-4-oxo-4-phenylbut-2-enoate (58) 
 
3-benzoylacrylic acid (250 mg, 1.0 eq., 1.42 mmol) was dissolved in freshly distilled DCM (8 mL) and 
DIPEA (495 µL, 2.0 eq., 2.84 mmol) was added .The solution was chilled to 0 °C and then 
pentafluorophenyl trifluoroacetate (265 µL, 1.1 eq., 1.56 mmol) was added and then the reaction 
warmed to room temperature. After 3 h, the reaction was filtered through silica (30 g) in DCM and 
then evaporated in vacuo to give the desired product (466 mg, 1.36 mmol, 96%) as a yellow solid which 
was used without further purification. 
Acrylamide-(platinum cleavable linker)-MMAE (59) 
Alcohol 55 (12 mg 3.9 eq., 38.1 µmol) was dissolved in freshly distilled DCM (5 mL) and pyridine (30.8 
µL, 39.1 eq., 381 µmol) was added followed by DMP (48 mg, 11.6 eq., 113 µmol) at room temperature. 
After 2 h, further DMP (48 mg, 11.6 eq., 113 µmol) was added, and again after 2 h DMP (64 mg, 15.5 
eq., 151 µmol) was added. After 2 h, 10% aq. Na2S2O3 and basified to pH < 10 with sat. aq. Na2CO3 and 
stirred for 1 h at room temperature. The layers were separated and the aqueous layer extracted with 
DCM (3 x 10 mL). The organics were dried over MgSO4, filtered and evaporated in vacuo. To the crude 
aldehyde, tBuOH (1 mL), 50 mM pH 7.4 NaPi (1 mL), 2-methyl-2-butene (80.6 µL, 78.0 eq., 761 µmol) 
and NaClO2 (17 mg, 19.2 eq., 188 µmol) were added at room temperature and the reaction stirred for 
2 h. The reaction was evaporated in vacuo to ~½ volume, diluted to 3 M HCl (20 mL) and extracted with 
DCM (3 x 10 mL). The organics were dried over MgSO4, filtered and evaporated in vacuo. The crude 
acid was dissolved in dry DMF (2 mL) and DIPEA (66.2 µL, 39.0 eq., 380 µmol) was added followed by 
HATU (14 mg, 3.9 eq., 38.0 µmol). After 1 h, MMAE (7 mg, 1.0 eq., 9.75 µmol) was added and the 
reaction stirred for 6 h before evaporating in vacuo at 40 °C. The crude product was dissolved in CHCl3 
(5 mL) and washed with water (5 mL). The crude material was dissolved in 4 M HCl/dioxane (2 mL) at 
room temperature and stirred for 2 h. The reaction was evaporated in vacuo, and the crude ammonium 
chloride dissolved in dry DMF (1 mL) and DIPEA (66.2 µL, 39.0 eq., 380 µmol) was added followed by 
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activated ester 58 (13 mg, 3.9 eq., 38.0 µmol). The reaction was stirred for 6 h, evaporated in vacuo, 
then redissolved in 1:1 MeCN:H2O, filtered and purified by preparative HPLC to give the desired 
product (0.7 mg, 0.644 µmol, 6.6%). 
1st purification:  
50% MeCN/H2O + 0.1% TFA: Rt = 12.5-14.0 min – peak confirmed by high-res mass spec. 
 
 
MS(ESI): calcd. for C60H91N6O12 [M+H]+ 1087.6689, found 1087.6669 
2nd purification:  
0-20 min 40% MeCN/H2O + 0.1% TFA, 20-30 min 40-70% MeCN/H2O + 0.1% TFA: Rt = 29.3 min – peak 




MS(ESI): calcd. for C60H91N6O12 [M+H]+ 1087.6689, found 1087.6663 
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5.4 NMR spectra for Chapter 3 
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(E)-N-(16-Hydroxy-3,6,9-trioxa-12-thiahexadec-14-yn-1-yl)-4-oxo-4-phenylbut-2-enamide 






5.5 NMR spectra for Chapter 4 
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6-((Dibenzylcarbamoyl)oxy)hex-4-ynoic acid (38) 
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iso-Butyl morpholine-4-carboxylate (42) 
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